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There is an increasing emphasis on building closed loop systems in human 
health where real time monitoring and analysis is connected to feedback and 
treatment. Building such systems requires bridging the information loop across the 
different signal modalities of biology and electronics. In this work, I have created two 
  
different networks at biology-electronic interface to enable the communication from 
biology to electronics and vice versa. 
The first network is a multi-step enzyme cascade assembled on a microchip to 
enable conversion of biologic information into electro-chemical information. I first 
devised a modular construction approach using microbial transglutaminase (mTG) 
based conjugation chemistry where multiple enzyme components are assembled on an 
abiotic surface in a ‘plug and play’ fashion. Integration of bio-components with 
electronics requires a scaffold material for functionalization of the bio-electronic 
interface. To address this challenge, I engineered a self-assembling Tobacco Mosaic 
Virus-Virus Like Particle into a 3D scaffold displaying desired functional groups at 
the interface. Using the 3D scaffolds and mTG mediated conjugation chemistry, I 
assembled a synthetic 3-enzyme cascade on a microchip for conversion of methyl 
cycle intermediates into homocysteine, an electrochemically readable molecule. The 
modular construction approach and the scaffold materials that I developed can enable 
facile assembly of multi-subunit bio-components and diversify the range of 
metabolites that can be detected on a microchip for use in biosensing applications. 
Next, I focused on mediating communication from electronics to specific 
genes in the genome of biological systems. An electrogenetic promoter that is 
responsive to the electrical stimuli was reported in E. coli. In this work, I integrated 
the precise gene targeting capabilities of the CRISPR-Cas9 system with the 
electrogenetic promoter to target specific host transcriptional processes. I displayed 
temporal silencing of several host defense mechanisms against the electrical signals 
resulting in an overall enhancement for electrogenicity in E. coli. A more 
  
sophisticated control of host transcriptional processes by the CRISPR-Cas9 system is 
a valuable addition to the existing electrogenetic toolbox, one that could enhance the 
interoperability of electrogenetic systems and mediate bio-electronic communication 
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Chapter 1 Introduction 
1.1 Digital systems in medicine 
In the era of artificial intelligence and self-driving cars, it is not too farfetched to 
expect autonomous health monitoring and control systems to play a crucial role in 
human health. A GPS enabled smartphone in addition to a heart rate sensor can 
accurately track various fitness parameters. Several wearable and implantable bio-
sensors monitor vital parameters like heart rate, cardiac rhythms, sleep patterns, 
glucose levels independently or in tandem with a smartphone.[1, 2]. Through extensive 
information gateways in place, information gathered by the sensors can relayed and 
analyzed in real time and a suitable feedback can be provided. With smartphone being 
at the center of this new diagnostic ecosystem (termed as ‘mHealth’), newer models of 
patient centric health care need to be put in place.[3, 4] This not only includes sensors 
for real time monitoring and analysis but also newer ways of delivering effective 
feedback including ‘smart’ drug delivery devices that autonomously communicate to 
sensors in real time.  
1.2 Closed-loop systems: therapeutic systems ensconced 
with feedback 
Intelligent therapeutic delivery systems that adapt to body conditions and 





use and development and it is not a coincidence that many of these systems have first 
sprung in the field of neuromodulation where application of electric signals for neural 
stimulation and therapy is well established. Epilepsy, Parkinson’s and motor pain are 
some of the conditions for which closed-loop systems have been developed till date.[5] 
Developing closed-loop systems for non-neuromuscular conditions can be a challenge 
because of the lack of sensing and drug delivery techniques that are integrated  with  
Scheme 1-1 Elements of a closed loop system.  
Closed loop systems integrate sensing, analysis, and feedback. Sensing and feedback 
can be performed by a variety of techniques and analysis can be done at various levels 
by the doctor, patient or a software. 
 
and controlled by electrical systems. In 2016, FDA approved a closed-loop insulin 
pump that automatically senses glucose levels and delivers insulin.[6, 7] Several other 
technologies aiming to address the close-loop challenge in diabetes have appeared 
including the use of a microneedle patch filled with glucoresponsive-insulin[8]; an 
optogenetic circuit in mice that responds to a smartphone signal with insulin production 





is not to be missed that most of the sensing is capitalized on the rich literature available 
for glucose sensing.  
 
Scheme 1-2 Optogenetics based closed-loop system for diabetes. 
Scheme of the optogenetics based closed-loop system demonstrated by Shao et.al, in 
Science Translational Medicine [9]. A genetically engineered mouse that responds to 
far-red light source with production of insulin is created. Glucose levels in mice are 
sensed with glucose sensors and relayed to smartphones which in turn controls a far-
red light source. Duration and intensity of far-red light controls the amount of insulin 
secreted in mice.  
 
Therefore, to create closed-loop systems for other important conditions 
(Scheme 1-1), there is a need to create new sensors to mediate communication across 
the signal modalities. On the other end of the information loop, new methodologies 
need to be developed to mediate reverse signal transduction from electrical systems to 
biological systems to deliver or actuate therapeutics with electrical signals like the 
vagus nerve stimulation for epileptic seizures, deep brain stimulation for movement 
disorders, wirelessly controlled human parathyroid hormone release using 





1.3 Sensing: One half of the closed loop 
1.3.1 New age digital sensors  
New age digital sensors are being developed that not only monitors various 
physiological parameters but also relays information in real time. Some of the sensors 
already approved by FDA include 1: Blood pressure through applanation tonometry 
across the radial artery in the hand through watch like sensors[11]; 2: A fully 
implantable ‘CardioMEMS device’ for pulmonary artery pressure monitoring 
system[12, 13]; 3: Smart drug digital sensor for reporting treatment compliance.[14] 
All the above mentioned sensors are completely integrated with smartphones or other 
digital systems so that the information is obtained, analyzed and relayed to the 
caregiver or back to the user enabling instantaneous feedback.  
1.3.2 ‘Traditional’ sensors- Point of Care (POC) diagnostic devices 
Predating the ‘digital’ sensors, there is a generation of sensors developed for 
POC invitro diagnostic applications. In fact, the earliest POC sensor was the urinalysis 
dipstick embedded with a pH dye for urinary protein measurements (1957) and the first 
glucose sensor was elaborated in 1962.[15] Since then there have been many sensors 
developed and the most common ones in use today include tests for pregnancy, glucose 
levels, cholesterol, cancer, HIV, drugs of abuse, microbes like E. coli and H. pylori 
etc.[1] Some of the targets for sensing includes metabolites such as glucose, 





for blood chemistry uses electro-chemical methods for detection of various blood 
components.[17] Proteins including enzymes and antibodies are the most common of 
all target molecules in POC applications with the most famous tests include pregnancy 
sticks through detection of human chorionic gonadotrophin (hCG) and Ora Quick 
ADVANCE Rapid Antibody test for HIV. Nucleic acid diagnostics, also referred to as 
‘molecular diagnostics’ uses nucleic acid sequence recognition as the mode for 
detection; whole cell both human[18, 19] and microbial[20] are also used as targets; 
small molecule drugs for abuse or contaminants in foods are also determinants of POC 
assays.[21] Mode of detection in POC assays include electro-chemical detection (as in 
the case of glucose sensor that is mass produced in the order of billions/year) and 
optical methods (used in lateral flow assays for pregnancy and fluorescent assays, 
produced in millions per year). Under electro-chemical detection techniques, there are 
amperometry, potentiometry, impedance measurements.[22, 23] Under optical 
methods, fluorescence[24], fluorescence resonance energy transfer (FRET) [25], 
luminescence[26], absorbance, surface plasmon resonance, light scattering techniques 
including rayleigh, mie, geometric, raman etc.[1] More sophisticated methods like 
magnetic particle detection using spin-valve methods are also used for single molecule 
detection. 
1.3.3 Fabricating enzyme for bio-device communication 
A typical biosensor is a device that combines a bio-logical component with an 





electric signal compatible with electronic circuits. An enzyme is the most preferred 
choice for bio-component assembly onto the electrode due to its molecular recognition 
capability and enzyme electrodes are one of the most versatile and well-studied of all 
biosensor types. Most of the current generation of enzyme electrodes have single 
enzyme (mostly oxido-reductases) immobilized on the electrode surface. While these 
enzymes have high direct electron transfer coefficients (DET) and better sensitivities, 
they reduce the range of analytes that can be detected.  
If methods of assembling multiple enzymes are ironed out, multi-enzyme 
cascade capable of detecting a wide range of analytes and converting into electroactive 
species could be assembled on electrode surface. Some existing methods and materials 
available for enzyme assembly onto sensors are detailed below. 
 





Scheme indicating different strategies used for enzyme immobilization. (Image 
adopted from Sassolas et. al.[27])  
1.3.3.1 Entrapment 
Entrapment is the most benign method for enzyme assembly. However, 
enzymes leach out due to the porosity of the matrix. Some of the materials used for 
entrapment and the enzymes immobilized are listed below. Electro-polymerization 
with naturally soluble electro conductive monomers like polypyrrole (PPy) are used for 
entrapment of enzymes. Glucose oxidase (GOD)[28], nitrate reductase[29], horse 
radish peroxidase based levetiracetam sensor[30] are some of the examples of enzymes 
immobilized. Polyaniline is another molecule used to immobilize enzymes like 
xanthine oxidase[31], tyrosinase.[32] Most of the sensors had long shelf life and 
produced repeatable results. Amphiphilic network comprising hydrophilic poly(2-
hydroxyl acrylate) (PHEA) and a hydrophobic phase of polydimethylsiloxane (PDMS) 
was used to trap horse radish peroxidase (HRP) to detect butylhydroxyperoxides.[33] 
Photo polymerization of poly(vinyl alcohol)-bearing styrylpyridinium (PVA-SbQ) 
groups are used for fabricating alcohol dehydrogenase in PVA-SbQ for an 
ampherometric ethanol biosensor.[34],[35] Sol-gel with tetramethoxysilane (TMOS) 
and tetramethoxysilane (TEOS) is another method in assembling enzymes. The 
disadvantage of this method is the extreme acidic or alkaline pH conditions and the 
short shelf life of the matrix.  
Polysaccharide based hydrogels including chitosan, alginate and agarose have 





gels are biocompatible [36, 37] but enzymes can leach out of the matrix with time 
leading to loss in sensitivity of the sensor. Chitosan is another example where 
Tyrosinase[38], glutamate dehydrogenase[39] have been immobilized. Carbon 
nanotube(CNT)-chitosan composites have been used as well to detect lactate[40, 41], 
ethanol[42], and cholesterol.[43] CNT is found to increase conductivity of matrix and 
CNT-chitosan on carbon electrodes have been used with high sensitivities. Agarose is 
another polysaccharide that dissolves in heat. Enzymes can be mixed with heated 
agarose solution and cast on electrodes (example: tyrosinase[44]). Here again, due to 
the porosity of the matrix, enzymes can leach out and to prevent that, enzymes have 
been crosslinked to beads and immobilized in agarose gels.[45] 
1.3.3.2 Adsorption 
The easiest means to immobilize proteins onto electrodes is through non-
specific adsorption where enzymes are bound through weak hydrogen bonds or van der 
Waals interactions. The drawback with it is that enzymes desorb from support due to 
changes in temperature, pH, ionic strength leading to poor life and storage stability. 
Lactate dehydrogenase was immobilized to polyaniline films by physical 
adsorption.[46]  
1.3.3.3 Crosslinking 
Crosslinking via glutaraldehyde is another method by which enzymes can be 
immobilized. The drawback of this method is that enzymes are non-specifically 
crosslinked to each other leading to reduced enzyme activity. Conversely, since the 





Cholesterol dehydrogenase, tyrosinase etc. have been used in this method to 
immobilize onto various supports like Nafion-Meldola blue modified screen printed 
electrodes[47], zinc oxide nanotube-modified electrode.[48]  
1.3.3.4 Covalent immobilization 
Enzymes have been covalently attached to the solid supports through activation 
of amine or carboxylic acid groups on solid supports. Activating agents like 1-ethyl-3-
(3-dimenthylaminopropyl) carbodiimide (EDC) in conjunction with N-
hydroxysuccinamide (NHS) have been used to targeting amine groups in the enzymes. 
Numerous sensors including sensors for cholesterol[49], glutamate[50] are fabricated 
using this approach. Self-assembled monolayers containing of long aliphatic carbon 
chains terminating with thiol groups have been used to self-assemble on solid supports 
and the terminal group is functionalized with enzymes using some of the previously 
described chemistries. Conversely enzymes have been engineered with cysteines and 
covalently assembled onto gold.[51]  
1.3.3.5 Affinity 
Enzymes have been immobilized on biosensors using affinity between specific 
functional group/moieties and activated supports. Advantage of this method is the 
control over enzyme conformation during immobilization onto solid supports. The 
most common affinity based chemistry used for enzyme immobilization is through 
biotin-streptavidin chemistry[52] or His peptide tag.  Various enzymes have been 





electrode surface using some of the above-mentioned materials like PVA-SbQ, 
polyaniline and polypyrrole and enzymes are reversible bound to metal chelators.  
1.3.3.6 Important design considerations for enzyme assembly 
The choice of enzyme, immobilization technique, materials used for 
immobilization, transducer and detection modality all play a vital role in biosensor 
sensitivity and stability. While physical absorption is the easiest method for 
immobilization, there is enzyme desorption. Entrapment is the least prohibitive 
approach for enzyme immobilization but enzymes can escape through the porous 
matrix. Crosslinking through glutaraldehyde provide tight assembly of enzymes to 
electrode surface but can be non-selective and reduce enzyme activity. Affinity 
chromatography based approaches can provide selective crosslinking put generally 
require engineering of proteins. In addition to this, the type of materials, physical and 
chemical conditions employed for enzyme immobilization can determine the overall 
efficiency of enzyme assembly.  
All these factors get compounded when multi-enzyme cascades are assembled. 
Enzyme stoichiometries accounting for relative enzyme activities, spatial 
arrangements, thermodynamic and kinetic conditions for cascade reactions are all some 
of the factors that needs to be considered. Some of the concerns in building multi-
subunit complexes are discussed in the Chapter 2 of this work that involves 
development of modular construction approach by which multi-subunit enzyme 





Next, I focus on using the modular construction approach detailed in Chapter 
2 of this thesis for integration of biological components with electronic components. 
To integrate the two class of components, an interface material capable of assembling 
on abiotic electronic surface and presenting various functional groups for conjugation 
of bio-components are required. In Chapter 4, I focus on virus like particles (VLP) 
and its use as 3D scaffolds for presenting enzyme cascades on electronic surfaces.  
1.4 Virus as interfacial materials at bio-electronic interface 
VLPs are a class of biomaterials containing protective coat proteins called 
capsids that self-assemble from few components into large nanoparticles with distinct 
size and shapes. Knowledge of the structure of viruses has enabled extensive 
engineering, both genetic and chemical, to display unique features with precise control 
over their spatial distributions.  
1.4.1  Genetic modification of Viruses  
Various genetic modifications are introduced both on the inside and as well as on the 
outside of both viruses and VLPs. Hepatitis B Virus has been genetically engineered to 
retain cargoes within the capsids. Cargoes are genetically fused to the termini of capsid 
subunit that is oriented towards the inside of the capsid.[53] VLPs. have also been 
genetically modified to display cargoes on the outside (GFP[54] and FLAG tag[55]). 
However, direct genetic fusion of large cargoes with capsid subunits may affect the 





1.4.2 Conjugation strategies for virus particles 
As an alternative to direct genetic fusion, various amino acids are introduced 
into VLPs that enable conjugation of cargoes post the assembly of the particles. 
Sortases have been used to covalently attach different proteins together. Bioorthogonal 
conjugation motifs that are recognized by different sortases are introduced into viral 
capsid structures for orthogonal conjugation of multiple cargoes.[56] Several amino 
acids are genetically introduced to enable chemical conjugation of cargoes. 
Introduction of cysteines at N termini of coat proteins is a preferred choice for 
sulfhydryl group based conjugation and for gold interactions.[38, 57-59] Lysines for 
NHS based assembly, aspartic acid for carbodiimide based activation, cysteines for 
Michael type addition, tyrosine for azo coupling etc. are some of the examples of amino 
acids being introduced for chemical conjugation.[60] Non-canonical amino acids such 
as O-methyl tyrosine, p-azidophenylalanine, p-acetylphenylalanine, p-benzoyl-
phenylalanine, 3-(2-naphthyl) alanine, p-aminophenylalanine are introduced at amber, 
ocher, opal codons for conjugation.[61-64] 
1.4.3 Virus particles as cages 
Viruses like Bacteriophage P22 and Cowpea Chlorotic Mottle Viruses (CCMV) 
have been exploited to act as cages for encapsulating a variety of molecules including 
drugs and nucleic acids for drug delivery applications and enzymes for nanoscale 





forms ‘Wiffleball’ structure with small nanometer scale holes in capsids enabling 
cargoes to move in.[65] CCMV virus capsids can undergo assembly and disassembly 
in response to pH or ionic strengths incorporating various cargoes.[66]  
1.4.4 Biocatalyst application 
Enzymes have been co-expressed with coat proteins leading to accumulation of 
enzymes inside VLPs. Lipases were the first to be displayed on PVX.[67] Later, in one 
study related to CCMV virus, capsids were engineered with a coiled coil linker that 
enabled assembly of enzymes PalB to capsid first and later capsids self-assembled into 
a full particle engulfing the enzymes.[68] P22 phage has been shown to encapsulate 
alcohol dehydrogenase. Coat proteins and enzymes were co-expressed at the same time 
and coat proteins engulfed the enzymes during its self-assembly into capsids.[65, 69] 
Even multi-enzyme complexes have been inserted in this fashion.[70] 
1.4.5 VLPs as materials for biodevice assembly 
Defined size and shape of the viruses in nanoscale makes viruses attractive for 
use as a material for biodevice assembly. Mineralization of high aspect ratio virus 
particles such as Tobacco Mosaic Virus(TMV) and M13 bacteriophage has led to 
development of nanowires. Self-assembly properties are exploited to assemble 
nanoscale viruses into mesoscale wire structures [56, 71-73] and for liquid crystal 
displays.[74, 75] Bio-batteries is another example for viruses being used as materials 





well as cathode for mineralization of carbon, Mn2+ and other metal ions and used in Li-
ion and Na-ion batteries.[56, 76-80]  
 
Scheme 1-4 Tobacco Mosaic Virus- Virus Like Particle(TMV-VLP) as materials for 
enzyme assembly at bioelectronic interface 
Nano scale TMV-VLP structures engineered with cysteines at the N termini enable 
self-assembly onto gold. The C termini of coat proteins can be exploited to genetically 
engineer functional proteins or peptides. Various cargoes can be loaded on the inside 
as well as outside of the particle.   
1.4.6 Viruses as materials for sensors 
 Combining the dual properties of viruses as materials for electronic integration 
as well as genetically modified biomaterial, new biosensors are being designed. A layer 
of M13 phage on an impedance sensor was used for detection of prostate cancer 
specific antibodies and antigens.[81] TMV virus particles in combination with 
polyaniline have been used as a thin film sensor for detection of methanol and 





gold surfaces. TNT binding peptides increased the local concentration of TNT at the 
electrode surface resulting in increased faradaic current.[83] 
1.4.7 Enzymes on VLPs for biosensing 
With extensive literature available on protein conjugation, enzymes are 
integrated with virus particles for biosensing. Two enzyme cascade containing glucose 
oxidase and horse-radish peroxidase has been assembled on the surface of cowpea 
mosaic virus[84] and TMV for detection of glucose.[85] Capitalizing on virus particles 
ability to integrate with electronics, multi-enzyme cascades can be assembled on virus 
particles for fabrication of novel electro-chemical and other sensor types. In this work, 
I focus on using TMV based virus like particles as 3D scaffolds to present sensor 
enzymes on electronic surfaces. I utilized the mTG mediated conjugation approach 
detailed in Chapter 2 to build a three-enzyme cascade on TMV-VLPs in Chapter 
4.  
1.5 Closing the loop from electronics to biology 
The critical segment in building closed loop systems is the transduction of 
information from electronic circuits to biological systems. Functional electrical 
stimulation (FES), a technique where low levels of electric current are applied across 
an intact nerve to target and restore impaired body parts is one such example of 





87] In this work, I would like to focus on mediating bio-electronic communication 
outside the purview of neuromodulation.  
1.5.1 Bio-electronic communication under microbial context 
Under the microbial context, bio-electronic communication may refer to bi-
directional electron flow with microbes producing electrical signals in response to a 
specific stimulus as well as application of electrical signals to microbes to elicit a 
designed genetic response.  Microbial fuel cell (MFC) falls under the first category of 
bio-electronic communication where microbes produce electric current. MFC’s are 
well characterized systems where microbes consume organic compounds to generate 
electrons that are passed over to the anode of a battery. [88-90] Some of the well 
characterized species in MFC’s include Geobacter sulfurreducens and Shewanella 
oneidensis.  Genetic studies have characterized the pathways that enable electron flow 
and c-type cytochromes are identified to be the major player in electron transport.[91-
93] Pili can also help in transfer of electrons to the electrode.[94] Genes that code for 
the proteins involved in electron transport to the electrodes are genetically engineered 
into non-electrogenic host such as E. coli to make them electrogenic.[95, 96]  
1.5.2 Electrogenicity in bio-electronic communication 
However, the electron flow in reverse direction from electrodes to cells is not 
well characterized. Very first report on electrical stimuli responsive promoters in E.coli 





expression profiles were studied.[97] Around 8 genes were upregulated and 42 were 
downregulated out of the total 1512 genes. Mild electrical induction in Saccharomyces 
cerevisiae led to elevated intracellular Ca2+ concentrations.[98]  In the recent past, two 
synthetic biology devices have been published where electrical signals are used to drive 
gene expression from electrogenetic promoters.[99, 100] First device involved 
mammalian cells engineered with aldehyde responsive promoters. Electrical signals 
were used for electrochemical oxidation of ethanol to aldehyde and drive transgene 
expression from aldehyde promoters.[100] Second device displayed electrochemical 
activation of oxidative stress response promoter SoxRS in bacteria to drive transgene 
expression.[99] More details about the SoxRS system are in Chapter 5. 
1.5.3 Synthetic transcription factors 
A significant capacity addition in the field of electrogenetics would be the 
ability to target specific genes and regulate host transcriptional regulation using electric 
signals. Several synthetic transcription factors (TF) that enable controllable and tunable 
regulation of genes have been established. Zinc-Finger proteins (ZFP’s), Transcription 
factor like effectors (TALEs) and CRISPR-Cas9 systems are some of the TF’s that 
enable transcriptional regulation[101]. However, extensive protein engineering that is 
required for programming ZGP and TALEs makes them unattractive. On the other 
hand, the CRISPR-Cas9 based transcriptional factors are easily programmable to target 





integration of the CRISPR-Cas9 system with electrogenetic SoxRS system to 
electrically modulate bacterial transcriptional regulation.  
 
1.6 Summary of aims and contributions 
In chapter 2 titled ‘Modular Construction of Multi-Subunit Protein Complexes 
using engineered tags and microbial transglutaminase’, I developed a facile method to 
assemble multi-subunit enzyme complexes for controlling metabolic flux as well as for 
construction of multifunctional complexes. This chapter was primarily designed and 
executed by me with the guidance from my advisor Dr. Bentley and was published in 
Metabolic Engineering[103] and Data in Brief[104].  
In chapter 3 titled ‘Facile Two-step Enzymatic Approach for Conjugating 
Proteins to Polysaccharide Chitosan at an Electrode Interface’, I developed a 
transglutaminase based conjugation approach to assemble proteins and enzyme 
cascades on chitosan coated microchips. This chapter was primarily designed and 
executed by me with the guidance from my advisor Dr. Bentley and was published in 
Journal of Cell and Molecular Bioengineering[105].  
In chapter 4 titled ‘Engineered Tobacco Mosaic Virus -Virus Like Particles 
(TMV-VLP) as self-assembling 3D scaffolds for multi-enzyme assembly using mTG 
mediated conjugation’, I developed TMV-VLP as self-assembling 3D scaffold to 
assemble a three-enzyme cascade on microchips. This chapter was primarily designed 





VLP’s and Adam Brown from Culver Lab helped in the initial purification of particles 
and electron microscopy.   Dr. Yi Liu from Payne Lab helped in the setting up of Quartz 
Crystal Microbalance (QCM) experiments. This chapter will be submitted for 
publication by March 2018. 
In chapter 5 titled ‘Integration of CRISPR with electrogenetic promoter systems 
for transcriptional regulation’, I integrated the CRISPR-Cas9 based transcriptional 
regulation systems with the SoxRS electrogenetic promoter systems. This chapter was 
primarily designed and executed by me with the guidance from my advisor Dr. Bentley. 
Kristina Theresa Stephens, a graduate student in the Bentley Lab performed the AI-1 
assays in the Appendix 1 and Eric VanArsdale, a graduate student in the Bentley Lab 
made the chitosan-alginate capsules in the Appendix 1. This chapter will be submitted 







Chapter 2 Modular Construction of Multi-Subunit 
Protein Complexes using engineered tags and 
microbial transglutaminase 
 
This chapter is adopted from the following publications with permission 
Bhokisham N. et al, Modular construction of multi-subunit protein complexes using 
engineered tags and microbial transglutaminase, Metabolic Engineering, Volume 38, 
November 2016, Pages 1-9.[103]  
and 
Bhokisham N. et al, Data on biochemical fluxes generated from biofabricated enzyme 
complexes assembled through engineered tags and microbial transglutaminase, Data 
in Brief, Volume 8, 2016, Pages 1031-1035.[106]  
2.1 Introduction 
 
Biofabrication is the assembly of biological components such as cells, tissues, 
proteins, polysaccharides, lipids, nucleic acids etc., using biological means or mimics 
thereof for the creation of devices and other functional constructs. These biological 
structures are often integrated within microfluidic and microelectronic systems where 
they execute an array of functions, including the biosensing of environmental samples 
[107-109]  and toxicity and efficacy testing in lab-on-a-chip devices [19, 110-112].  
Advances in genetic and protein engineering have enabled the design and construction 
of pathways that catalyze a diverse range of reaction products in an efficient manner 





cells where enabling cofactors and effector molecules are also nearby. These networks, 
called metabolons, mediate a variety of enzymatic reactions and their construction and 
assembly can involve extensive metabolic engineering of the host.  In vitro methods 
often feature simplified product recovery and minimal substrate toxicity [115, 116], but 
can suffer by providing limited access to needed co-factors and other effectors. 
Methods used for the in vitro construction of metabolons are many, including co-
localization of enzymes via covalent crosslinking and entrapment of enzymes into 
nanostructures or containers [117, 118].  Additionally, immobilization on solid 
supports, such as protein scaffolds where enzyme modules are engineered for selective 
affinity to the scaffolds have appeared [119]. While advantages of crosslinking over 
entrapment include active site proximity and reduced resistance for substrate or product 
transport, there are few means to enable domain-specific assembly of component parts.  
Genetic methodologies can provide control over subunit arrangement and 
conformation[120], some require long linker peptides as well as extensive selective 
binding domains.   
In this work, I enable metabolon construction by engineering subunits with simple, 
short linker tags (5-7aa). This linking system exploits the specificity of the crosslinking 
enzymes for assembly so that the tags provide for orientation of the to-be-assembled 
subunits. I demonstrate this concept by the assembly of two bacterial quorum sensing 
(QS) synthases, S-Ribosylhomocysteinase (LuxS) and S-Adenosyl homocysteine 
nucleosidase (Pfs). I further connected these enzymes to protein G, a Streptococcal 





convert S-Adenosyl homocysteine (SAH) to homocysteine (HCY) and autoinducer-2 
(AI-2), a QS signal molecule. I then targeted the protein G-QS enzyme complex to 
bacterial cells using anti-E.coli antibodies leading to biochemical reactions on surface 
of bacteria and site-specific delivery of the autoinducer to the cells.  
In Figure 2-1 Schematic of mTG-mediated protein construction. depict the overall 
scheme for protein assembly. In Figure 2-1A, the first subunit is selectively bound to 
a solid support (Co2+ resin) via an N-terminal hexahistidine tag. Then, the second 
subunit engineered with lysine tags on both termini is covalently grafted using mTG 
onto the glutamine tag of the first subunit (Q tag). The reaction mechanism is shown in 
Figure 2-1B. Then, in Figure 2-1A, I depict linkage of a third subunit comprised of a 
Q-tag also on the C-terminus for the eventual assembly of many structures covering 
the bead. In all cases, microbial transglutaminase (mTG) is used to graft adjacent 
glutamine and lysine residues forming a trans-peptide bond [121-128]. The linker tags 
engineered onto subunits Pfs, LuxS and Protein G were either hepta-lysine (7aa) and/or 
penta-glutamine (5aa) [124] and crosslinking was mediated by the addition of microbial 
transglutaminase (mTG). Schemes for each protein, its tags, and cleavage of the 
histidine tags are included in Figure 2-1C. After using these methodologies to make 
complexes, I evaluated enzymatic flux to produce AI-2. I note that LuxS can be rate 
limiting [129, 130]; I altered stoichiometry to generate a Pfs-LuxS-LuxS complex, our 
hypothesis being that the overall rate might be increased. Finally, as noted above, I 
added a protein assembly domain, Protein G thereby creating Pfs-LuxS-Protein G 





antibody to recognize bacteria.  I targeted the released complexes to bacterial cells and 
elicited quorum-sensing responses from bacterial populations; our hypothesis being a 
change in phenotype that was correlated to the AI-2 synthesis flux through the complex.  
 
Figure 2-1 Schematic of mTG-mediated protein construction.  (A) Scheme 
depicting construction of three subunit protein complex on beads using engineered tags 
and mTG. His tags are in black, Q tags in gray and K tags in purple. (B) Scheme for 
reaction catalyzed by mTG between glutamine of first subunit and lysine of second 
subunit to form a transpeptide bond between subunits. (C) Engineering subunits with 
lysine and glutamine tags. All subunits are engineered with His tags and enterokinase 
(EK) mediated cleavage is used to remove His tags in all subunits except the first 





2.2 Materials and Methods 
2.2.1 Plasmids and Strains 
 
All plasmids and strains used in this study are listed in Table 2.1. I performed all 
cloning and transformations as per standard protocols [131].  Clone designation 
includes the tag and the employed terminus (e.g., pTrcHisA-7K-LuxS-7K indicates a 
LuxS vector with a 7-residue lysine tag at both the N- and C- termini, the expressed 
protein is denoted KLK). All primers (Integrated DNA Technologies) used for 
engineering of proteins in this study are summarized in Table 2.2. All the engineered 
DNA sequences utilized Xho-1 and EcoR1 restriction sites at 5’ and 3’ ends of the 
DNA fragments. For cloning purposes, DNA was ligated with TOPO Blunt II vector 
(Life Technologies) and transformed into TOP 10 cells. Plasmids were sequenced at 
the DNA Core Facility of the Institute for Bioscience and Biotechnology Research. For 
expression, genes were inserted into pTrcHisA plasmid (Lab stocks) and transformed 
into respective expression hosts. I transformed LuxS containing clones into RK 4353 
(pfs-) for expression of LuxS proteins and the BL21 (luxS-) for expression of Pfs 
proteins. A His6 tag is part of the pTrc plasmid backbone; all expressed proteins have 
N-terminal His tags. Importantly, all His tagged proteins also contain an enterokinase 
cleavage site located between the His tag and the K/Q linker tag in the primary 






Table 2-1: Strain names and nomenclature  




BL 21 luxS- B strain, F-omp T[dcm] [Ion] hsd S(rB -, 
MB-) gal, ΔluxS 
Lab stocks 
RK 4353 pfs- RK 4353 strain, Δpfs(8-226):: kan Lab stocks 
CT 104 W3110 strain, ΔlsrFG, ΔluxS [132] 
   
Plasmids   
pTrcHisA-LuxS-7K pTrc derivative, expression of LuxS 




pTrc derivative, expression of LuxS 
with lysine tag at N and C termini, Apr 
This study 
pTrcHisA-LuxS-5Q pTrc derivative, expression of LuxS 
with glutamine tag at C termini, Apr 
[124] 
pTrcHisA-Pfs-7K pTrc derivative, expression of Pfs with 
lysine tag at C termini, Apr 
[124] 
pTrcHisA-7K-Pfs-7K pTrc derivative, expression of Pfs with 
lysine tag at N and C termini, Apr 
This study 
pTrcHisA-7K-Pfs-5Q pTrc derivative, expression of Pfs with 
lysine tag at N and glutamine tag at C 
termini, Apr 
This study 
pTrcHisA-Pfs-5Q pTrc derivative, expression of Pfs with 




pET 200 derivative, expression of 
Protein-G with glutamine tag at C 
termini 
Lab Stock 
pCT 06 pFZY1 derivative, containing lsrR and 
lsrR binding region with T7RPol, Apr 
[124] 
pET-200 DsRed pET200 derivative, expression of 
DsRed, Knr 
Lab Stock 

























EcoR1 site and K tag 
K-Pfs-K 
(Reverse primer) 
5’gccttgaattctatttttttttttttttttttttgccatgtgcaagtttctgc3’ Xho1 site and K tag 
K-Pfs-Q 
(Reverse primer) 
5’gccttgaattctattgctgttgctgctggccatgtgcaagttt3’ Xho1 site and Q tag 
2.2.2 Protein Purification 
 
I grew the expression hosts in LB media (Sigma-Aldrich) and induced at OD600 of 
0.4 with 1 mM IPTG (Sigma). After 4 hrs at 30°C, cells were centrifuged and 
resuspended in 15 mL of 10 mM phosphate buffered saline (PBS), pH 7.4 (Sigma) and 
sonicated for 15 min. Post sonication, lysed cells were centrifuged, soluble proteins 
were retained and purified via HiTrap columns (GE Healthcare). Purified proteins were 
subsequently dialyzed with PBS and stored at -20° C. I selectively removed His tags 
by incubation with enterokinase overnight at 4° C as per manufacturer’s specifications 
(EK-Away, Invitrogen). To ensure robust transglutaminase reactions, I rewashed all 
proteins using a second round of Co2+ resin. This served as a quality control to ensure 







2.2.3 Conjugation of Engineered proteins using mTG 
 
I aliquoted 20µl of Talon Metal Affinity resin (Clonetech) in a centrifuge tube and 
centrifuged to remove residual buffer. To the pelleted resin, I added 10 µl His-tagged 
protein (concentration varied as noted) with C-terminal ‘Q’ tags. These were mixed 
well to mediate attachment of ‘His’ tagged proteins to resin. Next, I added 10 µl of 
mTG (Ajinomoto, enzyme activity of 12 U/mg) at concentrations to reflect the desired 
molecular ratio between reacting protein and mTG (indicated as β), and mixed well at 
RT. Immediately, I also added 10µl of reacting ‘K’ tagged protein (concentration varied 
with experiments) to the protein-resin mix and incubated with shaking at room 
temperature for 60 min. After incubation, I washed the resin 3x with PBS to remove 
unbound proteins and residual mTG. In cases where a third subunit was attached, I 
added another round of subject protein with reaction mixtures exactly as before. To 
elute the conjugated proteins, I treated the resin with PBS+200mM Imidazole for 10 
min on ice and later centrifuged to remove the eluted protein complexes from beads.   
2.2.4 Measurement of Homocysteine using Ellman’s Assay and 
Cyclic Voltammetry 
 
I measured homocysteine using calorimetric Ellman’s assay as described in [112] 







2.2.5 Construction of Antibody-Protein complexes 
 
I built the Pfs-LuxS-Protein G complexes on beads as described above. To 
characterize quantities, I added 10 µg of FITC-labelled anti-E.coli antibodies (AbD 
Serotec) to the protein G-enzyme complexes on the beads and incubated at RT for 30 
min. I washed three times using PBS to remove non-specifically or unbound antibodies. 
Later I eluted the antibody-bound Protein G-enzyme complexes from beads as 
described before and measured their fluorescence using a plate reader (SpectraMax). 
The final reaction volume was 200 µl for fluorescence measurements. 
2.2.6 Flow Cytometry measurements for targeted enzyme reactions 
 
To ascertain deployment capabilities of our constructed complexes, I eluted the 
Protein G-Pfs-LuxS complexes from beads, incubated them with FITC labelled anti-
E.coli antibodies for 30 minutes, and quantified them via fluorescence microscopy and 
FACS. I grew E. coli CT104 cells [132] with pCT06 and pET-DsRed plasmids (Table 
S1) overnight at 30°C (they can respond to AI-2 by inducing DsRed expression [132]). 
I pelleted 0.1 OD of cells, incubated with 5% BSA for 30 min, and washed three times 
with PBS. I next incubated the cells with Antibody-Protein G-Enzyme complexes for 
30 min and washed 3x with PBS to remove unbound antibodies and enzyme complexes. 
I pelleted the cells and incubated them with DPBS (Dulbecco’s Phosphate buffered 





and analyzed using flow cytometry. I used a minimum of 20,000 cells for analysis of 








2.3.1 Reactivity of engineered K and Q tags mediated by mTG 
 
I first studied the effect of engineered tags on the crosslinking of proteins freely 
suspended in buffer. In Figure 2-2, I incubated mTG with enzymes LuxS (L) and Pfs 
(P) without linker tags (Figure 2.2 Panels 1 and 2), LuxS with C-terminal K and Q tags 
(Panels 3 and 4), and Pfs with C-terminal K and Q tags. I used a β of 100 (β, the molar 
ratio of reacting subunit to mTG) and incubated at RT for 0, 15, 30 and 60 minutes 
(i.e., four lanes are depicted). I stopped the reactions via heat denaturation at 95°C for 
5 minutes and assayed crosslinking by SDS-PAGE and Western blot using anti-His 
antibodies. I note that untagged LuxS and Pfs (L and P, respectively) exist as 
homodimers in their native states [134, 135]  and without mTG treatment appear as 
monomers on gels under denaturing conditions. With mTG, native L and P formed 
small quantities of dimers after ~30-60 minutes (Figure 2.2 panels 1 and 2). Next, I 
incubated ‘K’ and ‘Q’ tagged LuxS (LK and LQ) with mTG under identical conditions 
as the native enzymes (Figure 2.2 panels 3 and 4). As noted in Methods, the prefix and 
suffix indicate tags at N and C termini, respectively. For example, LK indicates LuxS 
with ‘K’ tag at the C terminus. While LK formed dimers more readily than native L, LQ 
actively cross-linked to form oligomers. The arrows indicate dimer, trimer and tetramer 
bands; the quantity of each increased with incubation time. Interestingly, Pfs with ‘K’ 





but with less oligomerization for the ‘K’ tag. While only showing two proteins, these 
data suggest the ‘Q’ tag is advantageous for mTG-mediated protein oligomerization. 
That is, ‘Q’ tagged protein cross-linked to itself more than untagged native proteins 
and those with ‘K’ tags.   
 
Figure 2-2 mTG mediated crosslinking of enzymes in solution.   Western blots 
indicating the mTG-mediated crosslinking of soluble enzymes (duration, 60 min). 
Panels 1-6 indicate crosslinking of proteins L, P, LK, LQ, PK and PQ, respectively. Each 
panel has 4 lanes indicating 0, 15, 30 and 60 min reactions. Arrows indicate the 
monomers, dimers and trimers formed. 
I next studied how β (molar ratio of the subunits to mTG) played a role in 
determining the extent of crosslinking of the engineered proteins. Figure 2-3 depicts 
mTG-mediated crosslinking of PQ using mTG with varied β at two time points, 15 and 
60 minutes. With β =1 (same amount of protein as mTG), a smear of PQ was formed in 
both samples, whereas with β = 100 I observed well-defined dimers and trimers which 
increased with time. With β = 1000, PQ was relatively unreactive at 15 minutes and 
formed dimers after 60 min. Similar time and molar ratio profiles of other engineered 
proteins are provided in Figure 2-4. In sum, these results indicate that β, the ratio of 





mechanisms by which this appears to function are unclear, but the trends observed 
could be anticipated (e.g., more enzyme, more crosslinking).   
 
Figure 2-3 Kinetics of mTG mediated crosslinking of PQ. Western blots indicating 
progression of crosslinking of soluble PQ at 15 and 60 min with different β’s (β is the 
ratio of PQ to mTG). 
 
Figure 2-4 Kinetics of mTG mediated crosslinking of LK, LQ and PK.  Western blots 
indicating progression of crosslinking of soluble LK, LQ and PK at 15 and 60 min with 
different β’s (β is the ratio of PQ to mTG). Three lanes in each panel indicates β of 1000, 
100 and 1 respectively. Left panels indicate LK and LQ crosslinking at 15 and 60 
minutes. Right panels indicate PK crosslinking at 15 and 60 minutes. Arrows indicate 





I next tested the kinetics associated with conjugating two different enzymes 
together and whether the linked AI-2 synthesis pathway could function to make AI-2. 
In this case, I employed both ‘Q’ and ‘K’ tagged proteins. I also note that Pfs-LuxS 
chimera have been expressed as an intact fusion protein in E. coli and when purified 
and resuspended in buffer with SAH, produces AI-2 [112]. Thus, the test here evaluates 
whether LuxS and Pfs can be crosslinked using the engineered ‘K’ and ‘Q’ to produce 
AI-2.  Both PQ and LK were reacted with mTG with a β of 100 for 60 minutes (Figure 
2-5). I found a preponderance of homodimers, rather than heterodimers when cross-
linked in solution.  
 
Figure 2-5 Crosslinking of Pfs and LuxS in solution using mTG.  Crosslinking of 
LK and PQ mediated by mTG in solution is indicated with four time points (0 to 60 min 
in lanes L1-L4, respectively). 
To explore whether I could promote heterodimer formation and selectively remove 
homodimers, I first assembled one ‘anchor’ protein on Co2+ affinity resin using the N-
terminal His tag, the aim being to restrict access to the N-terminal fusion tag. I then 





associated fusion tags. For this, the second subunit was treated with enterokinase (EK) 
to remove N-terminal His tags (Methods), precluding subsequent His-mediated 
assembly on the Co2+ resin. After reaction with mTG for 60 minutes, I washed the beads 
3x with PBS to remove unreacted subunits and mTG. I then eluted the cross-linked 
subunits from beads via ion exchange (Methods) and assayed using Western blots. In 
lane L1 of left blot in Figure 2-6, unreacted PQ was loaded as control. In lane L2, I 
reacted PQ with mTG for 60 min with a β of 100 and observed oligomerization as in 
the case of reactions in solution (Figure 2-5). In L3, I show heterodimer formation on 
the beads by the creation of PQ-LK.  That is, to the bead bound first subunit, PQ, a second 
subunit engineered with ‘K’ tags were added (in this case KLK; LuxS with ‘K’ tags at 
both N and C termini) along with mTG at β of 100. PQ-KLK heterodimers were revealed 
as a lighter band than the homodimers (e.g., PQ2). In addition to PQ-KLK, I observed 
PQ2-KLK heterotrimers, all indicating crosslinking of Pfs and LuxS enzymes. Control 
reactions where the second subunits had no engineered tags yielded no heterodimers 
indicating the importance of engineered lysine tags to mediate heterodimer formation 
(Figure 2-7). As expected, the lack of mTG for crosslinking also yielded no 
heterodimers (Figure 2-7). Under these crosslinking conditions with β = 100, by image 
analysis I estimate that ~25% of Pfs enzymes were crosslinked to LuxS (Figure 2-8). 
The crosslinking percentage can be improved by employing β of 1. However, in this 
condition the ability to discern heterodimers and homodimers under denaturing SDS 
gel is diminished (as seen in Figure 2-3). To decrease side product formation, I 





(Figure 2-6, blot on the right). I observed a reduction in nonspecific product formation 
in comparison to when Gln tagged proteins were immobilized on the bead.   
 
Figure 2-6 Modular construction of multi subunit complexes.  (Left) Scheme 
depicting modular construction of protein complexes on beads. (Right) Samples were 
isolated and analyzed via Western blot (L1, L2 and L3). Controls including soluble PQ 





Figure 2-7 Controls of mTG mediated modular construction.   Western blot 
indicating controls for Figure 2-5. Lane C1 contains the PQ without mTG treatment. 





without mTG. Lane C3 contains PQ crosslinked to native LuxS (L) with mTG. Arrows 
indicate the monomers, dimers and trimers formed. MW indicates molecular weight. 
     
Figure 2-8 Estimation of formation of heterodimers through ImageJ. The two lanes 
L2 and L3 from Figure 2-5 (Left) are used to analyze relative percentages of various 
oligomers using ImageJ. Table (Right) indicates the relative percentages of various 
structures in each lane. Mean and standard error were calculated using 3 measurements 
from the same blot.   
In summary, these results indicated that lysine and glutamine rich tags engineered 
onto the C- and N-termini of the two AI-2 synthases enabled crosslinking, but 
additional measures (binding to Co2+ spheres) were needed to guide linkages to form 
heterodimers. That is, selective immobilization on beads when combined with 
engineered tags and mTG, lead to somewhat improved formation of heterodimers, but 







2.3.2 mTG mediated control of metabolic flux 
 
I next explored the capability of these assembled enzymes to mediate metabolic 
flux (in this study, I defined flux as the rate of product generated per unit time by the 
assembled complexes).  Pfs and LuxS are bacterial enzymes involved in the activated 
methyl cycle and act together to convert S-Adenosyl homocysteine (SAH) into 
homocysteine (HCY) and (S)-4,5-dihydroxy-2,3-pentanedione (DPD) in a two-step 
process [136] ultimately yielding autoinducer-2 (AI-2) which is normally secreted by 
bacteria (Figure 2-9). I hypothesized that (i) the engineering tags would not destroy 
activity, and (ii) that proteins coupled by mTG would retain activity providing complete 
pathway synthesis. Further, I hypothesized that the proximity of the coupled enzymes 
could provide efficient substrate utilization. 
 
Figure 2-9 Scheme of Pfs-LuxS and Pfs-LuxS-LuxS complexes using mTG to 
mediate biochemical flux.  
In Figure 2-10, I immobilized 3µM ‘Q’ tagged Pfs on Co2+ beads as before and 
crosslinked with 3µM of  corresponding ‘K’ tagged second subunit (LK) by mTG (as 





min and β = 1. As before, I washed the beads 3x with PBS to remove unreacted enzyme 
and mTG. I then incubated bead bound enzyme complexes with 1mM SAH at 37°C for 
60 min. I measured homocysteine (HCY) using a colorimetric assay (Ellman’s 
sulfhydryl assay, see Methods). Homocysteine levels were markedly different in 
samples with and without mTG. When coupled with Western oligomerization data, 
these results indicate that mTG-crosslinked LuxS and Pfs function to make 
homocysteine.    
 
Figure 2-10 Assembly of Pfs-LuxS complex on the bead  Pfs-LuxS complex 
assembled on the bead can mediate flux. Pfs enzyme is assembled on beads and LuxS 
is crosslinked to Pfs using mTG (with β = 1). After wash, the assembled Pfs-LuxS 
complex is incubated with 1mM SAH and HCY generated is measured biochemically 
through Ellman’s assay after 1 hour incubation at 37°C. 
I next studied if I could change the yield of homocysteine by varying the subunit 
quantities in the crosslinked complexes (Figure 2-11). With bead-bound PQ held 
constant, I varied the concentrations of LK and crosslinked exactly as before.  After 
washing 3x with PBS, the beads were incubated with 2mM SAH for 60 minutes and 
HCY generated was measured. Importantly, I found a linear increase in HCY generated 





performed exactly analogous experiments using native L (without ‘K’ tag), and there 
was no significant accumulation of HCY indicating minimal non-specific binding of 
the LuxS to either the resin or the loaded Pfs. This also indicated that mTG 
preferentially recognized ‘K’ and ‘Q’ tags more than any exposed lysine or glutamine 
residues on the enzyme subunits. Having demonstrated LK reacted with Co2+ 
immobilized PQ, I next studied how bi-tagged LuxS (KLK, LuxS with ‘K’ tag at both N 
and C termini) could crosslink to PQ.  Again, as before, I crosslinked KLK with PQ using 
mTG.  I then provided SAH and observed for HCY generated (Figure 2-14). 
Interestingly, the HCY doubled, perhaps suggesting an advantage to having ‘K’ 
residues on each end of the enzyme. Western blots (Figure 2-13) indeed showed 
enhanced crosslinking of KLK to PQ (relative to LK); correlating with HCY yields 
determined by Ellman’s assay.  
 
Figure 2-11 Increase in HCY obtained from crosslinking varying concentrations 
of LuxS to Pfs. Enzymes were incubated with 2mM SAH for 60 mins and HCY was 





In Figure 2-12, I sought to assemble Pfs-LuxS-LuxS trimers on beads to enhance 
LuxS activity relative to Pfs, thereby increasing the overall reaction rate. To the PQ-
KLK complex initially built on beads, I added LQ and mTG for a second round of 
crosslinking exactly as before, expecting that any unreacted lysine tags on KLK could 
crosslink to LQ. After washing 3x, I provided 1mM SAH, observed for HCY yields 
using Ellman’s assay after incubation for 60 min at 37°C.  As anticipated, putative 
three-subunit complexes enhanced the biochemical flux resulting in increased 
generation of HCY. Negative controls with non-tagged L exhibited no increase in 
homocysteine and importantly, an incremental increase in yield was observed as the 
second incubation with LuxS was performed with higher LuxS concentration (from 1.5 
to 3 µM). Subsequent increases in LuxS resulted in no net gain in reaction, suggesting 
matching of LuxS with Pfs activity. Also, I note that all three subunit complexes were 
built on the two-subunit complexes from the 3µM LuxS incubation, and in all cases the 
yields of all three subunit complexes were higher than the corresponding two subunit 
complexes on which they were built. As controls, I built analogous two and three 
subunit structures without mTG and all of them generated negligible yields of HCY 
indicating the crosslinking was mediated by mTG. Figure 2-15 depicts HCY 
generation for an extended duration (240 min) from different Pfs-LuxS complexes. In 
these data, the three-subunit complex (PQ-KLK-LQ) enabled faster reaction flux than the 
two-subunit complexes (PQ-KLK) which, in turn, were faster than the first PQ-LK 
complex. Controls for these experiments were again structures built without mTG and 






Figure 2-12 Construction of two and three subunit enzyme complexes on beads.   
Three subunit complexes are built onto two subunit complexes constructed with 3µM 
LuxS. Assembled complexes were incubated with 1mM SAH for 60 min and HCY was 
measured using Ellman’s assay. Trend lines denote non-linear regression fit using 
equation y=ymax (1-exp (-kx)). 
 
Figure 2-13 Western blot indicating the differences in crosslinking of LK and KLK 
to PQ.   Lanes C1 and C2 indicate controls. C1 is PQ assembled on the bead and 
crosslinked with mTG. Lane C2 is PQ with LK without mTG. Lane L1 is PQ crosslinked 
to LK using mTG.  Lane L2 is PQ crosslinked to KLK using mTG. Arrows indicate the 
monomers, dimers and trimers formed. MW indicates molecular weight. Pfs assembled 
on the bead is engineered with His tag at N termini. Anti-His antibodies are used in 








Figure 2-14 Differences in crosslinking between LK and KLK to PQ.   PQ -KLK and 
PQ- LK complexes are assembled on beads and incubated with 1mM SAH for 1 hour at 
37°C. Homocysteine generated is measured by Ellman’s Assay after 1 hour. Error bars 
indicate standard deviation with n=3. Regressed lines included denote linear best fit. 
 
 
Figure 2-15 Time course measurements of homocysteine from two subunit and 
three complexes.  Time course measurements of homocysteine from two subunit (PQ-





Assay. Error bars indicate standard deviation with n=3. Trend lines denote non-linear 
regression fit using equation y=ymax (1-exp (-kx)). 
Interestingly, results from western blots were inconclusive for trimer construction, 
suggesting non-conformationally assembled enzymes.  Thus, in Figure 2-16, I 
examined in more detail, the differences in HCY generated by the addition of third 
subunit. That is, I built two and three subunit complexes as before but in one case, I 
replaced the KLK with an inactive subunit (I KLK, obtained from periodic freeze 
thawing). The inactive subunit provided no enzyme activity, but should have retained 
its crosslinking capability. I built three-subunit complexes with the inactive LuxS as 
the second subunit exactly as before and compared HCY yields against controls. 
Specifically, I had a two-subunit inactive complex and a three-subunit complex built 
on the two subunit inactive complex without mTG. I provided these complexes with 
SAH and observed HCY in real time using cyclic voltammetry and the results obtained 
are correlated to homocysteine concentrations [29]. Results indicated that the highest 
flux was obtained for the Pfs-LuxS-LuxS trimer, as expected. The next highest reaction 
rate was observed for the Pfs-LuxS dimer. Fluxes generated from the 3-subunit 
complexes built with an inactive second subunit LuxS (w & w/out mTG) were lower 
than the flux generated by two-subunit complexes built with active LuxS. It is 
noteworthy that the Pfs-inactive LuxS-LuxS construct exhibited almost exactly one 
half the activity of the Pfs-LuxS-LuxS construct. Additional tests were performed with 





generated from the Pfs-Pfs-LuxS complexes were lower than the Pfs-LuxS complex. I 
note, however, that in these cases the maximum activity was obtained by the addition 
of 6 µM LuxS and this was similar to the maximum activity observed for the Pfs-LuxS 
construct built with 3 µM LuxS, again suggesting LuxS rate limitation. In sum, these 
results could be rationalized by at least two factors: (1) the extra spacing (either 
partially inactive LuxS or Pfs between active Pfs and LuxS enzymes contributes to a 
reduced reaction rate; and/or (2) there is less binding of third subunits to second 
subunits than of second subunits to first subunits. Results from Figure 2-12 illustrate 
that the addition of the third subunit depends on its concentration, thus some level of 
optimization is needed to maximize linkage to the second subunit and even after 
optimization, results may not show as much linkage as a second subunit to its first.  
 Thus, data in Figure 2-10 - Figure 2-16 demonstrate that I built two and three 
subunit crosslinked complexes on beads using engineered ‘Q’ and ‘K’ tags and mTG. 
The complexes assembled were shown to display altered reaction kinetics based on the 
number of rate-limiting enzymes. In addition, I found that as the number of desired 
enzymatic subunits to be crosslinked was increased, the per enzyme reaction rate 







Figure 2-16 Real time HCY generated from two and three subunit complexes 
measured electrochemically through cyclic voltammetry.   Complexes involving 
Inactive KLK are indicated with red markers while complexes with active LuxS are 
indicated with black markers. Error bars in all cases represent standard deviation with 
n = 3. Trend lines for data in red circles and diamonds denote linear best fit. Trend lines 
for rest of the data are generated through non-linear regression fit. Non-linear 
regression fit is obtained using equation y=ymax (1-exp(-kx)).  
2.3.3 Assembly of multi-functional complexes using mTG 
 
Beyond linkage of biosynthetic enzymes, I next studied whether mTG mediated 
cross-linking could be used for the construction of multi-functional protein complexes, 
again in a flexible manner. In addition, I wanted to explore further the limitations found 
by sequentially attaching two LuxS enzymes. I constructed a Pfs-LuxS complex (as 
before) but then coupled this with Streptococcal protein G [137]. Protein G has the 
ability to bind the Fc region of IgG. I suggest this enables the assembly of covalently 
tethered complexes with targeting antibodies, enabling the localized generation of 





that could be coupled with anti-E. coli antibodies in order to direct the enzymes to the 
surface of E. coli (Figure 2-17) for localized AI-2 synthesis. 
 
Figure 2-17 Scheme depicting construction of multifunctional complexes on beads.   
Pfs-LuxS-ProteinG complexes are assembled on beads and transplanted to reporter 
cells to mediate varied metabolic response. 
I first studied whether protein G could be crosslinked to Pfs-LuxS complexes using 
the same linking motif (‘L’ and/or ‘Q’ tags). That is, I sought to create Pfs-LuxS-
Protein G complexes comprised of PQ, KLK and GQ (protein G engineered with ‘Q’ tag 
at C terminus). I loaded PQ on the beads and crosslinked the second subunit (KLK) using 
mTG for 60 min at RT with β = 1. After washing the beads 3x with PBS, I crosslinked 
GQ as before.  I used Dylight 633-labeled protein G for visualization. Beads were again 
washed 3x to remove unbound protein G. Analogous to the LuxS-capped complexes, 
controls for these tests were two subunit complexes, incubated with labeled GQ but 
without mTG.  I eluted the assembled complexes from beads and measured 
fluorescence (Figure 2-18). I found the fluorescence from complexes built with mTG 
was proportional to the concentration of GQ added, again suggesting crosslinking 





of protein G yielded a doubling of fluorescence, suggesting that incremental protein G 
was fully linked to the two subunit complexes. Analogous controls built without mTG 
had negligible fluorescence indicating lack of GQ crosslinking. Importantly, these 
results support our hypothesis that the third subunit, GQ, was bound to two-subunit 
complexes on the beads.  
 
Figure 2-18 Construction of Pfs-LuxS-Protein G complex.   Assembly of Pfs-LuxS-
ProteinG complex is shown by crosslinking Protein G labelled with Dylight 633 
fluorescent dye to Pfs-LuxS complexes on the bead. Assembled complexes are eluted 
from beads to measure fluorescence using plate reader. Trend lines denote linear best 
fit. 
To further evaluate assembly, I added 10 µg of FITC-labelled antibodies to these 
three-subunit complexes (unlabeled in this case). After incubation for 30 minutes, I 
washed the beads 3x with PBS to remove unbound IgG and eluted the protein 
complexes from beads via ion exchange.  I measured fluorescence of the complexes 
“loaded” with the labelled antibodies (Figure 2-19) and found a linear increase with 
antibody until ~5 µM, when the fluorescence appeared to saturate. Corresponding 
controls consisted of the same incubations but without mTG; there was minimal 





lack of antibody assembly. These data support our original hypothesis that IgG bind 
protein G that, in turn, are the terminal addition to PQ- KLK complexes.  Moreover, the 
additional antibody was nearly stoichiometrically similar to the added protein G (e.g., 
antibody, provided in excess, was bound in proportion to the added protein G until 
8µM, when fluorescence became saturated). Being a ‘third’ subunit, these data suggest 
that a progressive inefficiency of subunit addition may not have been a primary factor 
for the decreased flux observed in Figure 2-16(albeit this addition is not enzymatically 
mediated). 
 
Figure 2-19  Binding of antibodies to Protein G in Protein-Enzyme complex.   
Antibody binding to the Pfs-LuxS-Protein G complex is measured by loading the Pfs-
LuxS-Protein G complex on the beads with FITC-labelled antibody. Assembled 
protein-antibody complexes are later eluted to measure the FITC fluorescence in plate 
reader. Trend lines denote non-linear regression fit using equation y=ymax (1-exp (-kx)). 
I then tested whether the assembled three-subunit (PQ-KLK-GQ) complexes retained 
enzymatic activity. Three-subunit complexes were assembled on beads using mTG 
exactly as before. Control tests were performed on two-subunit complexes without 
protein G (PQ-KLK). I provided the bead bound complexes with substrate 1mM SAH, 





resulted in 4-fold lower homocysteine levels than PQ-KLK complexes (without protein 
G), suggesting that addition of Protein G to KLK resulted in a significant decrease in 
enzymatic activity (p < 0.05) (Figure 2-20). I then replaced protein G with EGFP (EQ, 
EGFP with Q at C terminus) to test whether this effect was subunit specific; the 
decrease in HCY was similar (Figure 2-21) suggesting crosslinking of an additional 
subunit to LuxS in a Pfs-LuxS two-subunit complex resulted in reduction in enzyme 
activity. Recall that our previous tests suggested that LuxS was limiting, so I suspected 
the additional subunit might have interfered with the first LuxS activity (e.g., linked on 
both termini). I then changed the relative positions of the subunits creating a GQ-KPK-
LQ complex where LuxS was added at the end. Thus, I assembled GQ first and created 
GQ- KPK -LQ using mTG exactly as before. In this configuration, HCY yields from GQ-
KPK-LQ were lower but not significantly different from PQ-KLK (p > 0.05) (Figure 2-20) 
indicating that the subunit re-arrangement had rescued the original enzymatic activity. 
The slight decrease could have been attributed to decreased linkage of LuxS as a third 
subunit. Overall, these data highlight the flexibility of our modular construction 
approach for building multi-subunit complexes through enzyme mediated termini-






Figure 2-20 Effect of sequence of crosslinking of enzymes on enzyme complex 
activity.  Change in order of crosslinking leads to altered enzymatic activity. 
Assembled enzyme-Protein G protein complexes are incubated with 1mM SAH for 1 
hour at 37°C and HCY yields generated is measured using Ellman’s assay. One tailed 
unpaired student t test is performed between samples (* indicates p <0.05). 
 
Figure 2-21 Effect of addition of non-enzyme components to enzyme complexes.   
Addition of EGFP leads to decrease in enzyme activity of Pfs-LuxS complex. 
Assembled protein complexes (Pfs-LuxS and Pfs-LuxS-EGFP) were incubated with 
1mM SAH for 2 hours at 37°C and HCY generated was measured using Ellman’s assay. 







2.3.3.1 Deployment of Multifunctional Complexes 
 
I next tested if I could ‘build’ and ‘transplant’ our protein complex to antibody-
targeted sites where they could carry out enzymatic reactions. I built PQ-KLK-GQ and 
GQ-KPK-LQ complexes on the beads using mTG, as before. I eluted these protein 
complexes from the beads and incubated with FITC labelled anti-E.coli antibodies.  
After 30 minutes, I added the enzyme-antibody complexes to E. coli CT104 reporter 
cells (these cells respond to AI-2 with DsRed fluorescent protein expression [132]). I 
note that AI-2 is a byproduct generated with HCY in equimolar amounts by the enzyme 
complexes. After an incubation time of 30 minutes, I washed the cells 3x with PBS to 
remove unbound protein-antibody complexes and suspended the cells in DPBS 
(Dulbecco’s Phosphate Buffered Saline) solution containing 1mM SAH at 30°C for 4 
hours without shaking. I used FACS to analyze the bacterial populations for their 
DsRed fluorescence. Controls for these experiments were the cells incubated with 
protein complexes but without the anti-E.coli antibodies. Representative fluorescence 
microscopy images of the experimental and control bacterial populations are provided 
in Figure 2-23 in [105].  Notably, populations incubated with antibody coupled enzyme 
complexes displayed ~15-fold more fluorescence overall than controls indicating that 
antibody bound complexes attached to bacterial cells, they were active, and synthesized 
AI-2 was delivered to the cells wherein they responded by altered gene expression 
(Figure 2-22).  Between the populations coupled with antibodies and enzyme 





That is, populations with Ab-GQ-KPK-LQ complexes had 6-fold higher mean 
fluorescence intensity than the populations with PQ-KLK-GQ-Ab (Figure 2-22). The 
differences in AI-2/HCY yields from complexes GQ- KPK -LQ and PQ-KLK-GQ measured 
in Figure 2-22 correlated well with bacterial population’s MFI in Figure 2-22. These 
results indicate that differences in enzyme activity that stem from the order of assembly 
were replicated by changes in gene expression of the cells exposed to the same 
complexes.   
 
Figure 2-22 Flow cytometry analysis of reporter cells deployed with ProteinG-
enzyme complexes.  Deployment of multi-functional complexes to E. coli CT104 
(reporter) cells and flow cytometry analysis to measure DsRed fluorescence from 
reporter cells. Cells fluorescing from coupling of Pfs-LuxS-Protein G and Protein G-
Pfs-LuxS complexes are compared. Control populations were incubated with enzyme-
Protein G complexes without antibodies. MFI indicates the mean fluorescence 







Figure 2-23 Fluorescence microscopy images of reporter cells deployed with 
ProteinG-enzyme complexes.  Fluorescence microscopy images of DsRed protein 
expression in E. coli CT104 reporter cells used in Figure 1.22. Top row images: Cells 
incubated with Enzyme-Protein G complexes coupled with antibodies. Bottom row 
images: Cells incubated with Enzyme-Protein G complexes without antibodies. 








In this work, I demonstrate a facile method for the assembly of multi-subunit 
protein complexes using engineered N- and C-terminal ‘Q’ and ‘K’ tags that are 
coupled using mTG on solid supports. I built a two-enzyme metabolon involving 
bacterial QS enzymes Pfs and LuxS and displayed control of metabolic flux across 
these enzymes. Through this method, I was also able to build a multi-functional Pfs-
LuxS-Protein G complex that was eluted from assembly beads and used for specific 
targeted enzyme applications. I displayed modularity and versatility in construction by 
switching of positions of the subunits in the multi-subunit complexes.  
2.4.1 Insights on structural variation using transglutaminase based 
conjugation approach: 
In enzyme based protein conjugation approaches, there is a strong inverse 
correlation between the specificity of conjugation and the quantity of specific 
conjugation products. Several different conjugation tags have been designed 
specifically for the mTG mediated conjugation chemistry to generate specific 
heterodimers and in most cases, the conjugation tag is comprised of a single lysine or 
a glutamine residue to facilitate specific conjugation[126]. However, in these cases, 
very low amounts of specific heterodimers were formed and various purification 
methodologies like size exclusion chromatography or salt precipitation needs to be 
employed to isolate these specific structures. To enhance conjugation, the number of 





of specificity. The balance between the percentage of conjugation and the specificity 
of conjugation needs to be ascertained on a case by case basis keeping in mind the 
relevant context and application for which the conjugation is employed.  
For construction of enzyme cascades under the biodevice context, I heuristically 
created conjugation tags comprising of seven lysine and five glutamine residues to 
facilitate enhanced conjugation of enzymes. Addition of mTG to Lys and Gln 
engineered proteins in solution resulted in more homodimer formation rather than 
heterodimers (Figure 2-5) and hence to drive heterodimer formation, I adopted bead 
based conjugation approach.  Under this approach, I optimized several factors that 
contributed to reduction of side products including β (the ratio between subunit and 
mTG), the position of K and Q tagged proteins in the bead based crosslinking process, 
and the duration of crosslinking. Firstly, β had a positive correlation with the extent of 
crosslinking overall. While I employed β of 100 for crosslinking to get 25% 
heterodimerization in Figure 2-8, I also observed decreased yield of crosslinked 
protein. On the other hand, I could decrease the β from 100 to 1 and obtain higher levels 
of protein conjugation, but at the cost of increased construct heterogeneity (Figure 
2-3).  
Secondly, positions of Q and K tagged proteins also provide a basis for control. 
While the ‘Q’ tags caused self-oligomerization when treated with mTG, I did not 
observe the same with lysine (‘K’) tags (Figure 2-2).  This behavior of Q tags can be 
attributed to the two-step reaction catalyzed by mTG, where first, the glutamines in the 





attack the lysines nearby. Considering that the proteins tested here exist as dimers, there 
is increased propensity to target lysines of their own leading to homo-oligomerization 
than target other enzymes or proteins. For the proteins engineered with ‘K’ tags, the 
glutamines present on the proteins are inaccessible to mTG, thereby making them inert 
to intra-crosslinking [138]. Hence, when positions of Q and K tagged proteins are 
switched, with K tag on the bead and Q tag in solution, the K tag is inert to mTG leading 
to reduced side products. Once the soluble Q tagged second subunit is added, mTG can 
react with its glutamine tag and mediate crosslinking. However, the percentage of 
crosslinking can remain low because the mTG-Gln intermediate complex can 
potentially crosslink to any soluble lysine, get washed away, or get hydrolyzed to form 
glutamate. Other conditions including temperature (not shown) and duration of 
crosslinking (Figure 2-3) play a role; these factors should be considered to control the 
variety of products formed using mTG based conjugation chemistry.  
 
2.4.2 Insights on characterizing flux across enzymes complexes 
built modular construction approach: 
In this study, I define flux as the amount of homocysteine generated per unit 
time by the assembled enzyme complexes. In Figure 2-21, addition of Protein G to the 
LuxS in the Pfs-LuxS complex resulted in reduction of flux generated by the protein 
complex. Enzyme activity was partially resuscitated by re-configuring the arrangement 





layer of the multi-subunit protein complex. A 4-fold reduction in flux when LuxS is in 
the second layer of multi-subunit complex can be attributed to inability of LuxS to form 
homodimers in the second layer of the multi-subunit complex. LuxS exists in a 
homodimeric form in solution and its enzyme activity is dependent on its dimeric 
structure.[139] Improvement in flux observed upon re-configuration of the structures 
with LuxS in the last layer can be attributed to enhanced steric flexibility of LuxS to 
form homodimeric complexes.   
The reduction in flux can also be attributed to structural variability in the 
products generated using the mTG mediated conjugation approach detailed in the 
section above. Formation of tetramers and trimers in the conjugation process can 
impede the natural orientation of these enzyme components resulting in loss of enzyme 
activity. The effect of structural variability on flux can be moderated by including 
flexible linker tags between globular structure of protein components and the 
conjugation tags to enhance steric flexibility of the individual protein components in 
the multi-subunit structure. The lack of clarity on the type and quantity of products 
formed further impedes the ability to determine effective enzyme concentrations (Et) 
that are factored by the percentage of enzymes conjugated and the impact of 
immobilization on enzyme activity.  Inability to accurately calculate Et makes this 
approach difficult to employ in substrate channeling studies.  
In this work, I also demonstrated control of metabolic flux by the addition of rate-
limiting LuxS (Figure 2-11 and Figure 2-12). The increased flux obtained from each 





to saturate with the number of added proteins (Figure 2-12 and Figure 2-16). Our 
approach was helpful in constructing multi-functional complexes (Figure 2-17) and 
this not only proved beneficial as I changed the orientation of complexes finding 
resuscitation of enzymatic activity, making them both effective and multifunctional, 
but also provided insight into the decrease in flux obtained per unit enzyme. That is, 
since the addition of Protein G and EGFP decreased the activity of LuxS, the rate-
limiting factor, I hypothesize that addition of subsequent LuxS subunits may also 
decrease the preceding LuxS subunit’s activity, thereby leading to overall decrease in 
per unit enzyme activity with each round of crosslinking. It would be interesting to 
study how these complexes perform in comparison to multiple gene fusions.   
The use of Co2+ beads provided control over crosslinking orientation and helped 
create ‘deployable’ complexes. Since I assembled enzymatic complexes that were 
involved in generation of QS responses, by controlling the sequence of crosslinking 
and orientation of the subunits, I could mediate and control small molecule 
communication between an assembled abiotic complex and cells leading to altered 
metabolic outcomes. I note this lysine and glutamine tag/transglutaminase 
methodology can be used to fabricate protein complexes that retain function of each 
assembled subunit.  
In addition to building complexes that have utility in solution, as demonstrated by 
altering QS communication in vitro, I expect this methodology will find utility in 
assembling biological components in conjunction with cells and tissues in lab-chip or 





sense, report and modulate the tissues and cells of interest [112]. Developing 
methodologies to assemble enzyme cascades in these systems would be valuable in 
providing greater access and even control. Hence I believe that the solid phase synthesis 
approach can be translated to microfluidic and microsystem environments where 
multiple components can be flowed in and immobilized to each other [118], rather than 







Chapter 3 Facile Two-step Enzymatic Approach for 
Conjugating Proteins to Polysaccharide Chitosan at 
an Electrode Interface 
 
This chapter is adopted from the following publication with permission 
Bhokisham, N.et al. Cel. Mol. Bioeng. (2017) 10: 134. https://doi.org/10.1007/s12195-
016-0472-5 [105] 
3.1 Introduction 
Biofabrication enables assembly of biological components including proteins, 
polysaccharides, DNA, cells etc. onto electronic devices to create microscale systems 
that mediate seamless interaction between the two[140-143]. While biological 
components are naturally evolved with capabilities to ‘sense’ and ‘perceive’ (e.g., cells) 
or ‘act’ (e.g., enzymes, cells), biology’s molecular information flow is incompatible 
with electronics. Also, electronic devices are designed to process and communicate 
information to and from the user, typically not with the biological system. 
Biofabricated devices are developed by integrating biologic and electronic components 
and the devices have immense potential for bi-directional information transfer, 
affecting a wide range of fields from biosensing, lab on chip systems, bio-batteries and 
biofuel cells to personalized diagnostic devices[144]. A second generation of 
biofabricated devices have been developed that not only combine the above mentioned 
characteristics but also display elements of ‘control’ and ‘actuation’[133] of biological 





One of the critical components for integration of biological and electronic 
systems is the interface material. It is desired to functionalize the surface of electronic 
components with reactive groups that can easily interact with biological 
components[144] and, importantly, in a way that precludes non-specific binding of 
materials at the electrode interface. Non-specific binding can be pronounced, eroding 
function and sensitivity in biosensors, for example. Various materials such as carboxy 
methylated-dextran, polyethylene glycol (PEG)-containing hydrogels[145], self-
assembled monolayers of alkane thiols[146], chitosan-N-poly(ethylene oxide)[147] 
have been developed to lower non-specific binding of proteins and increase sensitivity. 
I am interested in chitosan, a deacetylated polysaccharide from chitin, as a facilitator 
of biological assembly onto microelectronic devices, such as biosensors, and MEMS 
devices. Because chitosan’s solubility is easily controlled (via pH), it can be partitioned 
into various forms including hydrogels and coated on electrodes. In our work, chitosan 
enables electrode-based interrogation of cell signaling[112, 148, 149] as well as 
conveyance of molecular information to and from electrodes[133, 150].   
Proteins and enzymes have been coupled to chitosan using a tyrosine based 
chemistry (see Figure 3-1) mediated by tyrosinase[151]. However, tyrosinase 
oxidation of phenolic groups to quinones can be slow[152, 153]. In addition, the 
abundance of positive charges due to the amine groups on the surface of chitosan, a 
property that makes chitosan viable in a multitude of applications, can also lead to 
nonspecific binding of proteins[154]. The combination of both nonspecific binding and 





noise’ ratio for protein conjugation particularly when attempting rapid assembly. In our 
previous work, tyrosinase mediated coupling was shown to yield satisfactory ‘signal to 
noise’, but conjugation reactions were carried out overnight. 
 In an attempt to  accelerate this process and enhance ‘signal to noise’, I 
modified chitosan first using the tyrosinase-mediated coupling of a Lys-Tyr-Lys 
(KYK) tripeptide transforming the available primary amine to a pair of primary amines 
each on essentially a 4-carbon linker, then employed a microbial transglutaminase 
(mTG) to link proteins engineered with glutamine-rich tags[155] to peptide-chitosan 
complex. Importantly, mTG is a crosslinking enzyme with ~100 fold higher enzyme 
turnover number than tyrosinase[153, 156]. In this work, I specifically focus on the 
‘signal to noise’ ratio of these two approaches to assemble proteins onto chitosan (see 
Figure 3-1): the tyrosinase-mediated approach involving conjugation of proteins 
directly to chitosan and the two-step approach involving coating the surface of chitosan 
with KYK peptides using tyrosinase and direct conjugation of proteins to KYK 
peptides through transglutaminase. I further characterized the transglutaminase-
catalyzed approach by assembling a two-enzyme cascade onto gold chips coated with 
peptide modified chitosan. As model enzymes, I used S-Adenosylhomocysteine 
nucleosidase (Pfs) and S-Ribosylhomocysteine lyase (LuxS), both part of the activated 
methyl cycle in bacteria[157]. While Pfs converts S-Adenosylhomocysteine (SAH) to 
S-Ribosylhomocysteine (SRH), LuxS converts SRH to homocysteine (HCY) and (S)-
4,5-dihydroxy-2,3-pentanedione (DPD), a precursor to autoinducer-2 (AI-2), a quorum 





the level of homocysteine, an easily measured sulfhydryl-containing byproduct of AI-
2 synthesis. Using these methodologies, surfaces can be developed with tailored 
biochemical flux.   
 
Figure 3-1: Enzymatic assembly of engineered proteins onto chitosan films   
Enzymatic assembly of engineered proteins onto chitosan films. Left: a “one-step” 
tyrosinase mediated conjugation approach that utilizes mushroom tyrosinase to 
“activate” a tyrosine rich tag engineered onto the C-terminus of the assembled protein. 
Tyrosinase converts the phenolic functional group of tyrosine to an ortho-quinone 
which subsequently binds to the primary amine of chitosan (via Michael addition).  
Right:  Two-step approach utilizing the initial “coating” of chitosan films with Lys-
Tyr-Lys (KYK) peptides using tyrosinase (as on left), followed by conjugation of 
proteins engineered with C terminal glutamine-rich tags onto the KYK peptides using 






3.2 Materials and Methods 
 
3.2.1 Preparation of chitosan films in 48 well plates 
 
I prepared chitosan films using 1.5% chitosan (Sigma Aldrich) solution at pH 
5.6, dissolved in HCl. 200 µls of chitosan solution was added to each well of the 48 
well plate and vacuum dried at 65 °C for 24 hours.  After incubation, I washed the films 
thrice with PBS (Phosphate buffered saline; Sigma Aldrich), pH 7.5 and neutralized by 
immersing the films with 1M NaOH (Sigma) for 45 minutes at RT. Later I washed the 
films again 3X with PBS and used for experiments.   
3.2.2 Electrical deposition of chitosan onto gold chips 
 
I immersed clean gold chips in 1.5% chitosan solution and applied a current of 
4A/mm2 for 2 minutes to each chip. Later I air dried the gold chips and used for 
experiments.  
3.2.3 Conjugation of Lys-Tyr-Lys (KYK) peptide to chitosan films 
 
I prepared 1mM KYK peptide (Sigma Aldrich) solution using Phosphate 
Buffered Saline, pH 7.5 (PBS, Sigma Aldrich). I added 100 µl of KYK peptide solution 
along with tyrosinase from mushroom (Sigma Aldrich) at a concentration of 50U/ml in 
50 mM potassium phosphate buffer, pH 6.5.I incubated the films with peptide solution 





3.2.4 Conjugation of engineered proteins using tyrosinase and 
microbial transglutaminase 
 
 I used proteins engineered with tyrosine [158] (for one-step conjugation 
approach) and glutamines [106] (for two-step conjugation approach). For one-step 
tyrosinase mediated conjugation of proteins to chitosan films, I added tyrosine 
engineered proteins and tyrosinase (dissolved in 50 mM potassium phosphate buffer, 
pH 6.5) at either 3.5 U/µl or 11 U/ µl concentrations and incubated for 1hr at RT. For 
two-step transglutaminase mediated conjugation to peptide modified chitosan films, I 
added glutamine engineered proteins and incubated for 1 hr at RT with 0.00132 U/µl 
of mTG, purified from Streptoverticillium mobaraense (Ajinomoto) and dissolved in 
Phosphate buffered saline, pH 7.5 (Sigma Aldrich). 
3.2.5 Ellman’s DTNB assay 
 
I prepared Ellman’s DTNB stock solution containing 50 mM sodium acetate, 2 
mM DTNB (Sigma Aldrich) using water. I prepared assay solution containing 100 µls 
of 1M Tris-Hcl, pH 8, 50 µls of DTNB solution and 800 µls of water. I mixed 50 µls 
of solution containing homocysteine with 950 µls of assay solution and measured 










3.3.1 Lys-Tyr-Lys peptide prevents non-specific binding to 
chitosan 
 
I compared levels of non-specific binding of enzymes to chitosan films and peptide 
(KYK)-modified chitosan films (Figure 3-2).  I used S-Ribosylhomocysteine lyase 
(LuxS) as a model enzyme to measure non-specific binding of enzymes to chitosan. 
For this purpose, I engineered LuxS at its C terminus with either a penta-tyrosine tag 
(indicated as LuxSY) or a penta-glutamine tag (indicated as LuxSQ). All proteins are 
engineered with hexahistidine tags at the N-termini[106]. As controls, I also used native 
LuxS (with hexahistidine tag for purification) to measure non-specific binding. I note 
that both native and engineered LuxS’s displayed similar enzyme activities per 
molecule (data not shown). For these experiments, chitosan films were cast into 48 well 
plates. To each well, I added 200 µl of 1.5% chitosan solution, pH 5.6 and vacuum 
dried at 65 °C for 24 hours.  Dried films were later neutralized with 1M NaOH for 45 
mins at RT. Post neutralization, chitosan films were washed 3X with PBS (Phosphate 
Buffered Saline, pH 7.4) and used for experiments. To modify chitosan films with KYK 
peptide, I incubated neutralized films with 1mM Lys-Tyr-Lys (KYK) peptide and 
tyrosinase at 50U/ml concentration overnight at RT[155]. Post incubation, films were 
washed 3x with PBS. In Figure 3-2, to study levels of non-specific binding, I added 
15µM of native (LuxS) and engineered LuxS (LuxSY and LuxSQ) to empty and KYK 





and 200 µg per 100µls (10.6 µM and 30.3 µM, respectively) of bovine serum albumin 
(BSA, a common blocking agent). Post incubation at RT for 60 mins, I washed the 
films 3X with PBS.  I measured LuxS bound to films by measuring the enzyme activity; 
quantified by the sulfhydryl generation from LuxS byproduct, homocysteine.  I added 
190 µls of 1mM S-Adenosyl Homocysteine (SAH) and 10 µls of 20 µM enzyme S-
Adenosyl homocysteine nucleosidase (Pfs) and incubated the films for 60 mins at 37C.  
Pfs converts SAH to SRH and SRH is converted to homocysteine (HCY) by LuxS. 
Since LuxS is the rate limiting factor in this two-step reaction, HCY generated by LuxS 
is directly proportional to amount of LuxS on the chitosan film[105]. After incubation, 
I measured HCY levels using Ellman’s assay (sulfhydryl assay).  
In the left most panel of Figure 3-2, there was significant homocysteine 
generation (>0.01 µM/min/mm2) indicating significant non-specific binding to 
chitosan. There was no apparent difference due to the glutamine or lysine tags, nor was 
there a consistent influence due to BSA in the ranges of concentrations used (10-
30µM). Note that I co-incubated with BSA, I did not block with BSA first then add 
LuxS; the effect of BSA here was to demonstrate the capacity of binding sites for LuxS 
and to mimic the addition of either the tyrosinase or the transglutaminase which were 
added at similar levels. Interestingly, I observed the HCY levels from the peptide 
modified chitosan film to be 5 times lower on average than the HCY levels from the 
empty chitosan films (p value < 0.001). Again, there was no competitive advantage due 
to the addition of BSA at the conditions tested. Finally, I note both native and 





clearly demonstrated that addition of KYK peptide to the chitosan film reduced 5-fold 
the quantity of enzymatic activity bound to the films. In separate experiments (not 
shown here), I found the peptide when incubated in solution with the LuxS enzyme 
without chitosan present had no influence on enzyme activity. In sum, our results are 
consistent with the hypothesis that less enzyme was non-specifically bound in the 
presence of the KYK peptide. 
 
Figure 3-2: Lys-Tyr-Lys peptide prevents non-specific binding to chitosan 
Non-specific binding profiles of LuxS, LuxSQ and LuxSY onto chitosan film and 
chitosan-KYK peptide films. Blocking protein bovine serum albumin (BSA, 70µg 
BSA/100µl) was used; this level is the molar equivalent to 3.50U/µl of Tyrosinase; 
200µg/100µl of BSA is the molar equivalent to 1.1U/µl of tyrosinase and 60µM mTG. 








3.3.2 Enzyme activities of soluble LuxSY with tyrosinase and 
microbial transglutaminase 
 
As depicted in Figure 3-3, I studied the role of conjugation enzymes (tyrosinase 
and microbial transglutaminase) on enzyme activity of LuxS. In our previous 
work[112, 149, 158, 159], I demonstrated that Pfs was stable and that equimolar 
mixtures of Pfs and LuxS exhibited less activity than a Pfs-LuxS fusion. In part this 
was due to substrate channeling [160], but could have also been attributed to 
diminished LuxS activity. Here, LuxSY was incubated at RT for 60 minutes with 
following solutions: 1) phosphate buffered saline, pH 7.5; 2) microbial 
transglutaminase (at 00132 U/µl concentration) dissolved in phosphate buffered saline, 
pH 7.5; 3) potassium phosphate buffer, pH 6.5 and 4) tyrosinase (11 U/µl 
concentrations) dissolved in potassium phosphate buffer, pH 6.5. After incubation, 2 
µM of Pfs and 1 mM SAH was added and incubated at 37°C for 20 minutes. After 
incubation, Ellman's assay was performed to measure amount of homocysteine 
generated. Results indicated that incubations with both conjugation enzymes: microbial 
transglutaminase and tyrosinase exhibited reductions in LuxS activity. Tyrosinase at 








Figure 3-3: Enzyme activities of soluble LuxSY with tyrosinase and microbial transglutaminase 
Effect of tyrosinase and microbial transglutaminase incubation on activities of LuxSY. LuxSY was 
incubated with phosphate buffered saline, pH 7.4, potassium phosphate buffer, pH 6.5, tyrosinase (11 
U/µl) and microbial transglutaminase (.00132 U/µl) for 60 minutes at RT. After incubation, 2 µM of Pfs 
and 1 mM SAH was added and incubated at 37°C for 20 minutes. After incubation, Ellman's assay was 
performed to measure amount of homocysteine generated. Error bars indicate n = 3  
3.3.3 mTG catalyzed approach significantly improves ‘signal to 
noise’ for enzyme conjugation onto chitosan 
I next compared the one-step tyrosinase-mediated conjugation approach with 
the transglutaminase-catalyzed approach to measure the ratio between ‘signal’ from 
enzyme mediated specific conjugation and ‘noise’ from non-specific binding.  
For the tyrosinase-mediated approach, I used tyrosinase to crosslink LuxSY to 
empty chitosan film. After the chitosan film was assembled and neutralized, I added 15 
µM of LuxSY along with tyrosinase (dissolved in potassium phosphate buffer, pH 6.5) 
and incubated for 60 mins at RT. In Figure 3-4A, I used two tyrosinase conditions, 3.5 
U/µl and 11 U/µl. In previous work, I found 3.5 U/µl  was sufficient for coupling 
tyrosine tagged proteins to chitosan films[133, 161]; 11 U/µl  was the highest available 





and measured the enzyme activity as described earlier. In both cases, LuxS enzyme 
activity was significantly lower than the control without tyrosinase indicating that 
nonspecific binding of LuxSY to chitosan was surprisingly greater than with tyrosinase 
mediated conjugation  This reduction in activity of conjugated LuxS from chitosan 
films was due, in part, to a reduction of per unit enzyme activity of LuxS that is 
mediated by the tyrosinase itself (Figure 3-3) and the potential interference of non-
specific binding due to tyrosinase (as compared to BSA). Overall, the ratio of LuxS 
activity from tyrosinase mediated conjugation to non-specific binding was 0.33. I had 
previously demonstrated that tyrosinase linkage works well for two more stable 
proteins (GFP and Pfs) relative to non-conjugation controls, however in those studies 
the conjugation times were between 12-16 hours[149, 162]. At a conjugation time of 
60 mins, LuxS enzyme activity from specific conjugation was lower than the 
nonspecific binding controls.  
I next measured the analogous ‘signal to noise’ ratio for the two-step method.  
In Figure 3-4B, I added 15 µM of LuxSQ and 0.00132 U/µl of mTG to the peptide 
modified chitosan film. As a control, I used LuxSQ without mTG. I incubated the 
proteins at RT for 60 min and washed the films 3x with PBS. After washing, I measured 
activity using Ellman’s assay. I observed (1) that, as in Figure 3-4, there was minimal 
activity assembled onto the peptide modified chitosan films not treated with 
transglutaminase and (2) that enzyme activity from mTG-crosslinked proteins resulted 
in 6-fold more activity than the tyrosinase-mediated case. Again, all conditions, 





proteins assembled (Q vs Y tag) and the enzymes used to crosslink (tyrosinase vs 
transglutaminase). In solution, just like tyrosinase, I observed a decrease in per unit 
enzyme activity of LuxS (Figure 3-3) upon incubation with mTG, but this decrease 
was less than incubation with tyrosinase. Overall, the signal to noise ratio exceeded 20-
fold that of the negative controls.  
 
Figure 3-4: mTG catalyzed approach significantly improves ‘signal to noise’ for 
enzyme conjugation onto chitosan 
Comparison of tyrosinase mediated conjugation of tyrosine engineered LuxS (LuxSY) 
to chitosan films with the two-step transglutaminase (mTG) catalyzed conjugation of 
glutamine engineered LuxS (LuxSQ) to peptide-chitosan films. (4A) Tyrosinase 
mediated conjugation of LuxSY onto chitosan films. Controls indicated are for LuxSY 
without tyrosinase. (4B) Transglutaminase mediated conjugation of LuxSQ to the 
chitosan-KYK peptide films. Controls include LuxSQ incubated with chitosan-peptide 
films but without mTG. “S/N” indicates signal to noise ratio, where “Signal” is LuxS 
activity from enzyme mediated conjugation and “Noise” is LuxS activity from 






3.3.4 Characterization of transglutaminase-catalyzed approach to 
conjugation onto chitosan 
 
Having demonstrated that transglutaminase-catalyzed approach was potentially 
superior to the tyrosinase-mediated approach, I sought to further characterize the 
transglutaminase-catalyzed methodology. That is, in Figure 3-5 I varied the 
concentrations of LuxSQ added to the conjugation reactions. I prepared peptide 
modified chitosan films as described earlier and  in addition, I also blocked the films 
with 5% BSA for 1 hour. After incubation, I washed the films 3x with PBS to prep for 
subsequent enzyme assembly. I added varying amounts of LuxSQ to peptide-modified 
chitosan films and crosslinked the enzymes to films by mTG. The molar ratio between 
LuxS and mTG was constant at 1:3 for all cases. I discovered heuristically this was a 
good ratio for assembly. Controls consisted of identical experiments without mTG. 
After conjugation at RT for 60 mins, I washed the films 3x with PBS and measured 
enzyme activity. I observed that there was a monotonic increase in HCY generated with 
increased LuxSQ concentration. There were no significant differences among the 






Figure 3-5: Characterization of transglutaminase-catalyzed approach to 
conjugation onto chitosan.  
Capacity for binding LuxSQ. Activities exhibited from different concentrations of LuxS 
conjugated with chitosan films using the two-step microbial transglutaminase 
approach. Controls indicated include LuxSQ without mTG. Error bars indicate n = 3.  
 
3.3.5 Assembly of EGFP to peptide modified chitosan films on gold 
chips 
In Figure 3-6, I demonstrate the two-step approach of protein conjugation onto 
gold chips using fluorescent protein, EGFP, engineered with glutamines at its C termini 
(indicated as EQ). I electrically deposited chitosan onto gold chips (Methods) and 
crosslinked 1mM KYK tripeptide to chitosan using 50U tyrosinase at RT overnight. 
After incubation, I washed the gold chip 3X with PBS to remove unreacted peptide and 
tyrosinase. I then conjugated EGFP (0.5 mg/ml EQ) to the peptide modified chitosan 
via incubation with 30 µM mTG at RT for 60 min. After incubation, I washed the gold 
chip 3X with PBS. As controls, I performed the same reactions without mTG. 
Fluorescence microscopy images are included that indicate conjugation of EQ to 
peptide modified chitosan (experimental samples with mTG exhibited green 
fluorescence while the mTG negative controls had negligible green fluorescence). Data 






Figure 3-6: Assembly of EGFP to peptide modified chitosan films on gold chip.  
Assembling of EGFPQ on chitosan using ‘two-step’ mTG mediated approach.  KYK 
peptide was first crosslinked to chitosan using tyrosinase (Methods) and EGFP 
engineered with glutamines at C termini (Methods) was crosslinked to KYK peptide 
using mTG (Methods). Scale bar: 2mm. 
 
3.3.6 Assembly of two enzyme metabolic pathway to peptide 
modified chitosan on chips 
 
Having demonstrated the specificity of two-step approach, I next assembled 
two enzymes onto peptide modified chitosan and mediated flux between the two 
enzymes. For this purpose, I used both enzymes PfsQ and LuxSQ. That is, I generated 
Pfs engineered with penta-glutamine tag at C terminus (indicated as PfsQ) for this 
purpose. For conjugation, I used chitosan films both casted on plates as well as 
electrically-deposited chitosan films on gold chips and conjugated the KYK peptide to 
the chitosan films. (Scheme in Figure 3-7 and Methods). Later, both films were 
blocked with 5% BSA for 60 minutes. After incubation, films were washed 3x with 
PBS and used for experiments. To demonstrate assembly onto gold chips, I assembled 
green fluorescent protein (EQ) using the transglutaminase-catalyzed approach (Figure 





concentrations of LuxSQ to peptide modified chitosan using mTG (molar ratio of LuxS: 
mTG of 1:3). After a 60 min incubation, both the plates and chips were washed 3X 
with PBS. Under similar conjugation conditions, the second enzyme, PfsQ, was 
crosslinked to chitosan-peptide-LuxSQ film (again with a molar ratio of Pfs: mTG of 
1:3). After this second round of conjugation, plates and gold chips were washed again 
3X with PBS and incubated with 1mM SAH. After 2 hours of incubation at 37°C, the 
HCY generated was measured by Ellman’s assay.  HCY levels generated from enzymes 
assembled to both plates and chips are indicated in Figure 3-7B. Consistent with 
previous results, I found up to ~20 fold increases in biochemical flux through the 
assembled pathways. I also note that there were relatively minor differences due to the 
electrodeposited (denoted “On chips”) versus the cast chitosan films (denoted “On 





generated from negative control experiments were insignificant. 
 
Figure 3-7: Assembly of two enzyme metabolic pathway to peptide modified 
chitosan on chips. 
(A) Schematic indicating electrical deposition of chitosan films onto gold chips[157, 
161]. (B) Conjugation of LuxS and Pfs, representing a two enzyme metabolic pathway 
to peptide-chitosan films on gold chips and on microtiter plates. Controls include Pfs 
and LuxS enzymes incubated with KYK peptide chitosan films (as in Fig. 3) but 








In this study I compared two different biofabrication approaches for the 
assembly of proteins onto chitosan films. First, a tyrosinase-mediated approach 
involving conjugation of tyrosine engineered proteins to chitosan was examined for 
specificity and non-specific binding. In previous work, I demonstrated assembly of 
tyrosinase linked proteins on chitosan [158] but did not address the non-specific 
interactions between the enzyme (Pfs) and chitosan. In addition, our previous studies 
focused on Pfs and GFP, which are more stable than LuxS. The two-step approach here 
involving tyrosinase mediated coating of chitosan film with Lys-Tyr-Lys tripeptide 
followed by direct conjugation of glutamine engineered proteins to peptide modified 
chitosan film using transglutaminase was simple, and exhibited far less background 
activity.  
The reasons for reduced nonspecific binding is confounding given that I 
modified the surface of chitosan with peptides containing more positively-charged free 
amines. Beyond charges on the surface, there might be other factors at play that 
influence the extent of nonspecific binding of proteins to chitosan. The thickness of the 
modified chitosan films and the method of deposition of these films have been reported 
to play a role in nonspecific binding. Specifically, reduced binding was attributed to 
reduced mobility of the different chitosan films[147]. In our case, the addition of 
tripeptide might have reduced the mobility of the chitosan films resulting in reduced 





shown to bind to metal oxides[163]. There is a remote possibility that tripeptides 
containing lysines bound to the surface of gold, preventing non-specific binding of 
proteins to gold, however, given the thickness of the films, it is quite unlikely to have 
played a major role. Analogously, should the peptide bind both gold and chitosan, 
reduced mobility could be envisioned. 
Alternatively, proteins have been known to undergo refolding upon contact 
with a charged surface[164]. In this study, since the non-specific binding is reported 
indirectly through enzyme activity on the surface of the biosensors, LuxS, the rate 
limiting factor in the two enzyme QS pathway might have refolded upon contact with 
a tripeptide leading to reduced enzyme activity.  Perhaps this was a contributing factor. 
In either case above, additional experiments would be needed to evaluate the 
mechanistic causality of the reduced non-specific binding.  
In sum, the two-step assembly process entails an extra step of modifying 
chitosan films with peptides prior to crosslinking with engineered proteins, thereby 
increasing the overall fabrication time. However, by switching from the use of empty 
chitosan films to peptide-modified films for crosslinking, I could transition from the 
low kcat tyrosinase to mTG for final assembly. In biosensor and other fabrication 
processes, the assembly of the enzyme onto the biosensor surface is the crucial time 
sensitive step. Here, I could accelerate crosslinking from 12 hours to 1 hour using mTG 
and peptides. Also, given the relatively low requirement for mTG (1.3U/ml), I believe 





modified films are relatively stable, the peptide modification of chitosan might be done 
ahead of time and kept ready for enzyme crosslinking.   
From a biofabrication standpoint, I have displayed construction of a two 
enzyme metabolic pathway on chips wherein enzymes/biomaterials can be specifically 
crosslinked within a short duration across a wide concentration range of 15 µΜ to 15 
nM and with minimal nonspecific binding at all concentrations.  I envisage using this 
methodology for the fabrication of biomaterials in bioMEMS devices, sensors and lab 
chip devices, some of which have already been shown. [112, 133, 161] In general, by 
combining the pH-controlled solubility of chitosan with peptide-mediated reduced non-
specific binding, peptide-chitosan complexes created here using transglutaminase are 
likely to find utility in antigen-antibody and immunodetection assays and other sensing 













Chapter 4 Engineered Tobacco Mosaic Virus -Virus 
Like Particles (TMV-VLP) as self-assembling 3D 
scaffolds for multi-enzyme assembly using mTG 
mediated conjugation 
 
Sections from this chapter will be submitted for publication by January 2018 
4.1 Introduction 
Electronic components with signal processing and communication capabilities 
have been integrated with biomaterials for development of interesting devices and 
applications.[107, 108] The challenge in building these devices is the construction of 
‘bio-electronic’ interface to enable assembly of biocomponents on abiotic electronic 
surfaces and mediating communication across the interface. In general, biomaterials 
are one of the best examples of bottom-up assemblies with several simple biological 
components self-assembling into multi-component structures such as DNA 
origami[165, 166], protein origami[167], liposomes[168, 169], viruses[170], 
enzymes[171] etc. Various bio-inspired materials such as gold binding peptides[172, 
173], graphite binding peptides[174, 175] that self-assemble  into a 2D monolayer at 
bio-electronic interface have been engineered.  
However, biosensor fabrication typically requires facile assembly of 
biocomponents at high molecular densities and there is a need to develop 3D interfacial 
scaffolds with high aspect ratios as well as those with the capability to display desired 





a class of biomaterials derived from coat proteins of viruses are increasingly being used 
purely as materials for bio-device assembly.[170] Well established structures of VLPs 
have enabled genetic engineering of coat proteins to display multivalent conjugational 
moieties on the surface of the VLP with well-defined periodicities.  Individual coat 
proteins can self-assemble into hierarchical assemblies with different shapes and 
dimensions from nanoscale to mesoscale.[71, 176] Finally, introduction of cysteines 
into VLPs has enabled VLPs to self-assemble onto the gold surface and be used as 
interfacial materials at bio-electronic interface.[38, 57, 58]  
Capitalizing on the dual nature of virus like particles as materials for bio-device 
integration,  as well as easily modifiable biomaterial for biocomponent assembly[177], 
new biosensors are being designed using virus and virus like particles as interface 
material. M13 bacteriophage has been used as scaffold material in an impedance sensor 
for detection of prostate cancer specific antibodies and antigens.[81] Tobacco Mosaic 
Virus (TMV) in combination with polyaniline have been used in a thin film sensor for 
detection of methanol and ethanol.[82] TMV-VLP has also been genetically engineered 
to display functional peptides for TNT[83] and anti-body detection.[55] With extensive 
literature available on protein conjugation, enzymes have been integrated with VLPs 
for biosensing. Two-enzyme cascades containing glucose oxidase and horse-radish 
peroxidase has been assembled on the surface of cowpea mosaic virus[84] and TMV 
for detection of glucose.[85, 178]  
Capitalizing on VLP’s ability to integrate with electronics, facile assembly of 





biosensors and other types for biosensing. In this work, I engineered a self-assembling 
3D scaffold comprised of VLP to display assembly of multi-step enzyme cascades on 
electrode surfaces. Firstly, I engineered a self-assembling monolayer of TMV-VLP to 
display glutamines on the outer surfaces of the VLPs. I utilized the engineered 
glutamines for conjugation of biocomponents via mTG mediated conjugation 
chemistry.[105] Through our earlier described modular construction approach for 
assembly of bio components via mTG mediated conjugation[106], I displayed layer-
by-layer assembly of multi-component assembly on VLP monolayer on gold surfaces. 
In addition, I used the VLP particle and mTG mediated conjugation approach to display 
assembly of a novel three enzyme synthetic cascade to sense intermediates in methyl 
cycle: S-adenosylmethionine, S-adenosylhomocysteine and homocysteine on the 
surface of a gold chip.  
In Figure 4-1, I depict the overall scheme of enzyme assembly where TMV-
VLP coat proteins are engineered with Gln (a) and expressed in bacteria. Engineered 
coat proteins self-assemble into long rod-shaped VLP (b). In the second step, a first 
layer of enzyme engineered with Lys at both the N and C termini are conjugated to Gln 
in VLPs using microbial transglutaminase (c). In the third step, a second layer of 
enzymes engineered with Gln at the C termini are conjugated to the first enzyme 
through another round of mTG mediated conjugation (d). Finally, VLPs functionalized 







Figure 4-1Engineered Tobacco Mosaic Viruses-Virus Like Particles 
(TMV-VLP) as 3D scaffolds for enzyme cascade assembly onto 
microchips. 
(a) TMV capsid subunit engineered with 1 Cys at the N termini and 2 Gln’s at the C 
termini. (b) Self-assembly of capsids into VLPQ with cysteines exposed at the 3’ end 
of the particle and glutamines on the outer surface. (c) Enzymes engineered with Lys 
at the C termini or the N termini or both are conjugated to VLPQ using microbial 
transglutaminase. (d) Second layer of enzymes are conjugated to the first layer of 
enzymes through another round of mTG mediated conjugation. (e) Multi-enzyme 






4.2 Materials and Methods 
4.3 Strains and Plasmids 
All plasmids and strains used in this study are listed in Table 4-1. I performed 
all cloning and transformations as per standard protocols[131].  Primers (Integrated 
DNA Technologies) used for engineering of proteins are summarized in Table 4-2. 
pET28a-TMV1Cys plasmid (obtained as a gift from Dr. James N. Culver) was used as 
template for all VLP engineering done in this study.  
Table 4-1: List of Plasmids 
 




TMV capsid protein engineered 
with Cys at 1st amino acid position [179] 
TMV-10aa-
QQQQQ 
TMV1Cys engineered with 10aa 
linker and 5 Gln’s at C’  
This study 
TMV-GSGSQQ TMV1Cys engineered with 4aa 
linker and 2 Gln’s at C’  
This study 
TMV-GSGSQQQ  
TMV1Cys engineered with 4aa 
linker and 3 Gln’s at C’  
This study 
TMV-GGGSQQ 
(Referred to as 
VLPQ)  
TMV1Cys engineered with 4aa 
linker and 2 Gln’s at C’ 
This study 
TMV-GGGSQQQ  TMV1Cys engineered with 4aa 
linker and 3 Gln’s at C’  
This study 





Tam engineered with 7 Lys’s at both 
the N and C termini 
This study 








Pfs engineered with 7 Lys’s at both 
the N and C termini 
pTrc-LuxS-7Lys LuxS engineered with 7 Lys’s at the 
C termini 




Fusion Enzyme with both Pfs and 
LuxS and engineered with Gln tag at 
the C termini (FEQ) 
[180] 
Strain Relevant genotype/property Reference 
BL 21 luxS- B strain, F-omp T[dcm] [Ion] 
hsdS(rB -, MB-) gal, ΔluxS 
(For LuxS and Tam expression) 
Lab stocks 
RK 4353 pfs- RK 4353 strain, Δpfs(8-226):: kan 




E. coli B F–ompT hsdS(rB -, MB-) 
dcm+ Tetr gal endA Hte [argU ileY 
leuW Camr] 
(For VLP expression) 
Lab stocks 
Table 4-2: List of Primers 





Nde-1 restriction site, 
overlaps with pET28a and 







Xho-1 restriction site, 
overlap with pET28 and C 







Xho-1 restriction site, 
overlap with pET28 and C 







Xho-1 restriction site, 
overlap with pET28 and C 







Xho-1 restriction site, 
overlap with pET28 and C 











Xho-1 restriction site, 
overlaps with pET28 and C 




cactcgagatgtctgactggaaccc Xho-1 restriction site, 
overlaps with pTrcHisA and 





Eco RI restriction site, 7 Lys, 
overlaps with pTrcHisA and 






Xho-1 restriction site, 7 Lys, 
overlaps with pTrcHisA and 





EcoRI restriction site, 7 Lys, 
overlaps with pTrcHisA and 
Tam gene in E. coli 
 
4.3.1 Protein expression and purification: 
I grew the expression hosts for enzymes Tam, Pfs, LuxS and FE (fusion of Pfs and 
LuxS) in LB media (Sigma-Aldrich) and induced at OD600 of 0.4 with 1 mM IPTG 
(Sigma). After 4 hrs at 30°C, I centrifuged the cells and suspended in 15 mL of 10 mM 
phosphate buffered saline (PBS), pH 7.4 (Sigma-Aldrich). To lyse the cells, I 
performed sonication for 15 min and centrifuged again at 20,000g for 20 mins to 
remove soluble proteins. To purify his-tagged enzymes, I performed immobilized metal 
ion chromatography via HiTrap columns (GE Healthcare) and subsequently dialyzed 
the purified enzymes with PBS and stored at -20°C. I selectively removed His tags of 
all KEnzymeK’s (enzymes engineered with Lys tags at both the N and the C termini) 





manufacturer’s specifications (EK-Away, Invitrogen). Enzymes were stored for further 
use at  -20°C.  
4.3.2 Tobacco Mosaic Virus-Virus like Particle (TMV-VLP) 
Purification and visualization: 
I transformed plasmids containing engineered TMV-VLPs into BL21 
CodonPlus (Agilent) for protein expression. I grew the strains in LB media at OD600 of 
0.4 induced with 1mM IPTG for protein expression. After induction for 24 hrs at 30˚C, 
I pelleted the culture and  suspended in 2.5 mL of Bugbuster (EMD Millipore), 2µL of 
1M DTT (Sigma) and 1 µL of Lysonase (EMD Millipore) and gently shaken for 45 
min at room temperature. After incubation, I added 10% (v/v) of chloroform to each 
tube, vortexed and centrifuged at 4000 rpm for 20 minutes. I separated the supernatant 
and pelleted in an ultracentrifuge at 30000 rpm for 60 min at 4ºC. Later, I re-dissolved 
the pellets in 2 ml of 0.1M phosphate buffer, pH 7 by gently shaking the pellets for 
overnight at 4ºC and transferred into 10% - 40%sucrose gradients in 0.1M phosphate 
buffer, pH 7 and centrifuged at 22500 rpm for 60 min at 4ºC. I extracted the TMV-
VLPs in the gradient and centrifuged again at 30000 rpm for 60 min. Finally, I re-
dissolved the VLP pellet in 0.1M phosphate buffer, pH 7 and used them for further 
experiments. To visualize the TMV-VLP particles, I loaded 0.5µg of VLPs onto 
transmission electron microscope grids and coated the VLPs with 2% aqueous uranyl 





4.3.3 Nickel Plating for Scanning electron microscopy 
For the plating procedure, I prepared palladium stock solution containing 0.01g 
Na2PdCl4 in 1.5 mL methanol and nickel stock solution containing 0.6g NiCl2 
hexahydrate, 0.45g glycine, 1.5 g sodium tetra borate and 0.77g dimethylamine borane 
complex in 25 mL H2O. I covered 5mm2 gold chips (Platypus Technologies) with 25µg 
of VLPQ in solution and incubated for overnight at 4ºC.  Following overnight 
incubation with VLPs, I washed the chips with 30 mL of PBS and submerged in a 30X 
dilution of palladium stock solution for 30 minutes at RT. After 30 min incubation, I 
washed the chips with PBS and submerged the chips in 2X dilution of nickel stock 
solution. After 30 min, I washed the chips again and dried for 5 mins and used for 
scanning electron microscopy.  
4.3.4 Assembly of VLPs onto gold chips 
I added 25µg of VLPs onto 10 mm2 gold chips and incubated the chip at 4°C for 
overnight. After incubation, I washed the chips with 30 mL of 0.1M phosphate buffer, 
pH 7 to remove unbound VLPs on gold chips. Later, I blocked the chips with 100 µL 
of 5% bovine serum albumin (BSA) solution and incubated at 37°C for 60 min. After 
incubation, I washed the chips again and used for further experiments. 
4.3.5 Conjugation of EGFP to VLPs in a Layer by Layer assembly 
I conjugated EGFPK (EGFP engineered with lysines at the C termini) to VLPQ 
by addition 7.5 µM EGFPK and 10 µM microbial transglutaminase (mTG) to VLPQ’s 





All the solutions were mixed well and spread to cover the entire area of the 10 mm2 
and chips were incubated at RT for 60 min. After incubation, I washed the chips with 
0.1M phosphate buffer, pH 7 and used further for fluorescence microscopy. 
4.3.6 Measurement of Homocysteine using Ellman’s Assay and 
Cyclic Voltammetry 
I measured homocysteine using calorimetric Ellman’s assay as described in               
Fernandes et al [112] and electrochemically using cyclic voltammetry as described in 








4.4.1 Engineering and assembly of engineered VLPs 
I first intended to assemble a TMV-VLP particle engineered with glutamines 
on the outer surface. I used a TMV1Cys Virus Like particle (VLP) engineered with one 
Cys residue at the N termini of each TMV capsid subunit enabling the VLP to self-
assemble as a monolayer on gold.[179] I intended to create a Gln engineered VLP 
(VLPQ) that forms a monolayer on the gold surface and conjugate enzymes to the 
engineered Gln’s in the VLPQ monolayer via mTG mediated conjugation 
chemistry.[106]  
In this pursuit, I engineered the TMV1Cys VLP with a 10aa flexible linker 
peptide and a penta-glutamine tag at the C termini of coat protein (Table 4-1). 
However, I was unable to express and purify a fully assembled VLPQ particle (data not 
shown) and hence, I replaced the long 10aa linker with a short 4aa linker and reduced 
the number of Gln residues from 5 to either 2 or 3 (Table 4-1). With fewer glutamine 
residues and shorter linker sequences, I successfully expressed and purified VLPQ’s in 
bacteria (See 4.3.2). Figure 4-2a depicts a 4-20% denaturing SDS-PAGE gel 
containing aliquots from various stages of the purification process of a TMV-VLP 
particle engineered with GGGSQQ sequence at C termini (referred further as VLPQ). 






 Next, to verify if the engineered VLPs assembled into a complete filamentous 
rod like structure, I used transmission electron microscopy (See4.3.2). TEM image of 
purified particles (Figure 4-2b) indicated that VLPQ’s assembled into complete rod 
like structures. When interacted with a gold surface, Cys residue at the N termini 
enables formation of self-assembled monolayer (SAM) of VLP. To verify if the 
engineered VLPQ’s can self-assemble into a monolayer, I covered a ~5 mm2 gold chip 
with 0.25mg/ml solution of VLPQ and incubated the chips at 4⁰C for overnight., Next 
day, I washed the chips with water and coated the particles with nickel (See 4.3.3) and 
performed scanning electron microscopy. Figure 4-2c indicated that VLPQ’s self-
assembled to form a monolayer on gold, as expected. 
In conclusion, I engineered the VLP particles with glutamine residues at C 
termini and purified fully assembled particles in bacteria. I also displayed that the Gln 






Figure 4-2 Purification and Assembly of engineered VLPQ  
(a) 4-20% SDS PAGE gel indicating different stages of the VLPQ purification process. 
(b) TEM image indicating the fully assembled TMV-VLPs engineered with glutamines 
(VLPQ); Scale: 200 nm. (c) SEM image indicating VLPQ assembled on the surface of 
gold coated microchip; Scale: 1 µm.   
 
4.4.2 Conjugation of proteins onto engineered VLPQ via mTG 
mediated conjugation chemistry 
After displaying the assembly of the VLPQ monolayer on the gold surface, I 
next ascertained if the engineered Gln residues in VLPQ can be utilized for conjugation 
of proteins using microbial transglutaminase (mTG).  To this end, I used an enhanced 
green fluorescent protein engineered with 7 lysines at the C termini (denoted as EGFPK) 
and conjugated it to the VLPQ using mTG (Figure 4-3). 
As qualitative evidence, I first used fluorescence microscopy to determine the 





(See 4.3.4) and conjugated 7.5 µM EGFPK to VLPQ’s using 10 µM microbial 
transglutaminase (mTG). After incubation at RT for 60 min, I washed the chips with 
0.1M Phosphate buffer, pH 7 and air dried the gold chips. As controls, I also performed 
experiments without mTG. Fluorescence microscopy images Figure 4-3b indicated 
that in the presence of mTG, EGFPK is conjugated to VLPQ while the negative controls 
displayed negligible fluorescence.  
Next, to quantify the amount of EGFPK conjugated to the VLPQ monolayer on 
gold chips, I performed ex situ quartz crystal microbalance (QCM), Figure 4-3c. 
Initially, I measured the resonant frequency (FCell) of each individual gold coated quartz 
crystal sensor (ICM, Oklahoma, USA) used in the QCM experiments. Later, I 
assembled the VLPQ monolayer on the sensor (area: 2 mm2) using 25 µg of VLPQ.  
After incubation at 4˚C for overnight, I removed the excess VLPQ’s by washing with 
Super Q water, vacuum dried the sensor chips at RT for 60 min and measured the 
resonant frequency again (FVLP). I observed a shift in frequency corresponding to the 
addition of the VLPQ monolayer and determined the frequency change (ΔF1) between 
FCell and FVLP. Next, I added 7.5 µM EGFPK and 10 µM microbial transglutaminase 
(mTG) to the VLPQ monolayer and incubated at RT for 60 min. Post incubation, I 
washed the crystals again with Super Q water; vacuum dried the sensors and measured 
the frequency again (FmTG/EGFP). Post conjugation, I noted a yet another shift in the 
frequency (ΔF2) between FCell and FmTG/EGFP indicating conjugation of the EGFPK to 
VLPQ monolayer. As expected, control experiments without mTG or EGFPK showed 





ΔF2 to the amount of material assembled on the sensor at each step of the assembly 
process. I estimated that ~100 ng of VLPQ’s was assembled on the sensor surface (0.2 
cm2) and ~1.15ng of EGFPK was conjugated per 1 ng of VLPQ on the sensor, indicating 
~47% coverage of VLPQ surface with EGFPK. Both conjugation controls had ~0.1ng 
of proteins assembled per 1 ng of VLPQ’s indicating a 10-fold difference between mTG 
mediated conjugation and nonspecific binding of EGFP on sensors.  
These qualitative and quantitative results indicated that proteins engineered 







Figure 4-3 Qualitative and Quantitative evidence for protein assembly 
onto VLPQ via mTG mediated conjugation 
(a) Assembly of EGFPK (EGFP engineered with Lys tag at C termini) onto VLPQ 
monolayer on chips using microbial transglutaminase and engineered tags. (b) 
Qualitative fluorescence microscopy images of EGFPK conjugated to VLPQ; Scale: 50 
mm (c) Quantitative quartz crystal microbalance data indicating conjugation of EGFPK 
to VLPQ in the presence of mTG. Resonant frequency of empty sensor (Fcell), after 
addition of VLPQ (FVLP) and after conjugation of EGFP to VLP (FmTG/VLP) is measured. 
Change in the frequency due to addition of VLPs onto sensors (ΔF1) are indicated by 
black circles. Change in the frequency due to the assembly of proteins onto VLPs are 
indicated by red squares (ΔF2). Error bars indicates standard deviation across three 
independent sensors used for each condition. 
 
4.4.3 Conjugation of enzymes to mTG 
After displaying conjugation of proteins to the VLPs, I intended to display 
assembly of enzyme cascades on the VLPQ monolayer assembled on gold chips. To 
display this, I assembled a three-enzyme synthetic cascade for conversion of S-
adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) to homocysteine 
(HCY), all part of methyl cycle. I employed three E. coli enzymes namely 1) trans-
aconitate methyl transferase (Tam) for conversion of S-adenosylmethionine (SAM) to 
S-adenosylhomocysteine (SAH)[182]; 2) S-adenosylhomocysteine nucleosidase (Pfs) 
for conversion of SAH to S-ribosylhomocysteine (SRH)[130] and 3) S-
ribosylhomocysteinase (LuxS) for conversion of SRH to homocysteine (HCY) and 
autoinducer-2(AI-2), a quorum sensing (QS) enabling molecule[129] (Figure 4-4a).  
While Pfs and LuxS are part of the activated methyl cycle in bacteria, Tam is not known 
to be involved. However, tam is part of lsr quorum sensing operon and is directly 





Since I had already characterized Pfs and LuxS in earlier chapters of this thesis, 
here I first studied Tam. I cloned tam gene out of E. coli genome, engineered with 7 
Lys amino acids at C termini (denoted as TK) and purified the enzyme (See Methods).  
To determine whether Tam can convert SAM into HCY, I added 3 µM concentrations 
of each soluble with 1mM SAM and incubated for 60 min at 37°C. After incubation, I 
measured amounts of HCY generated using a calorimetric assay (Ellman’s sulfhydryl 
assay, See Methods) (Figure 4-6). I also characterized an electrochemical method 
using cyclic voltammetry to detect HCY (Figure 4-7). Results indicated that there was 
a 100% conversion from SAM to HCY. Going further, I assumed 3 µM enzyme 
concentration and 60 min incubation at 37°C as non-rate limiting conditions for 
reactions involving soluble enzymes.   
Next, I individually immobilized each enzyme of the cascade onto the VLPQ 
monolayer and determined their relative enzyme activities in immobilized state. I used 
Tam, Pfs and LuxS enzymes engineered with 7 lysines at both the N and the  C terminus 
(denoted as KTK, KPK and KLK respectively) and conjugated them to VLPQ monolayer. 
In all experiments, I first assembled the VLPQ monolayer onto the gold surface by 
incubating 25 µg of VLPQ’s onto 1 cm2 gold chips and performed blocking and washing 
steps as detailed before.  
Firstly, I conjugated LuxS, the last enzyme in the three-enzyme cascade onto 
VLPQ monolayer assembled on gold chips. I added 20 µM and 50 µM concentrations 
of LK along with 10µM of mTG for conjugation and incubated for 60 min at RT. As 





incubation, I washed the chips with Phosphate buffer and provided 1mM SAH and 
soluble Pfs (at 3 µM concentration) in 10mM Phosphate Buffered Saline, pH 7.4 (PBS) 
to the VLP-LuxS monolayer on chips. After incubation at 37°C for 2 hours, I measured 
the amount of HCY generated through Ellman’s assay. Results indicated that with 
increasing concentrations of LuxS conjugated to VLPQ monolayer there was increasing 
amounts of HCY generated with 50 µM conjugation condition yielding 20% 
conversion from SAH to HCY.  (Figure 4-4b). These results confirmed with earlier 
results that LuxS was the rate-limiting factor among Pfs and LuxS enzymes. [106] 
Conjugation controls without mTG had negligible HCY generations. As an additional 
control, I also conjugated LK onto empty-VLP monolayer lacking the engineered 
glutamines at the C termini of TMV capsids(TMV1Cys). Interestingly, there was small 
yet significant HCY generation from empty-VLP monolayer in comparison to its own 
conjugation control indicating enzyme conjugation to native glutamines in the TMV 
capsid. However, HCY yields from empty-VLP monolayer was still lower than yields 
from VLPQ monolayer indicating enhanced protein conjugation due to engineered 
glutamines in VLPQ.     
Next, I conjugated Pfs, the second enzyme in the enzyme cascade. I conjugated 
20 µM of PK onto VLPQ monolayer under similar conjugation conditions as before. 
After conjugation, I washed the chips and added 1mM SAH and 3 µM of soluble LuxS 
in PBS. After 2 hours of incubation at 37°C, I measured HCY yields. Results indicated 
85% conversion of SAH to HCY indicating that PK had higher enzyme activity than 





conversion of SAH to HCY (Figure 4-4c). These results again indicated that Pfs was 
not the limiting factor. I repeated similar conjugation experiments for Tam, the first 
enzyme in the cascade. After conjugation, I provided 1mM SAM as substrate for Tam 
along Pfs and LuxS (each 3 µM) and incubated for 2-hour incubation at 37°C. I 
measured HCY yields and the results indicated 20% to 30% conversion of substrate 
SAM to HCY. Conjugation controls without mTG had negligible HCY yields (Figure 
4-4d). I also independently immobilized all the enzymes in the cascade onto the VLP 
monolayer on gold surface and characterized the km, Vmax and kcat values for each 
enzyme (Figure 4-8).    
In sum, I studied the relative enzyme activities of all three enzymes when 
conjugated independently to VLPQ monolayer through mTG mediated conjugation. 
Second enzyme in the cascade, Pfs had the highest enzyme activity in comparison to 
Tam and Pfs. Under the conjugation conditions used, Tam displayed a marginally 







Figure 4-4Assembly of enzymes involved in conversion of S-
adenosylmethionine (SAM) to Homocysteine (HCY) onto microchips. 
(a) Three enzyme synthetic cascade for conversion of S-adenosylmethionine (SAM) to 
Homocysteine (HCY). Tam converts SAM to S-adenosylhomocysteine (SAH). Pfs 
converts SAH to S-ribosylhomocysteine (SRH). LuxS converts SRH to homocysteine 
(HCY) and Autoinducer-2. (b, c and d) Each individual enzyme engineered with 
Lysine tags (7 Lys at both the N and the C termini) are conjugated separately to VLPQ 
assembled on the surface of microchips. These immobilized enzymes are provided with 
1mM SAM (for Tam) and 1mM SAH (for Pfs and LuxS) and the other remaining 
enzymes for HCY generation at non-rate limiting conditions (3 µM of each enzyme). 
Reaction is incubated at 37°C for 2 hours and the amounts of HCY generated was 






4.4.4 Layer by Layer assembly of enzymes onto VLPQ 
After displaying the assembly of individual enzymes of the cascade onto VLPQ 
monolayer, I intended to display layer-by-layer assembly of multiple enzymes on VLPQ 
monolayer. To display multi-layer assembly, I first constructed a two-enzyme cascade 
comprising of Pfs and LuxS for the conversion of SAH to HCY. For this, I adopted our 
earlier described modular construction approach of assembling multiple enzyme 
components using mTG (Figure 4-5a,b).[105, 106]  
To mediate construction, I used Pfs engineered with 7aa lysine tags at both the 
N and the C termini (KPK) and LuxS with 5aa Gln tags at the C termini (LQ). As with 
single enzyme assembly, I first assembled the VLPQ monolayer onto 10 mm2 gold chips 
as before. Then, I added 30 µM KPK and 10µM mTG for Pfs conjugation onto to the 
VLPQ monolayer. After conjugation for 60 min at RT, I washed the chips again and 
performed another round of mTG mediated conjugation as before to conjugate different 
concentrations of LQ (30 and 90 µM) onto the assembled VLPQ-KPK complex. After 
conjugation and wash steps, I provided 1mM SAH in PBS for 2 hrs at 37°C and 
measured the HCY yields through Ellman’s assay. I observed that with the increasing 
concentration of LuxS there was an increase in HCY generation indicating again LuxS 
as the rate limiting factor among Pfs-LuxS (Figure 4-5c). More importantly, HCY 
yields obtained from conjugation of LuxS in the second layer was lower than the HCY 
yields obtained from conjugation of LuxS in the first layer of assembly (Figure 4-4b). 
These results confirmed with our earlier results with layer by layer assembly where per 





Next, I intended to assemble a three-enzyme cascade comprising Tam, Pfs and 
LuxS for conversion of SAM to HCY. To overcome the kinetic limitations with both 
Tam and LuxS being rate limiting and the fabrication limitations with the layer-by-
layer approach (see page 114, Figure 4-10), I used genetically fused enzymes to 
reduce the number of layers required for the three enzyme assembly (Figure 4-5d). 
For this, I employed a fusion enzyme containing equimolar concentrations of Pfs and 
LuxS for conversion of SAH to HCY.[112] This fusion enzyme was also engineered 
with 5 Gln residues at the C termini (denoted FEQ) to enable conjugation via 
mTG[180].   I engineered Tam, the first enzyme in the cascade with 7 Lys residues at 
both the N and the C termini (labelled as KTK) and used KTK as the first layer of enzymes 
to conjugate onto VLPQ. I assembled the VLPQ monolayer onto 10mm2 gold chips as 
before and added 120 µM of KTK along with 60 µM mTG onto VLPs. To enable 
increased conjugation, I increased the conjugation time from 60 min to 2 hours at RT. 
After incubation, I washed the chips as before and conjugated     50 µM FEQ to VLP- 
KTK complex with another round of mTG mediated conjugation. After conjugation for 
2 hours, I washed the chips again and added substrates 1mM SAM and SAH separately 
and incubated the chips at 37˚C for 2 hours. HCY yields indicated that there was 22% 
conversion of SAM to HCY and 33% conversion of SAH to HCY (Figure 4-5e). 
Differences in conversion between SAM and SAH on chips could be attributed to lack 
of diffusion of substrate SAM and TAA, the methyl acceptor for Tam into the first layer 
of enzymes. Controls experiments containing just Tam assembled in the first layer on 





in percentage of conversion of SAM to HCY from 75% in controls to 22% again 
indicated reduction in per unit enzyme activity of FE assembled in second layer. 
Considering that I added low concentrations of second layer enzymes (50 µM) in 
comparison to the first layer of enzymes (120 µM) for conjugation, I could increase the 
concentrations of second layer enzymes to generate higher percentages of conversion 
of SAM to HCY 
In sum, I displayed that I could use the mTG mediated conjugation approach to 
build a three-enzyme cascade on VLPQ monolayers assembled on the gold surface. 
Enzyme activity decreased with increasing layers in the layer by layer assembly process 
and to circumvent this problem, I used genetically fused enzymes to minimize the 
number of layers required for a three-enzyme assembly. Alternatively, the possibility 
of fusing all the three enzymes into a single fusion protein to assemble as a single layer 






Figure 4-5 mTG mediated layer by layer assembly of three enzyme 
cascades onto gold chips 
(a) Scheme of layer-by-layer assembly of enzymes onto VLPs using transglutaminase 
chemistry. The first enzyme in the assembly, engineered with Lys tags at both the N 
and the C termini, is conjugated to VLP first through mTG. Unreacted Lys tag in the 
first layer is conjugated to second layer of enzymes engineered with Gln tags at the C 
termini. (b) Scheme of VLPs conjugated to Pfs and LuxS in a layer-by-layer process 
and the biochemical reaction catalyzed by the two enzymes assembled on chips. (c) 
Biochemical data from VLPQ-KPK-LQ complex assembled on chips. Enzyme complex 
is reacted with 1mM SAH and incubated for 2 hours and HCY is measured using 
Ellman’s assay. (d) Assembly of three enzymes Tam, Pfs and LuxS in two layers onto 
VLPQ.  First layer comprised of Tam engineered with Lys tags at both the N and the C 
termini and second layer comprised of Pfs-LuxS fusion protein engineered with Gln 





complexes are reacted with 1mM SAM as well as 1mM SAH and incubated for 2 hours 









In conclusion, I have developed a self-assembling 3D scaffold that displays 
desired functional groups for biocomponent functionalization on the sensor surface. In 
association with 3D scaffolds, I also adapted a bio-conjugation framework using which 
I built a three-enzyme cascade ‘layer-by-layer’ onto the VLPQ monolayer assembled 
on the gold surface. Combining the scaffold material and conjugation framework, I 
assembled a synthetic enzyme cascade at the electronic surface to convert methyl cycle 
intermediates (SAH and SAM) into homocysteine that can be detected through 
calorimetric and electrochemical means.  
The novelty of this approach is that I utilized bio-based materials and 
techniques for hierarchical assembly of interfacial materials and synthetic cascades on 
electronic surfaces. In addition to several conjugation chemistries that have been 
genetically engineered into VLPs for conjugation of cargoes, I have added mTG 
mediated conjugation chemistry for protein assembly onto VLPs and employed the 
facile and rapid mTG chemistry for multi-component assembly with nanoscale spatial 
resolutions.   
The significance of the work is that the process of integration of biological 
components with electronics is simplified due to self-assembly of interfacial material. 
3D scaffolds in combination with conjugation chemistry enables integration of more 





electrochemical means. TMV-VLP as 3D scaffolds are bio-compatible to human body 
and can be used as interface materials in in situ biosensors as well. Synthetic enzyme 
cascades assembled on the surface of the chip can be developed into a fully functioning 
biosensor for SAM and SAH detection. Stoichiometries of each individual enzymes 
needs to be optimized further to improve the response time and various sensor 
parameters like sensitivity, detection limit and linear range needs to be characterized 







4.6 Supplementary information 
4.6.1 Enzyme activity of Tam in solution 
After I purified the Tam enzyme (See 4.3.1), I ascertained whether the purified 
enzyme was active. I added all the three enzymes in the cascade, Pfs, LuxS and Tam 
(3 µM each) and added 1mM SAM as substrate for Tam along with 20 mM trans-
aconitic acid (TAA), the methyl acceptor for Tam in 0.4M HEPES buffer, pH 7.5 and 
incubated at 37°C for 60 min. After incubation, I measured the amounts of HCY 
generated by Ellman’s assay (Figure 4-6). I observed 100% conversion from SAM 
to HCY. Controls without Pfs and LuxS had no HCY.  
 
 
Figure 4-6 Enzyme activity of Tam in solution 
Measurement of conversion of SAM to HCY by soluble enzymes Tam, Pfs and LuxS 
(3 µM concentrations for each enzyme) using Ellman’s assay. Controls included just 






4.6.2 Electrochemical detection of HCY from SAM 
I had earlier used cyclic voltammetry (CV) to determine concentrations of HCY 
from SAH.[103] Here, I employed CV using a standard gold electrode (CH 
Instruments) to determine concentrations of HCY obtained from SAM. I incubated 
1mM SAM along with 3 µM each of Tam, Pfs and LuxS in solution and after 2 hours 
of incubation at 37°C I performed Ellman’s assay to measure HCY concentrations via 
Ellman’s assay.  Based on the concentrations obtained from Ellman’s assay, I prepared 
various dilutions of HCY and performed CV’s (Cyclic Voltammogram in Figure 
4-7a). I measured the total charge that was accumulated at the working electrode and 
built a standard curve correlating charge to HCY concentrations (Figure 4-7b). Based 
on the standard deviation of the blank sample (-2.1µC), I estimated the LOD of the 







Figure 4-7 Electrochemical detection of HCY 
(a) Cyclic voltammetry based detection of HCY from SAM. I swept potentials from 0 
V to 0.7 V and back and measured the amount of current that is generated with various 
concentrations of HCY in solution. (b) Standard curve correlating the charge 
accumulated in CV vs HCY concentrations, n=2.   
 
 
4.6.3 Michaelis-Menten kinetics on immobilized enzymes 
I intended to determine the km and Vmax values for each enzyme in the 
synthetic cascade when immobilized onto the VLPQ monolayer on the gold surface. To 
enable this, I used a gold coated 48 well plate (UMD FabLab) for the assembly of 





of VLPQ’s onto 1.4 cm2 wells in the 48 well plates. To the assembled VLPQ monolayer, 
I added 23 µM of each cascade enzyme separately along with 30 µM of mTG. All 
cascade enzymes were engineered with Lys tags at both the N and the C termini. After 
1hour incubation at RT, gold coated 48 well plates were washed with 0.1M phosphate 
buffer, pH 7.4 and incubated with varying concentrations of substrate SAM along with 
other soluble enzymes in the cascade required for generation of HCY at non-rate 
limiting concentrations (3 µM).   Rate of HCY generation (V) with various 
concentrations of the substrate SAM ([S]) were determined for each immobilized 
enzyme and plotted against substrate concentrations and fitted into Michaelis-Menten 
model in GraphPad software to determine km and Vmax values (Figure 4-8). kcat 
value for each enzyme was estimated by using 0.234 µM as effective enzyme 
concentration (Et) under following assumptions 1) assuming 50% coverage of VLPQ 
monolayer with each enzyme, and 2) assuming the efficiency of conjugation for each 






Figure 4-8 Plot of substrate-velocity for km and Vmax estimation. 
Determination of km, Vmax and kcat values for each enzyme in the cascade 
immobilized on the VLPQ monolayer. 23 µM of each enzyme in the cascade was 
immobilized onto the VLPQ monolayer and provided with varying concentrations of 
substrate S-adenosylmethionine (SAM). Other enzymes in the cascade required for 
HCY generation were provided at non-rate limiting concentrations (3 µM) in solution. 
(a) Plot of various substrate SAM concentrations ([S]) used and the velocity of 
homocysteine (HCY) generation (V) with all the three enzymes Tam, Pfs and LuxS for 
each SAM concentration employed. (b) Table indicating km, Vmax and kcat values for 
each of the immobilized enzyme obtained by fitting [S] and V values for all enzymes 








4.6.4 Conjugation of Enzymes to VLPs in solution 
As an alternative to layer-by-layer assembly, I intended to first conjugate 
enzymes to VLPs and then directly assemble the VLP-enzyme conjugates onto gold 
chips. To mediate conjugation of enzymes to VLPs in solution, I added 100 µg of 
VLPQ, 400 µg of EnzymeK and 16 µM mTG in a total reaction volume of 600 µls and 
incubated at RT for 2 hours with gentle shaking. To isolate VLPs and VLP-enzyme 
conjugates from the rest of the mixture, I performed ultracentrifugation at 112000g for 
two hours and re-dissolved the pellet in 100 µL of Phosphate Buffer, pH 7.0 by gentle 
shaking at 4°C for overnight. To characterize the enzyme activities of conjugates, I 
added various amounts of all the three VLP-enzyme conjugates onto 10mm2 gold chips 
and incubated at 4˚C for overnight. Post incubation, I washed the gold chips with 
phosphate buffer, pH 7 and provided 1mM substrate (SAM for Tam and SAH for both 
Pfs and LuxS) and other enzymes required for HCY generation. After 2-hour 
incubation at 37˚C, I measured HCY yields and results indicated that Pfs conjugates 
were the most active followed with LuxS and Tam conjugates (Figure 4-9a). As 
controls, I also performed relative enzyme activity measurements on VLP-enzyme 
conjugates in solution prior to adding on gold chips (data not shown). As expected, 
enzyme activities of conjugates in solution were higher than conjugates assembled on 
gold but the relative trends among the three enzyme-VLP conjugates were the same.   
However, I did not use this method for conjugation of VLPs and enzymes due 





recovery of conjugates from ultracentrifugation process. Hence, layer-by-layer 
approach was preferred to assemble the enzymes on chip. 
 
Figure 4-9 Measurement of relative enzyme activity of VLP-enzyme 
conjugates  
VLPs and enzymes were first conjugated in solution and purified. Relative enzyme 
activities of various VLP-enzyme conjugates on chips are displayed. VLP-LuxS and 
VLP-Pfs conjugates were provided with 1mM SAH and VLP-Tam conjugates were 
provided with 1mM SAM as substrates and incubated at 37°C for 2 hours. Other 
enzymes required for HCY generation are provided in solution at 3 µM concentration, 
n=3. 
 
4.6.5 Assembly of a three-enzyme cascade comprising individual 
Tam, Pfs and LuxS onto VLP monolayers 
I intended to assemble all the three individual enzymes Tam, Pfs and LuxS onto 
VLPs in a layer by layer fashion. However, since there was a reduction in enzyme 





to perform the three-enzyme cascade in two chips of equal sizes (10 mm2) placed side 
by side. I performed four conditions with different enzyme arrangements in each.  
In condition 1, I had 120 µM of KTK conjugated to VLPQ monolayer on gold 
chips and provided other two enzymes Pfs and LuxS (3 µM each) in solution. In 
condition 2, I had 120 µM of KTK conjugated to VLPQ monolayer on gold chips as the 
first layer of enzymes and PQ (20 µM) conjugated to KTK in the second layer. I also 
provided LuxS (3 µM) in solution. In condition 3, I had KTK and PQ on VLPQ 
monolayer, just like condition 2. In addition, I also had LK (60 µM) conjugated to the 
VLPQ monolayer in a second chip. In condition 4, I had 120 µM of KTK conjugated to 
VLPQ monolayer in chip 1 and VLPQ-KPK- LQ in chip 2. In all these conditions, I 
provided 1mM SAM as substrate, incubated at 37°C for 2 hours and HCY yields 
measured using Ellman’s assay.   
Results indicated that condition 1 with KTK conjugated to VLPQ monolayer had 
highest HCY yields with ~75% conversion of SAM to HCY. Condition 2 containing 
Tam and Pfs in a single chip had marginally lower yields than in condition 1 with ~60% 
conversion.  HCY yields from conditions 3 and 4 with LuxS in a second chip was lower 
than 20% indicating LuxS limitation in the cascade. To overcome these fabrication and 
kinetic limitations, I adopted a genetic fusion strategy to combine Pfs and LuxS into a 
single protein (labelled as Fusion enzyme, FE) and conjugated to Tam on VLP 






Figure 4-10 Assembly of a three-enzyme cascade comprising individual 
Tam, Pfs and LuxS onto VLPQ monolayers. 
Scheme (a) depicts various conditions used for the assembly of three enzymes in one 
and two chip configurations. Condition 1 had just one chip with Tam immobilized on 
the VLP monolayer. Condition 2 had 1 chip with both Tam and Pfs. Condition 3 had 
two chips, with Tam and Pfs in one chip and LuxS in the second chip. Condition 4 had 
two chips, with Tam in one chip and Pfs and LuxS in second chip. (b) Relative HCY 
yields from all 4 conditions after incubation with 1mM SAM for 2 hours at 37°C. Other 







Chapter 5 Integration of CRISPR with 
electrogenetic promoter systems for transcriptional 
regulation 
Sections from this chapter will be submitted for publication by March 2018 
5.1 Introduction 
5.1.1 Concept of electrogenetics 
The term electroceuticals was coined by the pharmaceutical company 
GlaxoSmithKline, refers to the application of electrical impulses to stimulate nerves 
and muscles for alleviation of pain[183], movement disorders[184], urinary 
functions[185], wound healing[186]  etc. However, these are examples of systems level 
perturbations in human body targeting nerves and muscles and the potential of targeting 
specific genes in the host system using electrical signals for modulating transcriptional 
regulation is largely unexplored.  
Synthetic biology,  an interdisciplinary field involving assembly of 
standardized biological parts to replicate basic engineering functions like logic Boolean 
gates, band pass filters, oscillatory functions etc. in biologic systems[187],  has 
produced two electrogenetic promoter systems. First system involves a bacterial 
promoter system in mammalian cells that responds to electrochemical conversion of 
ethanol to aldehyde with expression of SEAP (secreted embryonic alkaline 
phosphatase).[100] Second system is an oxidative stress response promoter SoxS that 
responds to Pyocyanin (PYO), an oxidative stress inducing molecule in bacteria. SoxS 





Pyocyanin(PYO) and has been used for electrical activation of Quorum Sensing (QS) 
and chemotaxis in bacteria.[99]   
 In both the electrogenetic systems described above, specific transgenes were 
produced from electrogenetic promoters. In this work, I propose to enhance the 
capabilities of electrogenetic systems by integrating synthetic transcriptional factors 
(TF) with electrogenetic promoters. To achieve this goal, I planned to integrate the 
CRISPR-Cas9 system based TF’s with the E coli SoxS promoters and upon 
electrochemical induction, TF’s can be produced to target specific genes in the bacterial 
host system and regulate transcription.  Both components of our system, the 
electrogenetic SoxS promoters and the CRISPR-Cas9 based synthetic TF’s are 
introduced in the next few sections. 
 
Scheme 5-1 Connecting electrogenetic promoter SoxS with CRISPR for 
bacterial transcriptional regulation.  
SoxRS based electrogenetic promoter systems can be electrically induced using 
Ferricyanide (Fcn) and Pyocyanin (PYO).  The CRISPR-Cas9 based transcriptional 
regulation system comprising of transcriptional activator dCas9-ω and gRNA can 
target any specific gene in the genome and modulate transcription. Combining the two 






5.1.2 Electrogenetics based on SoxRS system 
The SoxRS system is one of the two-primary oxidative-stress defense response 
mechanisms in bacteria and comprises of two components, SoxR, the repressor for 
SoxRS system and SoxS, a MerR family transcription factor. Both soxR and soxS are 
expressed from overlapping SoxRS promoters and in the absence of oxidative stress, 
SoxR represses the SoxRS promoters. Upon exposure to oxidative stress, SoxR de-
represses the SoxS promoter resulting in ~100-fold upregulation of SoxS. SoxS is the 
primary mediator of host defense mechanism to oxidative stress[188] and directly 
upregulates transcription of ~15 genes including superoxide dismutases (sodA and 
sodB), fumarate hydratase (fumC),  glucose-6-phosphate dehydrogenase (zwf) among 
others.  All of them are related to reduction of oxidative stress in bacteria. 
In a previous work from our group, the SoxRS system was re-purposed into an  
electrogenetic device where the oxidative stress response promoter SoxS is activated 
through Pyocyanin (PYO) and Ferricyanide (Fcn (O)) to express specific genes of 
interest.[99] PYO, a phenazine class antibiotic produced by Pseudomonas aeruginosa, 
can oxidize the SoxR repressor leading to de-repression of SoxS promoters. Upon 
oxidation of SoxR, the now-reduced PYO can be recycled again by electron transfer 
across the electron transport chains with oxygen as the final electron acceptor in aerobic 
conditions. Intracellular PYO recycling can also be mediated by redox active electron 
acceptors like Ferricyanide (Fcn (O)) and Ferrocyanide (Fcn (R)) whose redox state 
can be controlled by application of an electric potential through an electrode. Under 





the redox capacitance of the system to accept electrons can be controlled leading to 
control over intracellular PYO recycling and in turn the SoxS promoter activity.  
5.1.3 CRISPR-Cas9 based synthetic transcriptional factors (TF’s) 
for transcriptional regulation 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9 is 
an adaptive immune system in bacteria that is used for defense against viruses. The S 
pyogenes CRISPR-Cas9 system comprises of two components: Caspase 9 (Cas9), a 
nuclease capable of inducing double stranded breaks in the DNA and the crRNA 
(CRISPR RNA) that directs the Cas9 to a specific location in the genome. In general, 
when a virus infects bacteria, a small part of the DNA from the invader’s DNA is 
incorporated into the CRISPR array of the host bacteria as spacers and transcribed into 
a CRISPR RNA (crRNA). In type II CRISPR systems, crRNA forms a complex with 
the trans activating RNA (tracrRNA) and recruits the Cas9 to target the complementary 
target DNA.[189] Alternatively, crRNA and tracrRNA can also be replaced with a 
single short guide RNA (gRNA) sequence to direct the Cas9 to a specific location.[190] 
The CRISPR-Cas9 system is re-purposed as an efficient genome editing tool 
and used for creating knock-ins, knock-outs and single strand breaks (nicks) at specific 
sites in a variety of host genomes. The Cas9 which is a nuclease protein has also been 
modified to eliminate its nuclease activity (labelled as dead Cas9 or dCas9). The dCas9 
can be directed to genes of interest to silence genes in the genome (referred to as 
CRISPRi).[191, 192] Alternatively, dCas9 has been fused to transcriptional activators 





sites and activate transcription (referred to as CRISPRa). In addition, the CRISPR-Cas9 
system can also be easily multiplexed to simultaneously target different sites. For 
example, the type II CRISPR system in S pyogenes can naturally processes the CRISPR 
array into several different crRNAs that direct Cas9s to multiple locations. 
Alternatively, self-cleaving ribozyme processing systems such as hammerhead 
(HH)[195] and hepatitis delta virus (HDV)[196] have also been used to self-cleave a 
single transcript into multiple gRNAs.[101]  
In an electrogenetic context, the CRISPR-Cas9 system can be utilized to 
electrically target a specific location in the genome to either edit, silence or activate 
transcription by insertion of a 20-base pair gRNA spacer sequence into electrogenetic 
promoters. In this study, I intend to integrate the CRISPR-Cas9 system with SoxRS 
based electrogenetic promoters to electrically modulate bacterial host gene 
transcription. 
5.1.4 Goals of this work 
Due to the presence of well-established eukaryotic transcriptional activators 
such as VP64, p53 etc., transcriptional activation achieved through CRISPRa is in the 
range of several thousand fold in eukaryotic systems.[197] However, in the microbial 
context, CRISPRa is largely unexplored. Bikard et al had originally displayed 
CRISPRa in bacteria with transcriptional activation of up to 23-fold using ω subunit of 
RNA polymerase as transcriptional activator. The ω subunit is the non-essential 
component in bacterial RNA polymerase and its function includes stabilizing the RNA 





mammalian transcriptional activators that actively recruit transcriptional factors for 
assembly of RNA pol II at target sites. Hence, there is a strong need to develop efficient 
transcriptional activators in bacteria.  Here, I studied whether increase in number of 
transcriptional activators (ω subunits) can lead to enhanced CRISPRa.  
Additionally, there is a need to create tunable and controllable CRISPRa 
systems for better integration with the existing synthetic biology tool set. In this study, 
I characterized various factors such as promoter and copy numbers of plasmids 
expressing CRISPR components; mode of spacer delivery through the short gRNA 
system and the tracrRNA: crRNA hybrid system; effect of mutations in the seed region 
of spacers on the effect of CRISPRa to obtain tunable, controllable CRISPRa. In 
addition, I also integrated the CRISPRa system into electrogenetic SoxS promoters to 
obtain an electrically tunable CRISPRa.  
One of the major challenges in synthetic biology is to make the assembled 
biological parts function uniformly across a vast variety of chassis strains.[200] Such 
challenges exists with the previously described electrogenetic systems as well.[99] 
Since, the electrochemical activation exploits the oxidative stress mechanisms in native 
bacteria, the native host oxidative stress defense mechanism are removed. I explored 
to see if CRISPR-Cas9 mediated temporal and reversible silencing of soxS might lead 





5.2 Materials and Methods 
Table 5-1: Table of strains and plasmids 
Strain Relevant Genotype and Property Reference 
NB101 ZK126[201] ΔrpoZ This study 
NB2031 ZK126[201] ΔrpoZ, ΔluxS This study 
JEN202 MG1655, ΔrpoZ [194] 
GC4468 Δ(argF-lac)169 λ IN(rrnD-rrnE)1 rpsL179(strR) [202] 
DJ901 DlacU169 rpsL DsoxRS901(GC4468 ΔsoxRS) [202] 
Plasmids Relevant Genotype and Property Reference 
pWJ89 pZS*24-MCS1, PAM-rich 5' UTR region, J23117, gfp-mut2 [194] 
pWJ66 pACYC184(CmR) with tracrRNA, cas9(D10A, H840A)-ω, 
repeat-BsaI spacer-repeat 
[194] 
p108gRNA 108-spacer in pgRNA-bacteria (Addgene plasmid # 44251) with 
pBR322 origin, Ampr, J23119 promoter 
This study 
pControl gRNA Control spacer in pgRNA-bacteria (Addgene plasmid # 44251) 
with pBR322 origin, Ampr, J23119 promoter 
This study 
pdCas9-ω ω was inserted into C termini of dCas9 in pdCas9-bacteria 
(Addgene plasmid # 44249), p15A, pLtetO-1, Cmr 
This study 
pdCas9-2ω Two ω’s was inserted into C termini of dCas9 in pdCas9-bacteria 
(Addgene plasmid # 44249), p15A, pLtetO-1, Cmr 
This study 
pdCas9-3ω Three ω’s was inserted into C termini of dCas9 in pdCas9-bacteria 
(Addgene plasmid # 44249) , p15A, pLtetO-1, Cmr 
This study 
pdCas9-ωssRA ssRA protein degradation tag added to the C termini of ω in 
pdCas9-ω 
This study 
pIntdCas9-ω pdCas9-ω with engineered Tet promoter and dCas9 RBS sites This study 





p108gRNA with single point mutations in the seed region of 108 
spacer 
This study 
pTrc-108gRNA 108gRNA sequence inserted in pTrcHisA plasmid(Invitrogen) This study 
pSoxS-
108gRNA 
108gRNA sequence inserted into SoxS promoter in pTT01[99] This study 
pSC-S108 SoxS-108gRNA, pSC101*, Kanr This study 
pMC-GFP pWJ89 with pBR322 and Ampr instead of pSC101* and Kanr This study 
pMC-LasI lasI instead of gfpmut2 in pMC-GFP This study 
pMC-LuxS luxS instead of gfpmut2 in pMC-GFP This study 
pMC-phiLOV phiLOV instead of gfpmut2 in pMC-GFP This study 
pS-1, 2 SoxS specific gRNA spacers (S1 and S2) inserted into pgRNA-
bacteria (Addgene plasmid # 44251) with pBR322 origin, Ampr, 
BBa_J23119 promoter 
This study 
pTT01 phiLOV under SoxS promoter, pBR322, Ampr [99] 
pNB01 SoxS specific S1 gRNA under BBa_J23119 promoter in pTT01 This study 
pNB02 S1 gRNA under SoxS promoter in pTT01 This study 







pNB04 HH-ControlgRNA-HDV-HH-108gRNA-HDV under SoxS 
promoter, pBR322, Ampr 
This study 
 
Table 5-2: Table of Primers 
Primer 
Name Sequence (5’-3’) Features 
p108gRNA 
N1 tccggcctgcagccagttttagagctagaaatagcaag 
Amplifies 108spacer with pgRNA-bacteria [for 
p108gRNA] 
N2 tcttccacaacacgcactagtattatacctaggactg 




Amplifies Control spacer with pgRNA-bacteria 
[for pControlgRNA] 
N4 ccgagactggtctcaactagtattatacctaggactg 
Amplifies Control spacer with pgRNA-bacteria 
[for pControlgRNA] 
pTrc- ω, pTrc- 2ω and pTrc- 3ω 
N5 gctagcctcgagggtggtggttcagcacgcgtaactgttcaggac Nhe-1, Xho-1; amplifies ω subunit-1 
N6 tgcagatcttgaaccaccaccacgacgaccttcagcaatagc Bgl-2; amplifies ω subunit-1 
N7 tcaagatctgcacgcgtaactgttcaggac Bgl-2; amplifies ω subunit-2 
N8 gcgaattcagaaccaccaccacgacgaccttcagcaatagcgg GGGS linker, EcoR-1; amplifies ω subunit-2 
N9 gaattcgcacgcgtaactgttcaggac EcoR-1; amplifies ω subunit-3 
N10 aagcttttaacgacgaccttcagcaatagcg Hind-3; amplifies ω subunit-3 
pdCas9- ω, 2ω, 3ω 
N11 gaaggtcgtcgttaaggatctccaggcatcaaataaaacgaaagg 
Stop site; amplifies vector pdCas9 [for pdCas9- 
ω, 2ω, 3ω] 
N12 aacagttacgcgtgctgaaccaccaccgtcacctcctagctgactcaaatcaatgc 
GGGS linker, overlaps ω, amplifies vector 
pdCas9[for pdCas9- ω, 2ω, 3ω] 
pdCas9- ssRA 
N13 gctaggaggtgacggtggtggttcagca Amplifies ω subunit-3 [for pdCas9-ωssRA] 
N14 atgcctggagatccttaagcagccagagcgtagttttcgtcgttagcagcacgacgaccttcagc 
Amplifies ω subunit-3 with ssRA tag and stop 
codon [for pdCas9-ωssRA] 
pdIntCas9- ω and pdIntCas9- ωssRA 
N15 Atcggcacaaatagcgtcgg Amplifies pdCas9 excluding pLtetO-1 [for  pIntdCas9-ω and pIntdCas9-ωssRA] 
N16 cattagagctgcttaatgaggtcgg Amplifies pdCas9 excluding pLtetO-1   [for  pIntdCas9-ω and pIntdCas9-ωssRA] 
pTrc-108gRNA 
N17 aattaaagaggtatatattaagcgtgttgtggaagatcc 
Amplifies 108gRNA, overlaps pTrcHisA [for 
pTrc-108gRNA] 
N18 tctcatccgccaaaacagccaaaaaagcaccgactcgg 
Amplifies 108gRNA, overlaps pTrcHisA [for 
pTrc-108gRNA] 
N19 ggatcttccacaacacgcttaatatatacctctttaatt 
Amplifies pTrcHisA, overlaps 108gRNA spacer-






Amplifies pTrcHisA, overlaps 108gRNA spacer-
scaffold [for pTrc-108gRNA] 
pSoxS-108gRNA 
N21 catgtttgacagcttatcatcgatattaaaaaagcaccgactcggt 
Amplifies 108gRNA, overlaps pTT01 [for 
pSoxS-108gRNA] 
N22 tgaaaagaggcagatttgcgtgttgtggaagatccg 
Amplifies 108gRNA, overlaps pTT01 [for 
pSoxS-108gRNA] 
N23 cggatcttccacaacacgcaaatctgcctcttttca Amplifies pTT01, overlaps 108gRNA spacer-scaffold [for pSoxS-108gRNA] 
N24 accgagtcggtgcttttttaatatcgatgataagctgtcaaacatg 
Amplifies pTT01, overlaps 108gRNA spacer-
scaffold [for pSoxS-108gRNA] 
pSc-S108 
N25 ctacgctctggctgcttaaggatcccatggtacgcgtgctagagg 
Amplifies pSC101, Kanr backbone (pWJ89) [for 
pSc-S108] 
N26 ttttcgtcgttagcagctttgtatagttcatccatgccatgtgtaatcccag 
Amplifies pSC101, Kanr backbone(pWJ89) [for 
pSc-S108] 
N27 aaatctgcctcttttcagtg Amplifies SoxR-pSoxS-108gRNA [for pSc-S108] 
N28 atcgatgataagctgtcaaa Amplifies SoxR-pSoxS-108gRNA [for pSc-S108] 
pMC-GFP 
N29 tacaagagccataagaacctctacaaactctttttgtttatttttctaaatacattcaaatatgtatc Amplifies Amp-pBR322 cassette [for pMC-GFP] 
N30 caggatgaggatcgtttcgccgcgttgctggcgtttttc Amplifies Amp-pBR322 cassette [for pMC-GFP] 
N31 aggttcttatggctcttg Amplifies pWJ89 excluding pSC101, Kan
r [for 
pMC-GFP] 




N33 ggatcccatggtacgcgtg Amplifies MC-GFP excluding gfpmut2 [for pMC-LasI] 
N34 ctagatttctcctctttaaaggaattcgc Amplifies MC-GFP excluding gfpmut2 [form MC-LasI] 
N35 tttaaagaggagaaatctagatgatcgtacaaattggtcgg Amplifies lasI [for pMC-LasI] 
N36 gcacgcgtaccatgggatcctcatgaaaccgccagtcg Amplifies lasI [for pMC-LasI] 
pMC-phiLOV 
N37 tttaaagaggagaaatctagatgattgaaaaaagctttgtgattac Amplifies phiLOV [for pMC-phiLOV] 
N38 gcacgcgtaccatgggatccttacacatgatcgctgcc Amplifies phiLOV [for pMC-phiLOV] 
N39 ctagatttctcctctttaaaggaattcgc Amplifies MC-GFP excluding gfpmut2 [for pMC-phiLOV] 
N40 ggatcccatggtacgcgtg Amplifies MC-GFP excluding gfpmut2 [for pMC-phiLOV] 
pMC-LuxS 





N42 gcacgcgtaccatgggatccttacctgcaacttctctttc Amplifies luxS [for pMC-LuxS] 
N43 ggatcccatggtacgcgtg Amplifies MC-GFP excluding gfpmut2 [for pMC-LuxS] 
N44 ctagatttctcctctttaaaggaattcgc Amplifies MC-GFP excluding gfpmut2 [for pMC-LuxS] 
pS1 and S2 
N47 gaataattttctgatgttttagagctagaaatagc Replaces 108gRNA with S1gRNA [for pS1] 
N48 aggatcttatcgcatactagtattatacctaggac Replaces 108gRNA with S1 gRNA [for pS1] 
N49 gaataattttctgatgttttagagctagaaatagc Replaces 108gRNA with S2 gRNA [for pS2] 
N50 aggatcttatcgcatactagtattatacctaggac Replaces 108gRNA with S2 gRNA [for pS2] 
pNB02 
N53 gaataattttctgatgttttagagctagaaatagc Replaces 108 spacer with S1 spacer in Sc-S108 [for NB02] 
N54 aggatcttatcgcataagcttaaatctgcctcttttc Replaces 108 spacer with S1 spacer in Sc-S108 [for NB02] 
pNB01 
N55 ggagtcgcataagggagagcgaattctaaagatctttgacagctagc Amplifies S1 gRNA with BBa_J23119 promoter 
N56 gaaggctctcaagggcatcgggcccagtctttcgactg Amplifies S1 gRNA with BBa_J23119 promoter 
N57 cgatgcccttgagagccttc Amplifies pTT01 backbone 










Overlaps with luxS for NB2031 strain 
 
5.2.1 List of Sequences and spacers 
Spacers: 
Spacer Control (5’-3’):  tgagaccagtctcggaagctcaaaggtctc 
Spacer 108 (5’-3’):   gcgtgttgtggaagatccggcctgcagcca 
Spacer NC-1 (5’-3’):  gcgtgttgtggaagatccggcctgcagcca 
Spacer NC-4 (5’-3’):   gcgtgttgtggaagatccggcctgcagcca 
Spacer NC-5 (5’-3’):   gcgtgttgtggaagatccggcctgcagcca 
Spacer S1 (5’-3’):   atgcgataagatcctgaataattttctgat 
Spacer S2 (5’-3’):   atgcgataagatcctgaataattttctgat 
 





























All the strains used in this study are listed in Table 5-1. Two new strains 
NB101 and NB2031 are created for use in Crispr experiments. E. coli NB101 (ZK126 
ΔrpoZ) was generated from E. coli ZK126[201] as background strain using primers 
described here.[194]  E. coli NB2031 (NB101 ΔluxS) was generated using primers N59 
and N60 listed in Table 5-2. Both strains were prepared using λ red recombinase.[203]  
5.2.3 Plasmid Preparation 
List of all the plasmids used in this study are listed in Table 5-1. List of all the 
primers used for each plasmid and strain construction are listed separately in Table 





5.2.3.1 Plasmids created using Site directed Mutagenesis 
I prepared p108gRNA and pControlgRNA by swapping spacers in the pgRNA 
vector (Addgene plasmid # 44251) through site directed mutagenesis and standard 
protocols (New England Bio labs). I prepared non-cognate gRNA1, 4 and 5 (pMC-
gRNA 1, 4 and 5) by site directed mutagenesis as well by swapping spacers with 
p108gRNA as vector. I prepared plasmid pS1 and pS2 for SoxS repression by swapping 
the 108-spacer sequence with spacer S1 and S2 in p108gRNA. I prepared pMC-
phiLOV ssRA by amplifying phiLOV overlapping primers encoded with ssRA tag. I 
prepared pNB02 by swapping 108spacer in pSC-S108 with S1 spacer. See 5.2.4 for 
plasmid maps. 
5.2.3.2 Preparation of pdCas9- ω, pdCas9-2ω, and pdCas9-3ω 
To study whether the number of ω subunits attached to each dCas9 molecule 
play a role in efficiency of transcriptional activation, I created pdCas9-ω, pdCas9-2ω 
and pdCas9-3ω respectively. I used a two-stage process to create these plasmids. 
Firstly, I PCR amplified ω1, ω2 and ω3 subunits separately and used pTrcHisA 
(Invitrogen) as a shuttle vector to add all the ω subunits. Firstly, I added ω3 subunit 
into pTrcHisA through NEB restriction enzymes EcoRI and Hind-III to create pTrc-ω. 
Then, I added ω2 subunit to pTrc-ω through restriction digestion with enzymes Bgl-II 
and EcoRI to create pTrc-2ω. Then, I employed another round of restriction digestion 
with enzymes NheI and Bgl-II to add ω1 subunit to pTrc-2ω to create pTrc-3ω. Then 





pTrc-3ω plasmids through restriction digestion with Xho-1 and EcoRI and Gibson 
assembled into pdCas9-Bacteria (Addgene plasmid # 44249) vector amplified with 
primers N11 and N12 to create pdCas9-ω, pdCas9-2ω, and pdCas9-3ω respectively. 
All ω subunits and dCas9 had a GGGS linker in between each of them.   
5.2.3.3 Preparation of plasmids with Gibson Assembly 
pdCas9-ωssRA: I PCR amplified ω subunit in pTrc-ω using primers encoding the ssRA 
tag and Gibson assembled into amplicon derived from pdCas9-Bacteria and primers 
N11 and N12. pIntdCas9-ω and pIntdCas9-ωssRA: A pTet promoter intergenic region 
containing synthetic promoter for Tet repressor and reduced strength RBS site for 
dCas9 was reported[204]. The sequence of the synthetic intergenic region is mentioned 
in list of sequences. I amplified plasmids pdCas9-ω and pdCas9-ωssRA with primers N 
15 and N16 and Gibson assembled into the synthetic intergenic region (gene fragment 
from IDT) to create pIntdCas9-ω and pIntdCas9-ωssRA. pTrc-108gRNA: I PCR 
amplified 108gRNA sequence from p108gRNA plasmid and Gibson assembled into 
pTrcHisA (Invitrogen). pSoxS-108gRNA: I PCR amplified 108gRNA sequence from 
p108gRNA plasmid and Gibson assembled into pTT01[99]. pSc-S108gRNA: I 
replaced Ampr cassette and pBR322 origin in pSoxS-108gRNA with Kanr and 
pSC101* cassette from pWJ89[194] though PCR and Gibson assembly. pMC-GFP: I 
replaced Kanr and pSC101* cassette in pWJ89 with Ampr and pBR322 cassette from 
pgRNA though PCR and Gibson assembly. pMC-phiLOV: I replaced gfpmut2 in 





I replaced gfpmut2 in pMC-GFP with lasI from pET200-lasI (lab stocks). pNB01: I 
PCR amplified S1gRNA and J23119 promoter from pS1 and Gibson assembled into 
pTT01. pNB03 and 04: Firstly, I synthesized gene fragments encoding HH-gRNA-
HDV for 108gRNA, ControlgRNA and S1gRNA. Additionally, I prepared a PCR 
amplicon excluding the 108gRNA from pSC-S108 and used it as vector to insert 
various HH-gRNA-HDV sequences under SoxS promoter. pNB03 contained HH-
S1gRNA-HDV and HH-108gRNA-HDV. pNB04 contained HH-ControlgRNA-HDV 












5.2.5 Media and growth conditions 
I used lysogeny broth (LB) for all experiments performed in aerobic conditions 
with 250 r.p.m shaking. I grew overnight cultures in LB media at 37⁰C and the 
following day re-inoculated the cultures in fresh LB media at 1:100 ratio and used as 
per instructions in each specific experiment.  For experiments performed in anaerobic 
conditions, I first grew overnight cultures in LB media at 37⁰C and the following day 
re-inoculated the cultures in fresh LB media at 1:100 ratio and grew the cells till OD 
0.6. Then I washed the cells, re-suspended in minimal-M9 (1 × M9 salts, 0.4% 
glucose, 0.2% casamino acids, 2 mM MgSO4, 0.1 mM CaCl2 and 100 mM 
MOPS) and used for further experiments. I created anaerobic conditions in a Coy 
anaerobic chamber (Grass Lake, MI) as per manufacturer instruction using 
nitrogen and a gas mixture comprising of 90% nitrogen, 5% carbon dioxide 
and 5% hydrogen.  
5.2.6 Fluorescence measurements using plate reader and flow 
cytometry 
I used plate readers to measure GFP fluorescence measurements with an 
excitation wavelength of 488nm and emission wavelength of 520nm. In each well, 
200µl of cells in LB media were used and LB fluorescence was removed from all 
measurements. I used flow cytometry to measure phiLOV fluorescence. I used a 
constant forward and side scatter settings to capture cells and measured mean green 





minimum of 50,000 cells were used for fluorescence measurements of each sample 
and analysis was done in FACSDiva and MS-Excel. 
5.2.7 Electrochemical set-up and electrochemical conversion of 
Fcn (R) to Fcn (O) 
Electrochemical experiments were performed inside the Coy anaerobic 
chamber. Our electrochemical set-up set up consisted of a wound gold wire (0.5 mm 
diameter, ~50 cm in length) as both working and counter electrodes and an Ag/AgCl 
electrode (CH Instruments) as reference. A CH Instruments, Inc. (Austin, TX) 600-
series potentiostat was used for controlling voltages. Agar salt bridges were prepared 
as described here[99]. Our sample setup consisted of two glass vials with one vial 
consisting of 1 ml of cells supplemented with 50 mM Fcn (R) and PYO and the other 
consisting of 1 ml of 50 mM Fcn(O). Two gold wire electrodes were immersed in 
both vials and the reference electrode in the vials with cells.  Both vials were also 
connected by two salt bridges. For electrochemical conversion of Fcn (R) to Fcn (O), 
I applied a voltage of 0.5V to cells via the working electrode and after oxidation, 
cells were removed from vials, transferred to culture tubes and incubated in a mini 
37⁰C incubator inside the anaerobic chamber without shaking. For time course 
experiments in Figure 5-7, 100 µls of cells was taken at each time point and fixed 





5.2.8 AI-1 reporter assay 
I grew AI-1 reporter cells (JLD271 strain containing pAL105[205]) overnight 
in LB media with kanamycin and tetracycline at 37°C and the next day diluted the 
reporter cells 2500x in fresh media.  Then, I added 10µL of each conditioned media 
sample with 90 µL of diluted reporter cells in FACS tubes (Becton Dickinson) and 
incubated for 3 hours in a 30°C shaker. After incubation, I measured luminescence 
using a GloMAX luminometer (Promega). For each experiment, I built a standard curve 







5.3.1 Optimization of a ‘tunable and controllable’ CRISPRa system 
in bacteria 
In this study, I intended to create a tunable and controllable CRISPR-Cas9 
mediated transcriptional activation (CRISPRa) system to target and activate specific 
genes in bacteria. In this pursuit, I characterized the strain used for transcriptional 
activation, optimized the expression conditions including promoters and copy numbers 
of plasmids expressing the two components of CRISPRa system: dCas9 based 
transcriptional activator and spacers; number of transcriptional activator subunits fused 
to dCas9 and the mode of delivery of spacers. 
First, I optimized the strain used for transcriptional activation experiments. 
Previously, Bikard et. al., had reported a 23-fold and 7-fold CRISPR mediated 
transcriptional activation (CRISPRa) of GFP with two different spacers namely 108 
and 105. RNA polymerase subunit ω (rpoZ) was used as the transcriptional activator  
and was genetically fused to S. pyogenes dCas9 in a ΔrpoZ strain of E. coli MG 1655 
(JEN202).[194] Since I had previously characterized Quorum Sensing (QS) in W3110 
strains and I intended to integrate QS with CRISPRa in this study, I first removed rpoZ 
in ZK126 (W3110 ΔlacZ) to create NB101. Then, I repeated the same CRISPRa 
experiments reported in Bikard et. al., in our lab and observed the transcriptional 
activation to be ~16-fold and 6-fold using spacers 108 and 105 in the JEN202 strain. I 





same 108 spacer and the GFP target plasmid (Figure 5-1). In further studies, I used 
NB101 strain as host strain for all our experiments. Subsequently, I also deleted luxS 
responsible for production of the QS enabling molecule Autoindicer-2 (AI-2) in the 
NB101 strain to create NB2031 strain. Deletion of luxS had no effect on CRISPRa (data 
not shown).  
 
Figure 5-1 Comparison of CRISPR activation obtained from NB101 
strain (ZK126 rpoZ-) and MG1655 rpoZ- strain. 
I performed CRISPRa experiment using the spacers (105, 108 and non-specific spacer), 
target plasmid (pWJ89) and MG1655 rpoZ- strain as detailed in Bikard et. al. I also 
used the 108-spacer in the newly created NB101 (ZK126 rpoZ-) strain and measured 
CRISPRa using GFP from pWJ89. Data indicates GFP fluorescence measured using 
the plate reader after 16 hours of re-inoculation, n=3. 
 
Previously, Bikard et. al., had used constitutive S. pyogenes promoters to 
express both dCas9-ω and 108 spacer for transcriptional activation and spacers were 






Here, I studied whether spacer expression can be moved from the tracrRNA: 
crRNA hybrid system to the short gRNA system for CRISPRa. In our study, I used the 
same spacer 108 to target GFP in the same plasmid as reported in Bikard et.al., 
however, I expressed the spacers in the form of short guide RNA(gRNA) placed under 
a strong constitutive promoter (J23119) in p108gRNA (See 5.2.3.1). In addition, I 
placed the dCas9-ω under a Tet promoter, pdCas9-ω (See 5.2.3.2) and examined 
dCas9-ω in absence of the inducer anhydrotetracycline (aTc) using only leaky 
expression from Tet promoter (Figure 5-2A). I grew NB101 cells harboring plasmids 
p108gRNA, pdCas9-ω and pWJ89 in LB media at 37°C and measured GFP 
fluorescence over time using a plate reader (See 5.2.6).  
I found that the combination of the use of gRNA instead of tracrRNA: crRNA 
hybrid, strong constitutive promoters for gRNA expression and leaky expression of 
dCas9-ω under the Tet promoters resulted in ~5-fold greater GFP activation (Figure 
5-2 B and C) in comparison to GFP activation with spacers expressed as tracrRNA: 
crRNA hybrids along with dCas9-ω from native S. pyogenes promoters. These results 
indicated the importance of relative expression levels of dCas9-ω and spacers and the 







Figure 5-2 Comparison of CRISPR activation from tracrRNA: crRNA 
and gRNA delivery systems. 
(A) Scheme of CRISPR-Cas9 mediated transcriptional activation (CRISPRa) of GFP 
in target plasmid pWJ89 using tracrRNA: crRNA and gRNA systems for spacer 
delivery. In tracrRNA: crRNA system, spacers were expressed as tracrRNA:crRNA 
hybrids  in combination with dCas9-ω from S. pyogenes promoters. In gRNA system, 
spacers were expressed as single short gRNA under constitutive J23119 promoters 
from p108gRNA and dCas9-ω from the Tet promoter in pdCas9-ω under leaky 
expression conditions. (B) Fluorescence and (C) OD measured using plate reader for 
10 hours after re-inoculation, n =3 
 
To increase CRISPRa, a common strategy used in eukaryotic CRISPRa systems 





VP160, a 10mer of eukaryotic transcriptional activator VP16 had greater CRISPRa 
than VP16.[193]  I attempted to study whether the increase in ω subunits fused to dCas9 
resulted in increased CRISPRa in bacteria.  
To this end, I engineered dCas9 with up to three ω subunits with flexible linker 
tags (GGGS) in between each ω subunit and dCas9 to create pdCas9-ω, pdCas9-ωω 
and pdCas9-ωωω (See 5.2.3.2). All dCas9-ω fusions were under a Tet promoter but I 
studied CRISPRa using leaky expression from the Tet promoter. I targeted these 
different transcriptional activators to the GFP plasmid (pWJ89) via the same 108-
spacer from p108gRNA (Figure 5-3 A) and measured GFP fluorescence mediated by 
CRISPRa. Fluorescence data indicated that unlike the eukaryotic transcriptional 
activators, dCas9 engineered with a single ω resulted in higher transcriptional 
activation than dCas9 fused with two or three ω subunits (Figure 5-3 B). Controls 
including dCas9-ω with nonspecific spacers (pControlgRNA) and dCas9 lacking ω 
subunits had negligible transcriptional activation.  
Considering that the distance between spacers and transcriptional start sites 
(TSS) of the target gene is important for transcriptional activation[194], I used the same 
spacer to test all the dCas9-ω fusions. With increasing number of ω subunits as 
transcriptional activators, it needs to be tested whether re-optimization of spacer 







Figure 5-3 Role of the number of ω subunits fused to dCas9 on 
CRISPRa in bacteria. 
(A) Comparison of the effect of the number of ω subunits fused to dCas9 for CRISPRa 
of GFP. I created different dcas9s (dCas9-ω, dCas9-2ω and dCas9-3ω) placed under 
the Tet promoter and measured CRISPRa of GFP (pWJ89) using leaky expression of 
dCas9 fusions from the Tet promoter in NB101 cells. (B) GFP Fluorescence and GFP 
Fluorescence/OD data indicating transcriptional activation from various dCas9-ω 







To create a tunable and controllable CRISPRa system, I intended to express the 
CRISPR elements, dCas9-ω as well as gRNA from inducible promoters. I tried to 
control expression of dCas9-ω from Tet promoters through induction of Tet promoters 
with aTc (Supplementary Figure 5- and Supplementary Figure 5-1), but I was 
unable to create a controllable CRISPRa response. So, I used leaky expression of 
dCas9-ω from the Tet promoters in all further experiments.  
Next, I studied whether controlling the levels of gRNA might lead to a tunable 
CRISPRa. I had performed all our experiments with gRNAs expressed from strong 
constitutive J23119 promoter in p108gRNA. I intended to study whether controlling 
gRNA expression by placing gRNA expression under inducible promoters might lead 
to a tunable CRISPRa.  
In this experiment, I moved gRNA expression from constitutive J23119 
promoter to the Trc and SoxS promoters (pTrc-108gRNA and pSoxS-108gRNA 
respectively, See 5.2.3.3) while retaining the same plasmid origin (pBR322) (Figure 
5-4A). I induced both the promoters (IPTG for pTrc and PYO for pSoxS promoter) and 
measured the gRNA levels expressed after 6 hours of induction. I also measured 
CRISPRa mediated GFP fluorescence at 4 and 8 hours.  
qPCR results (Figure 5-4B) indicated that there was an increase in gRNA 
expression from both the pTrc and pSoxS promoters with increasing inducer 
concentrations. However, fluorescence data indicated that there was no change in 





(Figure 5-4 C and D). Leaky expression of gRNAs from both the promoters displayed 
saturating CRISPRa response.  
To reduce leaky expression of gRNAs, I replaced the origin of the plasmid 
expressing gRNA under SoxS promoter from a high copy pBR322 origin to a low copy 
pSC101 origin to create pSC-S108 plasmid. Additionally, I also replaced pSC101 
origin in target GFP plasmid pWJ89 with pBR322 to create pMC-GFP (Figure 5-5 A). 
With this re-arrangement of copy numbers of target genes as well as promoters that 
express gRNA, I studied whether controllable gRNA expression from SoxS promoters 







Figure 5-4 Controlling gRNA expression using inducible promoters to 
control CRISPRa. 
Scheme of controlling gRNA expression from the inducible pTrc and pSoxS promoters 
to mediate a tunable and inducible CRISPRa response. I engineered 108gRNA 
sequence into plasmids with pTrc (pTrc-108gRNA) and pSoxS (pSoxS-108gRNA) 
promoters and transformed them along with pWJ89 and pdCas9-ω into NB101 cells. 
(B) I induced pTrc and pSoxS promoters with varying concentrations of inducers 
(IPTG and Pyocyanin for pTrc and pSoxS respectively) and performed qPCR at 6 hours 
to measure relative gRNA expression levels. Negative control was mRNA from an E 
coli strain lacking gRNA expression and positive control was gRNAs expressed under 
J23119 constitutive promoter from p108gRNA in NB101 cells. CRISPRa resulting 
from the gRNA expression induced from pTrc (C) and pSoxS (D) promoters was 






I transformed the newly created high copy number target plasmid pMC-GFP 
and low copy SoxS promoter expressing gRNA, pSC-S108 plasmid into NB101 cells 
along with pdCas9-ω. I induced the SoxS promoter with varying concentrations of PYO 
and measured the relative gene expression levels of gRNA from SoxS promoters 
(Figure 5-5 B) as well as measured the GFP fluorescence mediated by CRISPRa 
(Figure 5-5C).  Results indicated that with increasing concentrations of PYO, there 
was increase in concentration of gRNA expression from SoxS promoter as well as 
increase in GFP fluorescence from target plasmids due to CRISPRa.  
In sum, I have shown that by moving away from the tracrRNA: crRNA hybrid 
system from native S. pyogenes promoters to a short gRNA system under synthetic 
promoters, I could generate a ~5-fold higher CRISPRa response (Figure 5-2). In 
contrast to eukaryotic transcriptional activators, addition of more bacterial transcription 
activating subunits per dCas9 molecule did not result in increase of CRISPRa in 
bacteria (Figure 5-3). By varying the stoichiometric ratios of not just gRNA but also 
the number of targets, I was able to develop a tunable CRISPR based transcriptional 
activation system (CRISPRa) (Figure 5-5) in bacteria. 







Figure 5-5 Tunable CRISPRa system by controlling gRNA expression. 
 (A) Scheme of a tunable CRISPRa system. I placed pSoxS promoter expressing the 
gRNA for transcriptional activation in a pSC101* origin plasmid (pSC-S108) and 
moved the GFP target to a pBR322 origin plasmid (pMC-GFP). I transformed pSC-
S108, pMC-GFP and pdCas9-ω into NB101 cells and induced the pSoxS promoter with 
varying concentrations of Pyocyanin. (B) qPCR data indicating relative gRNA 
expression levels from SoxS promoter with different Pyocyanin concentrations after 6 
hours of induction. (C) CRISPRa mediated GFP expression using fluorescence 





5.3.2 Electrical control of CRISPRa 
Having shown that I can tune CRISPRa by controlling gRNA expression from 
a low copy SoxS promoter, I next wanted to display tunable electrical control over 
gRNA expression resulting in an electrically tunable CRISPRa.  Previously, electrically 
induced SoxS promoters were used for direct expression of specific transgenes in 
bacteria.[99]  In this study, I planned to use the same SoxS promoters to express gRNAs 
that in turn mediated the CRISPR-Cas9 mediated transcriptional activation (CRISPRa) 
of target genes. To display this, I first optimized the concentrations of mediators PYO 
and Fcn that are required for electrical activation of SoxS promoter.  
SoxS promoters can be induced by just PYO under aerobic conditions with 
oxygen acting as electron acceptor for intracellular recycle of PYO. Under anaerobic 
conditions, the role of electron acceptor can be taken up by redox mediators such as 
Ferricyanide (Fcn (O)). By electrically controlling the conversion of Fcn (R) to Fcn 
(O), the redox capacitance of the system can be controlled and as a result SoxS 
promoter activity can be controlled as well.[99] To perform experiments under 
anaerobic conditions without oxygen, I replaced the reporter gene from gfpmut2 in 
pMC-GFP with phiLOV through Gibson assembly to create pMC-phiLOV (See 
5.2.3.3) and used it as target for CRISPRa experiments. phiLOV is capable of 
fluorescing under both aerobic and anaerobic conditions.[206]  I transformed NB101 
cells with pSC-S108, pdCas9-ω and pMC-phiLOV and grew the cells aerobically in 
LB media at 37°C. At OD 0.6, I washed the cells and re-suspended them in M9 minimal 





To characterize gRNA expression from SoxS promoters and the resulting 
CRISPRa, I first directly added Fcn (O).  With a constant Fcn (O) concentration of 
5mM, I added different PYO concentrations, grew the cells for 6 hours at 37°C in both 
aerobic and anaerobic conditions and measured phiLOV fluorescence through FACS. 
I observed the CRISPRa response to increase with increasing concentrations of PYO 
under both aerobic and anaerobic conditions. However, with time, CRISPRa responses 
in aerobic and anaerobic conditions were directly opposite of each other with 
fluorescence increasing in aerobic conditions over time while decreasing in anaerobic 
conditions (Figure 5-6 A and B). I also varied the concentrations of Fcn (O) and PYO 
simultaneously and observed CRISPRa responses under anaerobic conditions after 2 
hours of induction. phiLOV fluorescence increased with increasing concentrations of 
Fcn (O) and PYO with the highest PYO and Fcn (O) concentrations (10µM and 50 mM 






     
Figure 5-6 Ferricyanide and Pyocyanin mediated control of SoxS 
promoters for gRNA expression and CRISPRa 
I optimized the Pyocyanin and Ferricyanide concentrations required for induction of 
gRNA expression from SoxS promoters. I transformed pSc-S108, pMC-phiLOV and 
pdCas9-ω into NB101 cells and measured gRNA mediated CRISPRa of phiLOV from 
pMC-phiLOV by FACS. With a constant Ferricyanide (Fcn (O)) concentration of 
5mM, I varied the concentrations of Pyocyanin and grew the cells under aerobic (A) as 





fluorescence. I also varied both Pyocyanin and Ferricyanide concentrations 
simultaneously and measured phiLOV fluorescence (C) after 2 hours. n=3.  
 
Next, I sought to display electrical control of CRISPRa by electrically oxidizing 
Fcn (R) to Fcn (O).  I prepared NB101 cells with pSC-S108, pdCas9-ω and pMC-
phiLOV plasmids as before in Figure 5-6. After growing to OD 0.6 in LB under 
aerobic conditions, I switched to anaerobic conditions and re-suspended the cells in M9 
minimal media containing 50mM of Fcn (R) and 5 µM of PYO. To electrically convert 
Fcn (R) to Fcn (O), I used a three electrode set-up connected to a potentiostat and 
applied an oxidation potential of +0.5V across the solution at room temperature to 
oxidize Fcn, as described earlier[99] (Figure 5-7 A). After oxidation, I moved the cells 
to 37°C and grew for 6 hours. I varied the total charge (represented in Coulomb) that 
is transferred from electrode to the solution for oxidation of Fcn (R) and measured the 
expression levels of gRNA from the SoxS promoter as well as phiLOV from CRISPRa 
(Figure 5-7 B). In addition, I also measured phiLOV fluorescence through FACS 
(Figure 5-7 C). Figure 5-7 B indicates the relative gene expression levels of gRNA 
and phiLOV after 2 hours of electrical induction. With increasing charge there was 
increasing levels of gRNA expression from the SoxS promoter as well as phiLOV 
expression due to CRISPRa mediated by gRNA and dCas9-ω. At -0.5C, however, there 
was a decrease in gRNA and phiLOV expression levels. Figure 5-7 C indicates the 
fluorescence obtained across 6 hours with varying levels of electric charge applied. As 
expected, with increasing charge of up to -0.4C, there was increasing fluorescence due 







Figure 5-7 Electrical control of SoxS promoters for gRNA expression 
and CRISPRa 
 
Scheme of electrical induction of SoxS promoters for gRNA expression. I transformed 
pSc-S108, pMC-phiLOV and pdCas9-ω into NB101 cells and grew them in LB media 
to OD 0.6. Later, cells were re-suspended in in minimal M9 media with 50mM 
Ferrocyanide (Fcn(R)) and 5 µM Pyocyanin and grown under anaerobic conditions at 
37⁰C. I electrically oxidized 50mM Ferrocyanide (Fcn(R)) to Ferricyanide (Fcn (O)) 





charge provided for oxidation of (Fcn(R)) to (Fcn (O)) is represented in Coulomb. Fcn 
(O) activated gRNA expression from pSoxS promoter resulting in CRISPRa. (B) qPCR 
data indicating the relative levels of gRNA expressed with different electrical charges 
after 2 hours of induction. (C) Fluorescence data indicating CRISPRa of phiLOV with 
different electrical charges applied. Fluorescence is measured across 6 hours using 
FACS. 
 
In sum, I have displayed PYO and Fcn mediated control of gRNA expression 
from SoxS promoters leading to a tunable CRISPRa response. I optimized 
concentrations of mediators required for CRISPRa (Figure 5-6) and displayed tunable 
electrical control of CRISPRa (Figure 5-7) by controlling the oxidative state of Fcn 
leading to ~13-fold change in transcriptional activation.  
5.3.3 Re-purposing CRISPRa for repression of SoxS in the genome 
to improve SoxS promoter responses 
Bacteria has well developed oxidative stress response mechanisms that are 
primarily mediated by SoxRS and OxyRS regulons.[207] Since Pyocyanin (PYO), an 
oxidative stress inducing molecule, is the primary component in electrical activation of 
SoxS promoters, I next studied whether repression of SoxS mediated oxidative stress 
responses resulted in increased electrical activation of SoxS promoters. To study this, 
I intended to repurpose the CRISPRa system for repression of SoxS and SoxS mediated 
oxidative stress responses in bacteria.  
One of the advantages of the CRISPR-Cas9 system is the ability to 
simultaneously target different sets of genes in the genome and modulate transcription. 
In cases where both transcriptional activation and repression functions needs to be 





silencing and activation functions in the same cell.[208] Transcriptional activators can 
also be repurposed for repression (labelled as CRISPRi) by simply targeting the dCas9 
activator fusion to the promoter region or downstream of TSS of target gene.[189, 209]  
I intended to re-purpose the bacterial CRISPRa system with transcriptional 
activator dCas9-ω for repression of the soxS in the genome of E. coli. The ideal location 
in a gene to target dCas9 for maximum repression is the -35 to -10 promoter 
region.[194] However, since I used the same E. coli soxS promoter in the pSC-S108 
plasmid for electrical activation of gRNAs, I chose to avoid the promoter region and 
target a region downstream of soxS transcriptional start site (TSS). soxS had two NGG 
PAM sites proximal to TSS at +4bp and +5bp in the non-coding strand. I designed 
gRNAs designated S-1 and S-2 (sequence of spacers in 5.2.1) with spacers targeting 
+4bp and +5bp sites respectively (Figure 5-8 A).  
I expressed S1 and S2 gRNAs from plasmids pS1 and pS2 using strong 
constitutive promoter J23119. As controls, I also used pControlgRNA. I transformed 
the respective gRNA plasmids and dCas9 plasmids into NB101 cells and grew the cells 
in LB media at 37⁰C. At OD 0.6, I induced the soxS in the genome with 5 µM PYO in 
aerobic conditions and after three hours of induction, I collected RNA samples and 
performed qPCR experiments. I compared the relative levels of soxS repression using 
gRNAs S1 and 2 in combination with both dCas9 and dCas9-ω (Figure 5-8B). With 5 
µM PYO and controlgRNAs, there was a ~12 to 17-fold increase in expression of soxS 
in comparison to the PYO nil condition. However, both soxS specific gRNAs S1 and 





addition, both dCas9 and dCas9-ω repressed soxS in the genome to basal expression 
levels using gRNAs S1 and S2 (Figure 5-8B). Since soxS repression from S1gRNA 
was marginally better than S2, I used S1 for all further experiments. 
With SoxS being a transcription factor, I expected that the repression of soxS 
via CRISPR might lead to prevention of upregulation of various SoxS regulated genes 
involved in the oxidative stress defense response. To prove this, I measured the gene 
expression levels of two SoxS regulated genes: sodA (Superoxide dismutase A) and 
fumC (Fumarate hydratase) using qPCR. Under aerobic conditions, I induced cells 
containing pS1 and dCas9-ω plasmids at OD 0.6 with 5µM PYO in LB media for 3 
hours and measured relative levels of sodA and fumC. As expected, in the presence of 
pS1 and dCas9-ω, both sodA and fumC were not activated above their basal expression 






Figure 5-8 Using dCas9-ω for repression of host oxidative defense 
mechanisms: 
 
Scheme indicating dCas9-ω mediated CRISPRi of soxS in the E coli genome resulting 
in repression of fumC and sodA. I targeted two PAM sites in the soxS coding region 
(+4 and +5 bp in the non-coding strand) with S1 and S2 gRNAs expressed from pS1 
and pS2 plasmids under J23119 promoters. Both pS1 and pS2 are transformed with 
dCas9 as well as dCas9-ω independently for repression of soxS in genome in NB101 





incubation, soxS repression was measured using qPCR. (A) indicates qPCR data 
comparing repression of soxS in E. coli using dCas9 and dCas9-ω fusions with S1 and 
S2 gRNA. (B) indicates the indirect repression of sodA and fumC due to repression of 
soxS in genome mediated by S1 gRNA and dCas9-ω.  
 
To re-confirm these results, I also added 0.5mM Paraquat, a known oxidative 
stress inducing molecule that targeted SoxRS regulon.[210] I performed similar 
experiments as in Figure 5-8 and induced the cells with 0.5 mM Paraquat in aerobic 
conditions. After three hours of induction, I collected RNA samples and performed 
qPCR experiments to measure relative levels of soxS, sodA and fumC. Addition of 
paraquat led to ~75-fold activation of the soxS with the control gRNAs (Figure 5-9A). 
In the presence of soxS specific gRNA S1 and dCas9-ω, soxS was repressed to pre-
Paraquat levels and similarly sodA (Figure 5-9B) and fumC (Figure 5-9C) genes were 






Figure 5-9 CRISPRa based repression of soxS with Paraquat as 
superoxide inducing molecule 
(A), (B) and (C) indicate repression of soxS, sodA and fumC respectively with 





Paraquat. All qPCR data indicate gene levels 6 hours after induction of SoxS promoter 
with Paraquat.  
 
Next, I studied if the repression of soxS in the E coli genome lead to improved 
SoxS promoter activity (Figure 5-10 A). To study this, I engineered S1gRNA sequence 
expressed under the  J23119 constitutive promoter into a previously described 
electrogenetic reporter plasmid pTT01 containing phiLOV under the SoxS 
promoter[99] to create pNB01 (See 5.2.4). I inserted this plasmid into NB101 cells 
along with pdCas9-ω, grew them at 37°C till OD 0.6 and then suspended the cells in 
M9 minimal media. Then under anaerobic conditions, I induced the cells with 5mM 
Fcn (O) and 5 µM PYO and measured phiLOV fluorescence levels through FACS. As 
controls, I also transformed pTT01 into NB101 and DJ901 cells (ΔsoxRS). phiLOV 
fluorescence measurements indicated that the addition of the S1gRNA component into 
the pTT01 reporter plasmid led to a 3 to 4-fold increase in phiLOV expression in 
NB101 cells (WT for soxS) and was comparable to DJ901 (ΔsoxRS) cells (Figure 5-10 
B).  I also engineered expression of S1gRNA under a SoxS promoter with a pSC101* 
origin in a plasmid labelled pNB02 (5.2.4). I transformed pNB02 into NB101 cells 
containing dCas9-ω and pTT01 phiLOV reporter plasmids. Upon induction with PYO, 






Figure 5-10 Repression of SoxS leads to enhanced SoxS promoter 
activity. 
(A) Scheme of soxS repression in E coli leading to repression of oxidative stress 
defense mechanism genes fumC and sodA and resulting in enhanced SoxS promoter 
activity. I inserted soxS specific S1 gRNA under J23119 promoter into reporter plasmid 
pTT01 expressing phiLOV from SoxS promoter to create pNB01. I also created pNB02 
expressing S1 gRNA from SoxS promoter. (B) I transformed pNB01 and pNB02 
independently into NB101 cells along with dCas9-ω and induced with 5mM Fcn (O) 
and 5 µM PYO under anaerobic conditions and measured phiLOV fluorescence 






In sum, I have displayed that the transcriptional activator dCas9-ω can be 
repurposed for CRISPRi by targeting the dCas9-ω downstream of the TSS of genes of 
interest (Figure 5-8). I also showed that by repressing global oxidative stress response 
mediator soxS, I could indirectly repress genes involved in oxidative stress defense 
response resulting in an overall enhancement of SoxS promoter activity with a ~3-4-
fold increase (Figure 5-10) in transcription from SoxS promoters.  
5.3.4 Simultaneous activation and repression of genes using 
CRISPRa  
Having shown that I could repurpose the dCas9 based transcriptional activator 
to repress genes, I sought to study whether the transcriptional activator can 
simultaneously perform CRISPRi and CRISPRa at different sites. With repression of 
soxS in the genome leading to a ~3-4-fold increase in SoxS promoter activity, I 
explored whether this enhancement from SoxS promoter activity can lead to an 
increased gRNA expression for CRISPRa.   
To display this, I intended to express two gRNAs from the SoxS promoter to 
mediate CRISPRa of reporter genes as well as CRISPRi of soxS in the E. coli genome.  
For this purpose, I engineered both S1gRNA targeting soxS in the genome and 
108gRNA targeting phiLOV in pMC-phiLOV into a single transcript and expressed it 
from the SoxS promoter in a plasmid labelled pNB03 (See5.2.3.3). To mediate gRNA 
processing, I introduced self-cleaving ribozyme hammerhead (HH)[195] at the 5’ end 





gRNA. I also built a construct (pNB04, See 5.2.3.3) expressing ControlgRNA and 
108gRNA for controls (Figure 5-11 A and B).  As additional controls for ribozyme 
processing, I also included pSC-S108gRNA plasmid expressing just the 108gRNA for 
phiLOV activation.  
I individually transformed these plasmids along with pdCas9-ω and target 
plasmid pMC-phiLOV into NB101 cells and grew the cells in LB media at 37⁰C. At 
OD 0.6, I suspended the cells in Minimal M9 and induced the cells with various 
concentrations of Fcn (O) and PYO under anaerobic conditions and measured phiLOV 






Figure 5-11 Simultaneous activation and repression of multiple genes using 
dCas9-ω. 
(A) Scheme of plasmids pNB03 and pNB04. pNB03 plasmid expresses two gRNAs 
(soxS specific S1gRNA for repression and phiLOV specific 108gRNA for activation) 
from the pSoxS promoter as a single transcript. Both gRNAs are flanked with 
ribozymes HH at the 5’ end and HDV at the 3’ end. Upon transcription, ribozymes self-
cleave leading to formation of two separate gRNAs. Similarly, pNB04 expressed a non-
specific control gRNA and 108 gRNA for phiLOV activation.  (B) I transformed 
pNB03 and pNB04 independently into NB101 cells along with dCas9-ω and pMC-
phiLOV, induced with 5mM Fcn (O) and 5 µM PYO under anaerobic conditions and 
(C) measured phiLOV fluorescence through FACS across 6 hours. As controls, I also 
used pSC-S108 plasmid expressing just 108gRNA for phiLOV activation. 
 
Results indicated that there was phiLOV fluorescence in all gRNA expression 
conditions indicating that the 108gRNA responsible for activation of phiLOV was fully 
functional (Figure 5-11 C). However, activation of phiLOV with pNB03 (expressing 
S1gRNA as well as 108gRNA) was not higher than activation of phiLOV with pSC-
S108 (expressing 108gRNA only) indicating that there was no improvement in  
CRISPRa arising from S1gRNA mediated soxS repression in the genome.  
To analyze whether the S1gRNA is functional post the ribozyme processing of                     
S1-108gRNA hybrids, I tested the effect of S1-108gRNA hybrid on SoxS promoter 
activity. Results from Figure 5-10 indicated that the S1gRNA, when expressed 
independently in pNB01 and pNB02, improved the activity of the SoxS promoter in 
pTT01 by ~3-4 fold. I expected the same from S1-108gRNA hybrid expressed from 
pNB03 as well. I transformed pNB03 with pTT01, the SoxS promoter containing 
reporter plasmid and pdCas9-ω in NB101 cells. As controls, I also used pS1 with 





cells as before and induced the populations with 5mM Fcn (O) and 5 µM PYO for 2 
hours under anaerobic conditions. Results showed that the pNB03 plasmids did 
enhance the SoxS promoter activity by 1-fold. These results indicated that S1gRNA 
that is expressed in combination with 108gRNA from pNB03 plasmids were functional 
post ribozyme processing. However, S1gRNA when expressed in combination with 
another gRNA gave just 1-fold increase in SoxS promoter activity in comparison to 3-
fold increase when expressed independently.  
 
Figure 5-12 Multiplexed gRNAs support feedback on SoxS promoters 
I transformed pNB03 (expressing both soxS specific S1 gRNA and 108gRNA for 
phiLOV) along with dCas9-ω and pTT01 reporter plasmid into NB101 cells, induced 
with 5mM Fcn (O) and 5 µM PYO under anaerobic conditions and measured phiLOV 
fluorescence through FACS across 6 hours. As controls, I also used pS1 plasmid 
expressing just soxS specific S1gRNA. n=3. 
 
 In sum, I have displayed simultaneous CRISPR based repression and activation 
of two genes using a transcriptional activator dCas9-ω (Figure 5-11 and Figure 5-12). 
I have also shown that while CRISPR based repression of soxS in genome leads to 4-





indicating the limitations of connecting feedback loops between CRISPRi and 
CRISPRa systems.  
Future Work: 
CRISPR based activation of Quorum Sensing (QS) is discussed in Appendix section 







In this work, firstly I did basic characterization of the poorly understood bacterial 
CRISPR-Cas9 mediated transcriptional activation (CRISPRa) system. I optimized the 
expression conditions including promoters, plasmid copy numbers for expression of 
gRNA as well as dCas9 based transcriptional activators and copy numbers of the target 
genes to create a tunable CRISPRa system. Secondly, I successfully integrated the 
CRISPRa system with the SoxRS based electrogenetic system to create an electrically 
tunable CRISPRa with a maximum ~13-fold transcriptional activation. Thirdly, I 
repurposed the dCas9 based transcriptional activator to repress the oxidative stress 
defense responses in bacteria resulting in a ~3-4-fold increase in electrogenetic 
promoter activity.  
While I created a tunable CRISPRa system by controlling gRNA expression, all 
our efforts to control dCas9 expression for the development of a tunable and 
controllable CRISPRa was unsuccessful. While minimal leaky expression of dCas9 
from Tet promoters was sufficient for transcriptional activation, any attempt to increase 
the expression of dCas9 from the leaky expression level was unsuccessful.  This 
problem has been overcome in the recent past in mammalian systems through various 
post translational approaches. Both dCas9 and transcriptional activators are engineered 
with dimerizing domains and expressed as two separate proteins. Upon optical[212] or 





activation. This approach of inducible transcriptional activations needs to be adapted 
in the microbial contexts.   
I successfully integrated CRISPRa system into electrogenetic circuits and 
activated phiLOV by up to ~13-fold. However, direct transcription of phiLOV from 
SoxS promoters was reported to be ~40-fold under similar copy number conditions.[99] 
The apparent differences in transcriptional activation can be attributed to the 
differences in the way transcription is initiated in these two scenarios. In SoxS 
promoters, the RNA polymerase is assembled on the promoter and upon SoxR 
oxidation there is a conformational change in -35 region of the SoxS promoter leading 
to transcriptional activation[214]. In CRISPR systems, transcriptional activator ω 
subunit works by recruiting and stabilizing RNA polymerase and the sigma factor at 
promoter sites, thereby making the process of transcription less efficient. However, 
incorporation of CRISPR as an intermediate layer between electrogenetic promoters 
and genes of interest provides the flexibility to electrically target, activate and repress 
multiple genes at the same time.  
In this study, I was able to successfully repurpose the dCas9-ω transcriptional 
activator for transcriptional repression. Direct repression of soxS, the global oxidative 
stress defense response mediating transcriptional factor in the genome led to prevention 
of upregulation ~15 genes whose products mediate defense against oxidative stresses. 
A net effect of all the repression led to ~4-fold increase in SoxS promoter activity 
indicated by Philov fluorescence. This ~4-fold increase in SoxS promoter activity can 





stress defense responses or alternatively with the sustained presence of reactive oxygen 
species (ROS) inside cells in the absence of oxidative stress defense responses that 
actively work to reduce ROS. Both theories need to be analyzed further to decipher the 
exact reasons for enhanced SoxS promoter activity.  
In conclusion, I propose a new paradigm by which direct connection between 
electronic signals and central dogma of host organisms can be mediated. Emergence of 
CRISPR provides the capability to target specific genes in the genome of organisms 
and integration of CRISPR with electronics provides the capability to electrically turn 
ON and OFF several genes simultaneously. As a proof of concept, I have demonstrated 
that I could use this capability to temporally silence host defense responses to electronic 
signals and drive better transgene activation in response to electrical signals. I believe 
that the further development of this capability to electronically target select genes 
across the host genome could be a significant new tool in bioelectronics research where 
so far the focus has been on targeting specific cells rather than specific genes in cells. 
This work also has potential applications in the field of synthetic biology where 
problems pertaining to chassis compatibility are ubiquitous. Simultaneous activation 
and repression mechanisms are crucial for moderating or supporting host behavior for 







5.5 Supplementary data 
5.5.1 Regulating dCas9 expression from Tet promoters for a 
controllable CRISPRa system 
In all the previous experiments, I had been using leaky expression dCas9-ω 
from the Tet promoter in pdCas9-ω. To create a controllable CRISPRa system, I 
intended to regulate expression of dCas9-ω under the Tet promoter in pdCas9-ω. To 
the NB101 cells containing p108gRNA, pdCas9-ω and pWJ89 plasmids, I added 
varying concentrations of inducer aTc from 100 nM to 10 pM at the time of re-
inoculation and grew at 37°C. After 6 hours, I measured the relative gene expression 
levels of dCas9-ω and GFP through qPCR (dCas9-ω was indicated by rpoZ encoding 
for ω subunit. ω was genetically fused to dCas9). In addition to the relative gene 
expression levels of dCas9-ω and GFP (Supplementary Figure 5- A), I measured GFP 
fluorescence (Supplementary Figure 5- B) and cell growth (OD) (Supplementary 
Figure 5- C) as well at 4 and 8 hours.  
qPCR data indicated that only the 100nM aTc concentration significantly 
increased dCas9-ω expression levels (indicated by rpoZ levels) over leaky expression 
from Tet promoter.  However, the gfpmut2 expression data at 6 hours showed a 
markedly different gene expression pattern with 100 pM condition displaying the 
highest gfpmut2 expression. aTc concentrations higher than 100 pM had lower gfpmut2 
levels. GFP fluorescence (Supplementary Figure 5- B) showed a consistent trend of 





post inoculation. OD (Supplementary Figure 5-C) followed a trend similar to GFP 
fluorescence as well.  
While there was no significant increase in dCas9-ω expression with increase in 
aTc concentrations from 0 M to 10 nM, there was still a consistent decrease in GFP 
fluorescence and OD indicating toxicity due to dCas9 induction.  
 
 
Supplementary Figure 5-Regulating dCas9 expression from Tet 
promoters for a controllable CRISPRa system. 
I transformed pdCas9-ω, p108gRNA and pWJ89 into NB101 cells and induced the Tet 
promoter in pdCas9-ω for dCas9 expression with different aTc concentrations. (A) 
qPCR data for rpoZ and gfp measured 6 hours after addition of anhydrotetracycline 





(B) and (C) indicates GFP fluorescence and OD obtained 4 and 8 hours after addition 
of various concentrations of aTc to induce dCas9-ω expression from the Tet promoter. 
GFP and OD were measured through plate reader. n=3 
 
To make dCas9-ω based CRISPRa system a controllable system where 
CRISPRa of target genes occurs only after induction of dCas9-ω, I attempted to 
regulate expression of dCas9-ω by engineering both at the level of transcription as well 
as translation.  
To remove leaky expression of dCas9-ω from Tet promoters, I added a protein 
degradative ssRA tag to the C termini of the dCas9-ω fusion (pdCas9-ωssRA, Error! 
Reference source not found. B). In addition, I removed the natural promoters for Tet 
Repressor and replaced with a stronger synthetic promoter for Tet repressor to increase 
expression of Tet repressor and in turn increase repression of the Tet promoter. In 
addition to that, I also reduced ribosome binding site (RBS) strength by 10 folds for 
dCas9-ω from the Tet promoter. These measures were reported to have reduced leaky 
expression of Cas9 resulting in increased genome editing efficiencies.[204] Promoter 
and RBS changes were introduced into both pdCas9-ω and pdCas9-ωssRA to create 
pIntdCas9-ω (Supplementary Figure 5-1 C) and pIntdCas9-ωssRA (Supplementary 
Figure 5-1D). I expected these changes to remove leaky expression of dCas9-ω and 
make dCas9-ω and in turn dCas9-ω mediated CRISPRa of GFP more inducible.  
I transformed all these different dCas9 expression plasmids with p108gRNA 
and pWJ89 plasmids in NB101 cells and induced varying concentrations of the inducer 





uninduced conditions with no aTc, CRISPRa of GFP due to leaky expression of dCas9-
ω decreased with increasing constraints on transcription and translation of dCas9-ω. 
CRISPRa from pdCas9-ω was the highest followed by the activation from pdCas9-
ωssRA. CRISPRa from pIntdCas9-ω and pIntdCas9-ωssRA were even lower 
(Supplementary Figure 5-1 E). These results indicated that the changes introduced 
both at translation level (addition of ssRA tags to dCas9-ω and reduced RBS strength 
for dCas9-ω) as well as transcriptional level (increased promote strength for Tet 
Repressor) reduced the leaky expression of dCas9-ω. At the same time, our effort to 
make Tet promoter controllable where upon addition of aTc there should be an increase 
in CRISPRa of GFP, was unsuccessful. There was no increase in transcriptional 
activation of GFP with addition of aTc in any of the conditions except in the case of 
pdCas9-ωssRA where 1nM aTc resulted in a minor increase. These results indicate that 
while efforts to contain leaky expression of dCas9-ω was successful, our efforts were 
unsuccessful for a controllable dCas9-ω mediated activation of GFP.  In all further 






Supplementary Figure 5-1 Engineering dCas9-ω transcription and 
translation processes to create an inducible CRISPRa system. 
(A) Tet promoter with dCas9-ω (pdCas9-ω). (B) Same as (A) with dCas9-ω engineered 
with a ssRA tag at the C termini of dCas9-ω fusion (pdCas9-ωssRA). (C) Engineering 
of a synthetic promoter for TetR to upregulate expression of Tet repressor and 
engineering of 10-fold reduction in RBS site strength to decrease translation of dCas9-
ω (pIntdCas9-ω). (D) Same as C with a ssRA tag at the C termini (pIntdCas9-ωssRA). 
(E) GFP fluorescence measured through plate reader after 6 hours of addition of 
different anhydrotetracycline (aTc) concentrations under different dCas9-ω expression 
conditions (pdCas9-ω, pdCas9-ωssRA, pIntdCas9-ω and pIntdCas9-ωssRA). n=3. 
 
5.5.2 Controlling gRNA for a tunable CRISPRa system 
While our efforts to regulate dCas9-ω expression were unsuccessful, I next 
focused our attention towards gRNAs, the second element of the CRISPR-Cas9 
transcriptional regulatory system in addition to dCas9 protein. gRNA based tuning of 
CRISPRi is well documented in bacteria with major criterions for tuning being relative 
levels of gRNA, spacer sequence similarity with target[215] and position of spacer in 





influence CRISPRa as well. Since the distance of spacer from TSS for RNA 
polymerase recruitment in CRISPRa was optimized earlier and I was already working 
with the best spacer reported  for CRISPRa[194], I examined other factors that may 
influence CRISPRa.  
I first analyzed whether sequence similarity between spacer and target sequence 
is a determining factor for a tunable CRISPRa. It is known that single point mutations 
in the seed region of a spacer sequence (the first four bp in the spacer near the PAM 
site) can significantly reduce the efficiency of CRISPRi[215]. To test if this factor plays 
a significant role in CRISPRa, I introduced single point mutations by replacing purines 
with pyrimidines or vice versa in the seed region to create non-cognate gRNAs 
(expressed in pNC-gRNA 1, 3 and 5). I transformed the non-cognate gRNA plasmids 
along with pdCas9-ω and pWJ89 plasmids into NB101 strains and grew them in 37°C. 
I expressed the non-cognate gRNAs from the same constitutive promoter (J23119) as 
the cognate gRNA (p108gRNA) and measured the effect of non-cognate gRNA on GFP 
activation. I measured GFP fluorescence levels using plate reader at 4, 8 and 24 hours 
after re-inoculation. Results indicated that the non-cognate gRNAs had no significant 
effect on CRISPRa of GFP across 4 and 8 hours (Supplementary Figure 5-2) 







Supplementary Figure 5-2 Engineering the sequence of spacers to modulate 
CRISPRa in bacteria.  
3 non-cognate gRNAs (denoted as NC1, NC4 and NC5) with single point mutations in 
the seed region of the cognate 108-spacer sequence are expressed under J23119 
promoters in pNC1, 3 and 5 plasmids to target GFP (pWJ89) for CRISPRa in NB101 
cells. I used dCas9-ω under leaky expression conditions from the Tet promoter in 







Chapter 6 Conclusion 
In this thesis, I have worked on two different fronts across the bioelectronic 
interface. On one end, I designed biofabrication frameworks for construction of enzyme 
cascades that enabled conversion of biological signals to electric signals. On the other 
end, I integrated the CRISPR-Cas9 based transcriptional regulation frameworks with 
electrogenetic promoter systems to mediate communication between electrical signals 
and specific genes in the genomes of bacterial systems.    
To enable construction of enzyme cascades for conversion of biologic and 
electronic signals, I first demonstrated a facile method for the assembly of multi-
subunit enzyme complexes on solid supports. I covalently conjugated individual 
components using engineered Lys and Gln tags and coupled the components using 
mTG. Using this method, I built a two-enzyme metabolon involving bacterial QS 
enzymes and displayed control of metabolic flux across these enzymes. Through this 
method, I was also able to build multi-functional enzyme-Protein G complex that was 
eluted from assembly beads and used for specific targeted applications.  
Next, I implemented the mTG based approach to build enzyme cascades on 
microchips. I first functionalized the chitosan coated gold chip with a Lys-Tyr-Lys 
tripeptide using Michael type addition. Then, I conjugated the Gln’s engineered 
enzymes to the Lys’s in the tripeptide layer using mTG. This approach of using 
tripeptides to coat chitosan for conjugation decreased the non-specific binding of 





the assembly process. To further simplify the fabrication process, I developed a self-
assembling 3D scaffold made up of TMV-VLP’s that displays desired functional 
groups (Gln’s) for biocomponent functionalization on the electronic surface. In 
association with 3D scaffolds, I also adapted the mTG mediated approach to build a 
three-enzyme cascade on the gold surface to convert methyl cycle intermediates SAH 
and SAM into homocysteine, an electrochemically readable molecule. 
 Finally, to electrically control transcriptional regulation in biological systems, 
I integrated the CRISPR-Cas9 based synthetic transcription factors into electrogenetic 
promoters in E coli. Firstly, I did preliminary characterization CRISPR-Cas9 mediated 
transcriptional activation (CRISPRa) system in E coli and integrated the CRISPRa 
system with the SoxRS based electrogenetic system to create an electrically tunable 
CRISPRa. I also repurposed the dCas9 based transcriptional activator to repress the 
oxidative stress defense responses in bacteria resulting in an overall increase in 








CRISPR based activation of Quorum Sensing communication 
Having shown that I could tune transcriptional activation by controlling the 
gRNA levels, I sought to develop a CRISPR based QS communication system where 
electrogenetic CRISPR cells can translate electric signals into QS molecules and QS 
molecules can mediate transcriptional change in other populations in a microbial 
consortium.  
To display this QS communication concept, I used the CRISPRa system to 
activate transcription of LasI, a Pseudomonas aeruginosa Autoinducer-1 synthase. I 
replaced the gfpmut2 in pMC-GFP with the lasI (pMC-LasI) and transformed it along 
with pSC-S108 and pdCas9-ω into NB101 for transcriptional activation. I referred 
these populations as AI-1 producer cells. I added different concentration of PYO to the 
producer cells at the time of re-inoculation under aerobic conditions and activated 
gRNA expression resulting in CRISPRa of LasI. After 4 hours, I collected the condition 
media from the cells and incubated with AI-1 reporter cells (JLD271 strain with 
pAL105) that luminesce in response to AI-1. Relative AI-1 activities are measured via 
an AI-1 reporter assay (See 5.2.8) after 4 hours (Figure 1).  Results indicated that AI-






Figure 1 Activation of LasI QS synthase using CRISPRa under aerobic 
conditions. 
I transformed pMC-LasI, pSC-S108 and pdCas9-ω into NB101 cells and induced with 
different concentrations of Pyocyanin under aerobic conditions for 4 hours in LB 
media. Conditioned media is collected and relative AI-1 activity is measured through 
luminescence from JLD271 strain containing pAL105 (See 5.2.8 for AI-1 assay). n=3.  
 
To spatially delineate electrically responsive AI-1 producer populations and 
responder populations and mediate communication between the two microbial 
populations, I intended to encapsulate these two populations in two different alginate-
chitosan capsules. I adapted a previously described alginate microfluidic encapsulation 
system[105] to generate AI-1 producer cell capsules. Cells were first re-inoculated 
from overnight cultures into fresh LB at a dilution of 1:100 and grown to an OD600 of 
~0.5. I then pelleted the cells and re-suspended the pellet in an equal volume of 2% 
alginate. This solution was then extruded through a microfluidic device1 which allowed 
the alginate solution to proceed at a fixed flow rate. Beads formed at the tip of the 





and I collected the beads in a solution containing 1% w/v Chitosan and 1% w/v CaCl2. 
After 30 minutes of incubation, I collected the beads by carefully decanting excess 
chitosan and CaCl2 and gently washed the capsules three times with MOPS-M9 media 
prepared without CaCl2.  I varied the frequency of the air pulses and collected the 
capsules. Figure 2 A shows the microscope images of the capsules collected with 
different frequencies and the differences in diameter of the capsules collected at 
different frequencies (Figure 2 B). With increasing frequency, the diameter of the 
capsules decreased as expected.  
To prove that the capsules containing AI-1producer cells can respond to PYO, 
I collected capsules with a 5Hz pulse. I varied the time of the 5Hz pulse from 20 to 160 
seconds and collected the capsules. Post treatments with calcium and chitosan, capsules 
containing AI-1 producing cells were incubated with 5 µM PYO in M9 minimal media 
under aerobic conditions for 2 hours at 37˚C. After incubation, I collected conditioned 
media and performed the AI-1 activity assay. As controls, I also had capsules incubated 
without PYO.  Results indicated that capsules incubated with PYO produced more AI-
1 than controls and with increase in time of the frequency pulse, there was a 






Figure 2 Activation of LasI QS synthase using CRISPRa from AI-1 
producer capsules 
 
Role of the frequency of pulse generator used to shear the capsules from the tip of the 
encapsulation system on capsule size, capsule number and AI-1 activity. (A) indicates 
microscopic images of capsules obtained using different pulse generator frequencies, 
scale bar: 2mm. (B) indicates the average size of the capsules obtained using different 
pulse generator frequencies. n=50. I also made AI-1 producer capsules and collected 
capsules with different exposure times (20-160 seconds) to a 5Hz pulse. I induced these 
capsules in minimal M9 media with 5µM Pyocyanin under aerobic conditions for 2 
hours at 37⁰C and measured AI-1 activity. Control capsule had no AI-1 producer cells.      
  
Next to verify whether AI-1 can enter the capsules and activate reporter cells, I 
prepared reporter cell capsules as before. In this experiment, I used Top10 cells 
expressing EGFP in response to AI-1 as reporter cells. To the capsules, I added varying 
concentrations of AI-1, incubated at 37˚C for 3 hours in LB media under aerobic 
conditions. After incubation, the capsules were washed and analyzed using confocal 





range of fluorescence from 0 to 1µM AI-1 concentration, beyond which there was 
saturation of fluorescence intensity (Figure 3).   
 
Figure 3 Confocal microscopy images of AI-1 reporter capsules 
Alginate-Chitosan capsules containing AI-1 reporter cells are incubated with AI-1 for 
3 hours at 37⁰C and fluorescence is measured through confocal microscopy. Reporter 
cells were encapsulated at an OD of 0.5 are incubated with different AI-1 
concentrations (left to right: 0 µM, 0.5 µM, 1 µM and 10 µM). Scale: 100 µm. (B) Plot 
of the average fluorescence intensity versus the AI-1 concentration. n=1. 
 
A fully working system with both AI-1 producing capsules and AI-1 responding 
capsules in the same environment with one capsule translating electrical signals into 
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